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ABSTRACT
Over the last decade, a great deal of research has described the medication 
safety risks in hospitals and institutional care both in Finland as well as 
globally. Less attention has been paid to the safety of medicine use in 
outpatient care, even though majority of the use occurs at home.  
The aim of this study was to enhance prospective medication risk 
management in outpatient care, by enhancing coordination of care with 
community pharmacists’ participation and use of risk management screening 
tools available. Specific objectives of studies I–III were: I) to demonstrate how 
community pharmacies can utilize their prospective surveillance system for 
screening clinically significant drug-drug interactions (DDIs) in outpatients 
and assess the rate of DDIs in a large national prescription sample. II) To 
integrate risk assessment tools, procedures and databases available in Finland 
to form a coordinated medication management model (CoMM) for older home 
clients involving home care nurses and practical nurses (PNs), physicians and 
community pharmacists. III) To assess the impact of the CoMM on medication 
risks identified in drug regimens of older home care clients over a one-year 
period. Medication risks assessed related to potentially inappropriate 
medications (PIMs), excessive use of psychotropics, anticholinergic and 
serotonergic load, as well as clinically significant DDIs. 
In study I, all DDI alerts issued by the online surveillance system were 
collected during a one-month period in 16 out of 17 University Pharmacy 
outlets in Finland, covering approximately 10% of the national outpatient 
prescription volume. The surveillance system was based on the FASS database, 
which categorizes DDIs into four classes (A–D) according to their clinical 
significance. Potential DDIs were analyzed for 276,891 dispensed 
prescriptions and they were associated with 11.2% of the prescriptions. 
Clinically significant DDIs categorized as FASS classes D (most severe, should 
be avoided) and C (clinically significant but controllable) were associated with 
0.5% and 7.2% of the prescriptions, respectively.  
Studies II–III were conducted in primary care in the city of Lohja, Southern 
Finland. Health care units involved were the home care, public primary 
healthcare center and a private community pharmacy. System-based risk 
management theory and the action research method were applied to construct 
the collaborative procedure utilizing each profession’s existing resources in 
medication risk management of older (>65 years, n=191) home care clients. 
Study II produced a 5-stage medication management model (CoMM) 
suitable for screening medications of a high number of home care clients and 
identifying clients with potential clinically significant drug-related problems 
(DRPs). The core of the model was the triage meetings that proved to be a 
feasible method for customizing comprehensiveness of collaborative 
medication reviews, according to their clinical needs while minimizing 
physicians’ time demands.  
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In study III, an RCT study design was used to assess the impact of the 
CoMM on medication risks identified in drug regimens of older home care 
clients over a one-year period. Participants’ (n=129) mean age was 82.8 years, 
69.8% were female and mean number of prescription medicines in use was 
13.1. The intervention did not show an impact on the medication risks between 
the original intervention group and the control group in the intention to treat 
analysis, but the per protocol analysis indicated a tendency for effectiveness, 
particularly in optimizing central nervous system medication use 
(benzodiazepines). Half (50.0%) of the participants with a potential need for 
medication changes, agreed on in the triage meeting, had none of the changes 
actually implemented. 
Study I demonstrated that community pharmacists can actively contribute 
to DDI risk management and systematically use their surveillance systems for 
identifying patients with clinically significant DDIs.  
In study II, the developed care coordination model (CoMM) was feasible 
for screening and reviewing medications of a high number of older home care 
clients in order to identify clients with severe DRPs and provide interventions 
to solve them, utilizing existing primary care resources. In study III, the CoMM 
intervention indicated a tendency for effectiveness when implemented as 
planned, particularly in optimizing CNS medication use during a 12-month 
follow-up.  
Our study revealed that organizations and health care units involved in 
home care clients’ medication therapy are currently working independently in 
silos, where no specific team membertakes holistic responsibility for 
medications. This study demonstrated the challenges to overcome when trying 
to change clinical practice and improve coordination between units involved 
in medication management of home care clients. Even though the outcomes of 
the intervention were not optimal, the value of the study is in discussing the 
real-world experiences and challenges of implementing new practices in home 
care.  
This study indicated that practitioners in Finnish health care are not well 
acquainted with systems thinking, a fact which needs to be addressed in the 
future. Further studies are needed on care culture and other contributing 
factors to high prevalence of PIM use and other risks for clinically significant 
DRPs identified in this study. Particularly, further investigation is needed on 
system-based factors contributing to situations where identified preventable 
clinically significant medication risks are left unsolved, as well as the 
relationship between inappropriate medication use and medication errors.  
A need for the organizational and national development of medication 
safety in primary care was identified in this thesis, which is line with the 
national and international publications, policy documents and 
recommendations. Furthermore, community pharmacists’ contribution to 
medication safety, particularly in older adults, should be better utilized in the 
future, as this thesis shows promising demonstrations. 
 
KEYWORDS 
Medication risk management, medication-related risk, drug-drug interaction, 
primary care, home care, older adult, community pharmacy 
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DEFINITIONS OF THE KEY CONCEPTS
Adverse drug event (ADE)  
Any injury occurring during the patient’s drug therapy resulting either from 
appropriate care or from unsuitable or suboptimal care (Council of Europe 
2006b). The definition includes adverse drug reactions (ADRs) and 
medication errors (MEs).  
 
Adverse event (AE) (also terms patient safety incident and medical error 
are used)  
An incident that results in harm to a patient (World Health Organization, 
WHO 2009). An adverse event is caused by medical management, in contrast 
to a process or complication of a disease (Council of Europe 2006a, 2006b).  
 
Adverse drug reaction (ADR)  
A response to a medicinal product that is noxious and unintended, resulting 
not only from the authorized use of a medicinal product at normal doses, but 
also from medication errors and uses outside the terms of the marketing 
authorization, including the misuse, off-label use, and abuse of the medicinal 
product (EU Directive 2010/84EU1).  
 
Clinical pharmacy  
An area of pharmacy concerned with the science and practice of rational and 
appropriate medication use (American College of Clinical Pharmacy 2008; 
The European Society of Clinical Pharmacy (ESCP) 2017).  
 
Community pharmacy 
In Finland, community pharmacy is an authorized health care unit which is 
responsible for the supply and distribution of medicines to the public in 
outpatient care, as well as ensuring their safe and appropriate/rational use 
(Medicines Act 395/1987). In Finland, sale of medicines is limited to 
community pharmacies (excluding nicotine replacement therapy products). 
The obligations set for a community pharmacy vary in different countries. 
 
Comprehensive medication review (CMR)  
A collaborative medication review procedure implemented nationally in 
Finland, requiring accreditation training for pharmacists (Leikola 2012; AATE 
2017; Kiiski et al. 2019). The procedure is based on collaboration between 
pharmacists and other healthcare professionals, particularly physicians. CMR 
includes 1) a patient interview and clinical medication review documented in 
a structured, evidence-based format and 2) a case report that documents 
recommended actions to manage clinically significant medication-related 
problems and a follow-up plan agreed upon in a collaborative case conference.  
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Coordination of care, care coordination 
Care coordination, or coordination of care, is defined by the WHO as “a 
proactive approach to bringing together care professionals and providers to 
meet the needs of service users to ensure that they receive integrated, person-
focused care across various settings” (WHO 2018). 
 
Deprescribing 
Deprescribing is an intervention intended to reduce harm associated with 
excessive polypharmacy. Deprescribing is defined as “the process of 
withdrawal of inappropriate medication, supervised by a health care 
professional with the goal of managing polypharmacy and improving 
outcomes” (Reeve et al. 2015; Page et al. 2018). 
 
Drug-related problem (DRP, also medication-related problem, 
MRP)  
An event or circumstance involving drug therapy that actually or potentially 
interferes with desired health outcomes (Pharmaceutical Care Network, PCNE 
2017).  
 
Geriatric pharmacotherapy 
Tailored pharmacotherapy for the older adults considering age-related 
changes in different organ systems and in the composition of the body, 
producing changes in pharmacokinetics (absorption, distribution, 
metabolism, and elimination) and pharmacodynamics of medicines. 
Furthermore, geriatric pharmacotherapy has a comprehensive approach to the 
medication therapy of older patients, considering multimorbidity, challenges 
with polypharmacy (e.g., drug-drug interactions, anticholinergic burden), 
potentially inappropriate medicines, as well as challenges in adherence and 
medicine use. Most often used age-limits for geriatric patients are: ≥65 years 
or ≥75 years (American Geriatrics Society 2019; Finnish Medicines Agency 
2019). 
 
Home care 
Home care may be defined differently depending on the health care system in 
place. Most commonly, it is defined as patients living at home with the support 
of professional caregivers (mostly nursing professionals), employed by a 
professional home care organization (Meyer-Massetti et al. 2018). In Finland, 
municipal home care services are a part of the public health care system, 
encompassing social and health services including home help and home 
nursing (Keskimäki et al. 2019). 
 
Medication error (ME)  
Any preventable event that may cause or lead to inappropriate medication use 
or patient harm while the medication is in the control of the healthcare 
professional, patient, or consumer (National Coordinating Council of 
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Medication Errors Reporting 1998). Such events may be related to 
professional practice, healthcare products, procedures and systems, including 
prescribing; order communication; product labeling, packaging and 
nomenclature; compounding; dispensing; distribution; administration; 
education; monitoring; and use.  
 
Medication safety  
A freedom from accidental injury during the course of medication use; 
activities to avoid, prevent, or correct adverse drug events which may result 
from the use of medications (Council of Europe 2006a and 2006b; World 
Health Organization 2009).  
 
Medicines optimization 
Medicines optimization is defined as “a person-centered approach to safe and 
effective medicines use, to ensure people obtain the best possible outcomes 
from their medicines” (National Institute for Health and Care Excellence 
2015). 
 
Multimorbidity 
Multimorbidity is defined as the presence of two or more chronic health 
conditions, which can include (a) defined physical and mental health 
conditions; (b) ongoing conditions such as learning disability; (c) symptom 
complexes such as frailty or chronic pain; (d) sensory impairment such as sight 
or hearing loss; and (e) alcohol and substance misuse (National Institute for 
Health and Care Excellence 2016; WHO 2019).  
 
Older adults (or older persons, elderly) 
Most developed countries have accepted the chronological age of 65 years as 
an age limit of 'elderly' or older persons (WHO 2010). The thesis applies this 
definition. 
 
Patient safety  
Freedom from accidental injury during the course of medical care; activities to 
avoid, prevent or correct adverse outcomes which may result from the delivery 
of healthcare (Kohn et al. 2000; Council of Europe 2006b; WHO 2009).  
 
Pharmaceutical care  
The core of pharmaceutical care is medication risk management by 
identifying, solving and preventing medication-related problems. According 
to the principles of pharmaceutical care, the role of pharmacists in patient care 
is to ensure the quality of medication therapies, with an emphasis on 
interprofessional collaborative care and patient interaction (Hepler & Strand 
1990; American Society of Hospital Pharmacists 1993; Cipolle 2004; 
American College of Clinical Pharmacy 2008; Pharmaceutical Care Network 
Europe 2013). 
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Polypharmacy 
Polypharmacy refers to the concurrent use of multiple medications. Although 
there is no standard definition, polypharmacy is often defined as the routine 
use of five or more medications (Masnoon et al. 2017; WHO 2019). This 
includes prescription medicines, over-the-counter and/or traditional and 
complementary medicines used by a patient. Excessive polypharmacy is 
defined as the concomitant use of nine/ten or more medicines taken regularly 
or as-needed (Onder et al. 2012). Polypharmacy can be appropriate or 
inappropriate (Scottish Government Polypharmacy Model of Care Group 
2018). 
 
Potentially inappropriate medication/medicine (PIM) 
Medication that may be inappropriate for older individuals. It can be 
considered as inappropriate because of questionable effectiveness, 
unfavorable benefit-risk ratio or because safer alternatives exist (Beers et al. 
1991; Dimitrow et al. 2011; American Geriatrics Society 2019).  
 
Primary care (PC) 
Primary care is a key process in the health system (WHO 2020). Primary care 
typically acts as the first contact and principal point of continuing care for 
patients within a healthcare system, and coordinates other specialist care that 
the patient may need. First-contact care is accessible at the time of need; 
ongoing care focuses on the long-term health of a person rather than the short 
duration of the disease; comprehensive care is a range of services appropriate 
to the common problems in the respective population and coordination is the 
role by which primary care acts to coordinate other specialists that the patient 
may need. PC is a subset of primary health care (PHC) (WHO 2020).  
 
Primary health care (PHC)  
Primary health care refers to the concept elaborated in the 1978 Declaration of 
Alma-Ata, which is based on the principles of equity, participation, inter-
sectoral action, appropriate technology and a central role played by the health 
system (WHO 2020). 
 
Risk management, prospective risk management  
Activities or measures taken by an individual or a healthcare organization to 
prevent, remedy or mitigate the occurrence or reoccurrence of a real or 
potential (patient) safety event (Dückers et al. 2009). 
 
Safety culture  
An integrated pattern of individual and organizational behavior, based upon 
shared beliefs and values, that continuously seeks to minimize patient harm 
which may result from the processes of care delivery (Council of Europe 
2006a).  
Systems approach  
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An approach to safety stating that errors are generally consequences of 
systemic factors, e.g., weaknesses in organizational structures and processes 
(Reason 2000). Building systemic defenses to reduce and prevent errors is the 
main method of safety improvement in a systems approach. 
 
Triage meeting  
In this study, triage meeting refers to the method used for customizing 
comprehensiveness of collaborative medication reviews for older home care 
clients according to their clinical needs while minimizing physicians’ time 
demands. 
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ABBREVIATIONS
AATE  The National Coordination Group of Professional Development 
of Pharmacy Services in Finland 
ADD  Automated dose dispensing 
ADE   Adverse drug event  
ADR  Adverse drug reaction  
AFP  The Association of Finnish Pharmacies 
AGS  American Geriatric Society 
ASHP  American Society of Health-System Pharmacists  
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DDI  Drug-drug interaction 
DRP  Drug-related problem  
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EU  European Union  
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(United States) 
ME  Medication error  
MSAH  Ministry of Social Affairs and Health (Finland)  
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(United States)  
NHS  National Health Service (United Kingdom)  
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Kingdom)  
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PCNE  Pharmaceutical Care Network Europe 
PN  Practical nurse 
PIM  Potentially inappropriate medicines 
RCT  Randomized controlled trial 
SII  Social Insurance Institution of Finland 
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THL  National Institute for Health and Welfare (Finland)  
WHO  World Health Organization 
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1 INTRODUCTION
Pharmacotherapies have evolved remarkably during the last few decades. 
Better therapeutic outcomes are being achieved and a growing number of 
medical conditions can be managed by modern pharmacotherapies. For many 
diseases, pharmacotherapy has become the primary form of treatment 
alongside lifestyle changes.  
At the same time as therapeutic outcomes have improved, medication loads 
of individuals have grown. Polypharmacy has become more prevalent, creating 
new challenges for healthcare providers in the design, implementation and 
monitoring of medication therapies on a patient-by-patient basis (WHO 
2019). This is particularly the case with pharmacotherapy of older adults. In 
Finland, for example, a high proportion of the medication load is concentrated 
on a small population segment aged >65 years and with multimorbidity 
(Saastamoinen & Verho 2015). 
If medication therapies are not properly implemented, the intended 
benefits may not be achieved and the risks may outweigh the benefits. This can 
lead to preventable harm and human suffering, as well as preventable direct 
and indirect costs caused by medicines. There is growing evidence that 
medicines are a major cause of errors in patient care, and many of these errors 
occur in older patients (WHO 2017a, 2019). 
Over the last decade, a great deal of research has described the risk 
situations and errors caused by medicines in hospitals and institutional care 
both in Finland and globally (Kohn et al. 2000; Holmström 2017; Schepel 
2018; Schepel et al. 2018; Schepel et al. 2019). Patient and medication safety 
work and monitoring of safety risks have been focused on institutional care. 
Less attention has been paid to the safety of medicine use at home, even 
though a majority of the use occurs at home (Panesar et al. 2016). 
The origins of this study date back 20 years, when a national program 
(TIPPA) was initiated in Finland in order to develop medication counseling in 
community pharmacies to promote rational and safe use of medicines (TIPPA 
Project 2004; Puumalainen 2005; Kansanaho 2006). The primary goal was to 
support each pharmacy to establish a long-term development plan for 
improving their counseling services. The four-year program was funded by the 
Ministry of Social Affairs and Health, the Social Insurance Institution of 
Finland (Kela), the Finnish Medicines Agency and the key stakeholders in 
community pharmacy sector. 
During the TIPPA project, it became evident that there were many 
problems and risks inherent in the medication therapies of outpatients that 
could not be solved by counseling the patients in the pharmacy: a need for a 
more comprehensive assessment of medication therapy in collaboration with 
the patient and professionals involved in their care was identified. This 
initiated a long, ongoing journey towards implementation of collaborative 
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medication reviews in Finland, which have evolved into various practices for 
different healthcare settings (Leikola 2012; Kiiski et al. 2019).  
The aim of this study was to find solutions for prospective risk management 
and quality improvement of pharmacotherapy of older adults that could be 
transferred to other similar local healthcare settings. This demonstration 
study, conducted in home care of city of Lohja in Southern Finland in 2015–
2018 and funded by the Social Insurance Institution of Finland (Kela), focused 
on enhancing coordination between home care and community pharmacy by 
developing a prospective medication risk management procedure for older 
home care clients. The aim was to make better use of the existing scarce 
resources, including home care, health center and pharmacy staff, home care 
clients and their family members, databases and tools available in community 
pharmacy to assist with medication risk management. 
The literature review of this doctoral thesis provides a basis for 
understanding the systems approach and prospective risk management of 
medication therapies and its implementation in primary care, especially in 
home care and community pharmacies. A special emphasis was placed on 
clinically significant drug-drug interactions as they were the first medication-
related risks that have been systematically screened with the help of electronic 
tools both in Finland and elsewhere. 
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2 REVIEW OF THE LITERATURE
2.1 PRINCIPLES OF PROSPECTIVE MEDICATION RISK 
MANAGEMENT
Although patient safety, i.e., the principle of not harming patients, has always 
been a priority in patient care, it received more visibility and concrete content 
in the early 2000s, when the principles of systems-based patient safety were 
introduced. The global systems-based patient safety movement was initiated 
by the US Institute of Medicine’s landmark report “To Err Is Human: Building 
a Safer Health System” which was launched in 2000 (Kohn et al. 2000).  
Since medications have shown to contribute to a high number of risk 
situations and actual medication errors, medication safety has been a central 
part of systems-based patient safety work from the outset (Kohn et al. 2000; 
Council of Europe 2006b; Institute of Medicine 2007; WHO 2009, 2017a). 
This chapter briefly describes the theoretical framework, key concepts and the 
shift in focus towards prospective risk management in the systems-based 
patient and medication safety work. 
2.1.1 THEORETICAL FRAMEWORK FOR SYSTEMS-BASED RISK 
MANAGEMENT IN HEALTH CARE
The simplest definition of patient safety is the prevention of errors and adverse 
effects to patients associated with health care (WHO 2009). Patient safety 
consists of the identification, analysis and management of patient-related 
risks and incidents, in order to make patient care safer and minimize harm to 
patients (WHO 2017b). 
In health care, risk management is defined as “clinical and administrative 
activities undertaken to identify, evaluate, and reduce the risk of injury to 
patients, staff, and visitors and the risk of loss to the organization itself” 
(Council of Europe 2006b). Prospective medication risk management focuses 
on developing strategies for 1) identifying and managing medication risks 
before harm occurs or 2) minimizing actual harm. 
One of the most widely used theories to explain safety risks and their 
management is psychologist James Reason’s Human Error theory (Reason 
2000). It has been facilitating the shift in risk management thinking from an 
individual to systems level (Reason 2000). Human Error theory introduced 
two approaches to the challenge of human error. The person’s approach which 
has been dominant in health care focuses on individuals as a cause of error. 
The individuals can be blamed for being forgetful, inattentive or incompetent, 
leading to harmful consequences. The systems approach focuses on the 
conditions under which people work and tries to build systemic defenses to 
prevent errors from occurring or minimizing their harmful effects.  
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Reason’s (2000) systems approach is often illustrated by the Swiss Cheese 
Model which visualizes the idea of managing the risks of organizational 
accidents (Figure 1). Concerning risk management in health care, the Swiss 
Cheese Model helps to evaluate health care processes and to identify potential 
safety risks. The same applies to systems and processes in medication therapy 
management: they need to be developed so that risks are identified, and 
appropriate systemic defenses are implemented in the process.  
The global systems-based patient safety work was initiated by the US 
Institute of Medicine’s (IOM) landmark report “To Err Is Human: Building a 
Safer Health System” (Kohn et al. 2000). The report highlighted the systems 
approach introduced by the Theory of Human Error (Reason 1990, Reason 
2000), and stated that the problem was not incompetent people in health care 
– it is that good people are working in bad systems which need to be made safer 
(Kohn et al. 2000). Wide-ranging recommendations were presented for 
improving patient safety, in the areas of leadership, improved data collection, 
and analysis, and development of effective systems at the level of direct patient 
care.  
 
 
Figure 1 The Swiss Cheese Model illustrating system accidents (Reason 2000) 
2.1.2 COORDINATION OF PATIENT AND MEDICATION SAFETY WORK 
AT GLOBAL, EUROPEAN AND NATIONAL LEVEL 
 
Following the IOM report (Kohn et al. 2000), the Council of Europe (CoE) 
established expert groups to evaluate the situation in Europe and to provide 
recommendations for improving patient and medication safety at the 
European level (Council of Europe 2006a, 2006b). The CoE stated that 
medication errors were poorly managed in Europe and suggested that 
European healthcare organizations start to work in the following areas to 
improve medication safety (Council of Europe 2006a, 2006b): 
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x Establish and use a common terminology concerning harm to 
patients caused by medication and promote a common taxonomy to 
facilitate the sharing of safety information in Europe; 
x Create a culture of safety and best practices; 
x Develop medication error reporting systems for both hospitals and 
primary care; and 
x Set up a national focal point for safe medication practices. 
 
Since then, various initiatives have been implemented in Europe to 
promote patient and medication safety. In 2008, the European Union (EU) 
launched the EUNeTPaS (European Union Network for Patient Safety) project 
to promote patient safety culture (European Union Network for Patient Safety 
2008). This was followed by the European Union Network for Patient Safety 
and Quality of Care (PaSQ) Joint Action, which was co-founded and supported 
by the European Commission, in order to support the implementation of the 
EU Council Recommendation on Patient Safety (The European Union 
Network for Patient Safety and Quality of Care 2012). Concerning medication 
safety, the PaSQ program mainly focused on establishing and improving 
medication reconciliation practices.  
At a global level, the WHO has taken a facilitating role in patient safety 
development, for instance with global patient safety challenges (WHO 2017a). 
The Global Patient Safety Challenges identify a patient safety burden that 
poses a significant risk to health, and then develop frontline interventions and 
partner with countries to disseminate and implement the interventions (WHO 
2017a). The first Global Patient Safety Challenge aimed to reduce healthcare 
infections through improved hand hygiene (Clean Care is Safer Care in 2004). 
The second one concerned risks associated with surgery (Safe Surgery Saves 
Lives in 2008). The third Global Patient Safety Challenge, released in 2017, 
focuses on medication safety (WHO 2017a). The goal of the “Medication 
without Harm” program is to reduce the level of severe avoidable harm related 
to medication by 50% over 5 years, globally. The Challenge focuses on 
improving medication safety by strengthening the systems for reducing 
medication errors and avoidable medication-related harm. The key areas of 
the challenge are high-risk situations, polypharmacy, and transitions of care. 
High-risk situations include high-risk settings, e.g., hospital settings with 
more serious clinical situations and the use of more complex medications, 
high-risk patients, e.g., young children, older adults, patients with 
concomitant kidney or liver disease and high-alert medications associated 
with a high risk of severe harm if used improperly.  
2.1.2.1 National level
Global patient and medication safety trends and their launch in Europe 
worked as a driving force for the initiation of the work undertaken in Finland 
in the early 2000s (Airaksinen et al. 2012; Holmström 2017; Schepel 2018). 
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The early phase medication safety work in Finland focused on adopting the 
prospective risk management approach through “Swiss Cheese thinking”. This 
may be due to the fact that Finland was an active member in the Council of 
Europe’s (CoE) expert groups on patient and medication safety in 2003–2006 
(Council of Europe 2006a, 2006b; Airaksinen et al. 2012). The CoE 
recommendations on medication safety inspired the National Centre for 
Pharmacotherapy Development (Rohto) to establish a multidisciplinary 
working group on medication safety in 2004. The working group developed a 
Finnish glossary of terms related to patient and medication safety using a 
systems approach (Stakes & Rohto 2006; Toivo & Airaksinen 2006). The 
glossary was based on the glossary published as part of the CoE medication 
safety report (Council of Europe 2006b) and it is still widely used.  
Another remarkable step in the early phase of systems-based medication 
safety work in Finland was the development of a guide of safe medication 
practices in health care organizations (Ministry of Social Affairs and Health 
2006). The core of the guide was instructions to create a unit-based 
medication safety plan which describes in-house safe medication practices. 
The plan was recommended to include a description of the medication use 
processes and medications in use in the unit, as well as competences, 
responsibilities, and tasks of the staff regarding safe medication management. 
The Safe Pharmacotherapy Guide emphasized learning from MEs through a 
systems approach (Ministry of Social Affairs and Health 2006; Airaksinen et 
al. 2012). The Guide was updated in 2015 and the third version is currently 
underway (Finnish Institute for Health and Welfare 2015). The organization-
based medication safety plans became obligatory in 2011, as part of patient 
safety plans (Health Care Act 1326/2010). Establishment of the medication 
safety plans has been supported by, e.g., audit tools that assist in identifying 
areas in medication management processes that need improvement (Teinilä et 
al. 2012; Celikkayalar et al. 2016; Suvikas-Peltonen et al. 2016).  
Crucial for the successful implementation of medication safety initiatives 
in Finland has been the fact that the medication safety work has been closely 
integrated into patient safety work since the beginning. The establishment of 
the National Patient Safety Network (2005) and the Patient Safety Steering 
Group (2006) by the Ministry of Social Affairs and Health were important first 
steps in this respect (Ministry of Social Affairs and Health 2009b; Airaksinen 
et al. 2012; Holmström 2017). The Patient Safety Network comprised of 
approximately 200 members representing healthcare professionals and 
providers, patients, non-governmental organizations, authorities, researchers, 
and educators.  
The mandate of the MSAH Patient Safety Steering Group 2006–2009 was 
to promote patient safety and to coordinate initiatives at national level. The 
key targets of the Steering Group were to establish the first national patient 
safety strategy and guidelines for reporting adverse events in health care 
(Holmström 2017). In its final report, the Steering Group emphasized the 
importance of a prospective approach in promoting patient safety (MSAH, 
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2009b). An important action was the launch of the reporting system of adverse 
events (HaiPro) in 2007, for the purpose of learning from errors and near 
misses. HaiPro is still widely in use in health care organizations and has 
provided valuable information on safety risks in Finnish health care 
(Härkänen 2014; Holmström 2017; Laatikainen 2020). As it also includes 
information on medication errors, it has helped to understand the magnitude 
of medication safety risks as part of all adverse events (Ruuhilehto et al. 2011; 
Härkänen 2014; Holmström 2017; Laatikainen 2020). Learning from 
retrospectively reported safety incidents has laid the foundation for 
prospective medication risk management actions (i.e., systemic defenses), 
particularly in hospitals. A good example of the earliest actions in this respect 
is establishing guidelines for safe use of high-risk medications (Tyynismaa et 
al. 2017; Schepel et al. 2018) . The challenge is that HaiPro is still primarily in 
use in inpatient care units: safety data is missing from outpatient care despite 
that most of the medicines are used in this context.  
A major effort of the Patient Safety Steering Group was the development of 
the first National Patient Safety Strategy (covering 2009–2013) (Ministry of 
Social Affairs and Health 2009). The goal was to use the Strategy as a vehicle 
for integrating patient safety into the existing healthcare structures. The 
integration was enacted in 2011 through the new Health Care Act (1326/2010, 
§8). 
The Finnish Society for Patient Safety was founded in 2010 to implement 
patient safety initiatives (Holmström et al. 2015b). The society has a special 
section on medication safety.  
Most recently, many of the challenges in managing medication risks have 
been addressed in the Rational Pharmacotherapy Action Plan 2018–2022, 
established in 2018, as well as in its implementation program (roadmap) by 
2030 (Ministry of Social Affairs and Health 2018, 2019). 
Community pharmacies have been actively involved in medication safety 
work. Pharmacies ran a national Medication Safety Program (APILA 2012–
2015) as part of nationally coordinated Patient Safety Program aimed to 
implement the first patient safety strategy (THL 2011–2014) (Airaksinen et al. 
2012). The goals of the APILA Program were two-fold (Airaksinen et al. 2012; 
Kuitunen et al. 2014). First, the goal was to promote medication safety within 
community pharmacies by improving their internal systems and processes. 
The second goal was to contribute to medication management systems and 
processes in primary care to improve medication safety. 
2.1.3 KEY CONCEPTS OF MEDICATION SAFETY
 
The Council of Europe’s working group on medication safety conducted an 
extensive inventory of concepts related to the systems approach to patient and 
medication safety (Council of Europe 2006b). The Council of Europe glossary 
was recommended to be translated into national languages for creating 
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awareness and establishing shared understanding of key patient safety 
concepts among healthcare providers. A condensed version was published in 
Finland in 2006 (Stakes & Rohto 2006; Toivo & Airaksinen 2006). 
The Finnish glossary illustrated the core elements of patient safety as 
presented in Figure 2 (Stakes & Rohto 2006; Toivo & Airaksinen 2006). Safety 
of pharmacotherapy was divided into product safety (i.e., drug safety) and 
process safety (i.e., medication safety). The term ‘drug safety’ was 
recommended to be used when evaluating adverse events during clinical trials, 
and when evaluating adverse drug reactions (ADRs) of correctly prescribed, 
dispensed and administered drugs (Council of Europe 2006b). Thus, the 
concept of drug safety relates to the safety of pharmaceutical products, 
focusing on adverse drug reactions (ADRs) which are studied with pre- and 
postmarketing activities in pharmacovigilance.  
On the other hand, medication safety (i.e., process safety) refers to 
managing medication errors (MEs) which are defined as unintended mistakes 
in the medication use process caused by omission (a mistake caused by not 
doing something that should have been done) or commission (a mistake 
caused by doing something wrong) (Figure 2), (Council of Europe 2006b; 
Stakes & Rohto 2006; Toivo & Airaksinen 2006). The CoE used the US 
definition of medication errors, which has been widely used internationally 
since its launch in 1998 (National Coordinating Council of Medication Errors 
Reporting and Prevention 1998). According to the definition, an ME is “any 
preventable event that may cause or lead to inappropriate medication use or 
patient harm while the medication is in the control of the healthcare 
professional, patient, or consumer. Medication errors may occur during any 
stage of the medication use process, e.g., when prescribing, dispensing or 
administering a medicine. Such events may relate to professional practice, 
healthcare products, procedures, and systems, including prescribing, order 
communication, product labelling, packaging and nomenclature, 
compounding, dispensing, distribution, administration, education, 
monitoring, and use”. A near miss (called also a close call or a potential adverse 
drug event), is an incident that has the potential to cause a serious medication 
error or adverse drug event, yet did not, either by chance or through timely 
preventive intervention (Figure 2) (Council of Europe 2006b). An adverse 
drug event (ADE) is defined as “any injury occurring during the patient’s drug 
therapy resulting from either appropriate care, or from unsuitable or 
suboptimal care” (Council of Europe 2006b). The definition of ADE includes 
ADRs and MEs. 
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Figure 2 Terms related to patient safety and medication safety as part of it (adapted from 
Stakes & Rohto 2006) 
Figure 2 remains valid for outlining patient and medication safety 
concepts, even though it was created in 2006. However, there has been, for 
example, integration of ME and ADR concepts in EU pharmacovigilance 
legislation since then. The current pharmacovigilance legislation was 
approved in 2010 and it came into effect in July 2012 (Directive 2010/84/EC 
and Regulation (EC) 1235/2012). The legislation introduced significant 
changes in ADR management (Santoro et al. 2017; Inácio 2018). One of the 
biggest changes relates to the widening of the legal definition of an ADR. An 
ADR is currently defined as a response to a medicinal product which is noxious 
and unintended, arising from the use of the medicinal product within or 
outside of marketing authorization, or from occupational exposure. The use 
outside of marketing authorization covers off-label use, overdose, misuse, 
abuse, and medication errors (European Medicines Agency 2017). 
2.1.4 PROSPECTIVE MEDICATION RISK MANAGEMENT 
Retrospective medication error reporting and analyzing medication error 
reports for learning purposes have been fundamental for understanding 
medication use processes and related patient safety risks in various health care 
settings (Kohn et al. 2000; Härkänen 2014; Council of Europe 2006a and b; 
Holmström 2017; Schepel 2018; Laatikainen 2020). Learning from 
medication errors and near misses has led to the restructuring of medication 
use processes and building up of new systemic defenses or strengthening 
existing ones in order to prevent risks and errors (Figure 2). Thus, an 
increasing shift towards prospective risk management can be seen in patient 
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and medication safety initiatives, although retrospective error reporting is still 
needed and recommended as part of risk management (e.g., WHO 2017). 
Various prospective risk management tools, including drug-drug interaction 
screening tools, criteria for potentially inappropriate medicines for older 
adults and various decision support systems, have been developed and widely 
implemented. 
The WHO’s Medication Without Harm program is a good demonstration 
of the current prospective risk management shift and its priority areas (WHO 
2017). The program has prioritized major risks and the best evidenced actions 
for their prevention. The risks seem to be universal, regardless of the health 
system.  
One of the core risk areas prioritized by the WHO is geriatric 
pharmacotherapy (WHO 2017). The evolution of prospective risk 
management methods and tools has been fast, especially over the last few 
decades, with increasing evidence of medication safety risks in this growing 
population segment (Airaksinen et al. 2012; Holmström 2012; Dimitrow 
2016). Among the useful tools to prevent medication risks have been explicit 
and implicit criteria to decrease prescribing of potentially inappropriate 
medicines (PIMs) for older adults (Beers et al. 1991; Spinewine et al. 2007b; 
Dimitrow et al. 2011; Lucchetti & Lucchetti 2017; American Geriatrics Society 
2019). In order to be effective, these criteria need to be implemented in routine 
clinical practice throughout health care. Recently, the implementation has 
been facilitated through electronic medication risk management databases, 
software applications and clinical decision support systems (CDSS), which 
have dramatically evolved over the last decade (Schiff et al. 2016). The 
databases and CDSS systems can prospectively detect PIMs and other 
medication safety risks, though qualified health care professionals are needed 
to make the final decision using clinical judgement based on comprehensive 
patient information.  
Finland is one of the countries with advanced national health portals, 
databases and prospective screening systems for managing medication-
related risks (Heikkilä et al. 2006; Dimitrow et al. 2014; Duodecim 2019). 
Within less than 20 years, a wide range of medication risk management tools 
have been developed, with the Finnish Medical Society Duodecim playing a 
major role in their development (Duodecim 2019). These tools are widely 
available in Finnish health care, including community pharmacies. Efficient 
use of these modern tools and skill-sets requires coordinated medication 
management processes in different healthcare settings. However, this is not 
the case in many countries, including Finland (Kallio et al. 2016).  
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2.2 PATIENT AND MEDICATION SAFETY IN PRIMARY 
CARE
Globally, primary care forms the foundation of any health system, and the 
majority of people in need of medical care are managed in primary care units 
(WHO 2012; Panesar et al. 2016; WHO 2016a). Therefore, the quality and 
safety of care in primary care is a major health policy and public health issue. 
However, patient and medication safety initiatives and research have mainly 
focused on hospital care (WHO 2016a), although understanding the 
magnitude and nature of safety risks in primary care has a growing 
importance. 
This chapter briefly discusses the structure and function of primary care in 
Finland, and its operation in relation to specialized care. Thereafter, patient 
and medication safety in primary care will be addressed in a global context in 
the light of the challenges raised by the WHO. 
2.2.1 PRIMARY CARE IN THE FINNISH HEALTH SYSTEM AND 
SAFETY CHALLENGES
In Finland, the health care system is based on a public system, which is 
complemented by private and occupational healthcare services. The services 
are divided into primary care and specialized care services. Municipalities are 
responsible for organizing primary healthcare services, which are mainly 
provided by municipal health centers (Health Care Act 2011). Secondary 
special healthcare is organized by central hospitals, each of them located in 
their own hospital districts (n=21) owned by federations of municipalities 
(Keskimäki et al. 2019). For special tertiary healthcare, Finland is divided into 
five areas of responsibility (Helsinki, Turku, Tampere, Kuopio and Oulu), each 
with a university hospital. Primary care carries the main responsibility of care, 
and all patients admitted to secondary or tertiary care need a referral from 
primary care. The care is coordinated by the patient’s primary care physician.  
Municipalities (i.e., local authorities) are responsible for organizing and 
financing primary and specialized care in the public healthcare system. The 
system is funded by multiple funding sources: municipalities, government, 
employers, and through taxation of residents as well as service fees for services 
users (Keskimäki et al. 2019; Ministry of Social Affairs and Health 2020). 
Funding channels are separate for primary and specialized health care. 
Legislation and general policy guidelines are prepared at the national level, 
with municipalities and hospital districts having a large degree of freedom in 
the organization of services. Three main acts, the Primary Health Care Act 
(1972), the Act on Specialized Medical Care (1991) and the Health Care Act 
(2010), set the framework for regulation and governance of health services in 
Finland (Keskimäki et al. 2019). 
All residents are equally entitled to public, municipal primary care. Primary 
care is provided by health centers, which provide primary curative, preventive 
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and public health services to its population. Typically, health centers provide 
the following services: 1) ambulatory curative care, both for acute and chronic 
patients; 2) preventive services, including maternity and child clinics; 3) home 
nursing for older people or for selected groups of chronic patients; 4) dental 
health services; 5) rehabilitation in various forms; and 6) mental health 
services and substance abuse services (Hetemaa 2018). The most typical 
patients of health centers are the very young and elderly, and those of lower 
socioeconomic or educational levels (Kestilä & Karvonen 2019). This is due to 
the co-existing occupational and private health care systems.  
Pharmacotherapy for primary care outpatients is dispensed from private 
community pharmacies and from university pharmacies owned by the 
University of Helsinki and the University of Eastern Finland (altogether 815 
pharmacy outlets in 2018). The community pharmacy system is highly 
regulated to ensure its commitment to the national health policy goals 
(Ministry of Social Affairs and Health 2018). By law, community pharmacies’ 
main functions are to ensure an adequate supply of prescription and 
nonprescription medicines, and their safe, appropriate and economical use for 
the general public (Medicines Act 395/1987). 
In pharmacotherapy, the key challenges in primary care relate to the lack 
of coordination of care, as identified in the National Medicines Agency’s 
program to optimize medicine use among older adults (Kallio et al. 2016; 
Kumpusalo-Vauhkonen et al. 2016). Information on individual patient’s 
medications and diagnoses is scattered and may vary at different levels of the 
public health service, and information does not transfer between health care 
providers involved in care team (Kallio et al. 2016).  
Even though the importance of an accurate and up to date medication list 
is acknowledged, many patients do not yet have it (Sinnemaki et al. 2014; 
Kekäle 2016; Schepel et al. 2019).  
With long-term medications, major development needs identified in 
medication use process relate to poor access to patient information and its 
transfer in healthcare, particularly the lack of reconciled medication lists and 
electronic health records; poorly functioning medication use process in home 
care and social care units; and limited patient involvement in their care 
(Mononen et al. 2020). Furthermore, the system-based factors have found to 
lead to a situation where no one truly takes comprehensive responsibility for 
patients’ medications, leading to medication safety risks (Kallio et al. 2016, 
Kumpusalo-Vauhkonen et al. 2016, Mononen et al. 2020).  
These identified challenges are considered in the ongoing Rational 
Pharmacotherapy Action Plan 2018–2022 by the Ministry of Social Affairs and 
Health (Ministry of Social Affairs and Health 2018). 
2.2.2 PATIENT SAFETY RISKS IN PRIMARY CARE – A GLOBAL VIEW
Every day, millions of people across the world use primary care services, as 
they provide an entry point into the health system (WHO 2016a).  Good quality 
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and accessible primary care may lead to fewer avoidable hospitalizations, 
while unsafe primary care can cause avoidable illness and harm, leading to 
unnecessary hospitalizations and in some cases, disability, and even death 
(WHO 2016a). Therefore, the potential and necessity to reduce primary care-
related harm is considerable. 
To date, however, most patient safety research has focused on hospital 
settings, and not on primary care where majority of health care is actually 
delivered (WHO 2016a, WHO 2017). There are differences in the type of 
clinical problems faced, the role of the patient, classes of medications used and 
the organization of services in primary care compared to hospital settings. This 
means that the risks posed in primary care and the solutions required may 
differ from those in hospital settings.  
The global shift towards primary care-based care structures has been 
supported by the WHO in low-income and middle-income countries and by 
economic pressures in industrialized nations (WHO 2012). Therefore, it has 
become essential to advance the understanding and awareness of the risks to 
patients in primary care, the magnitude and nature of preventable harm due 
to unsafe practices, and effective mechanisms to protect patients. Recognizing 
the limited information available on primary care, the WHO set up a Safer 
Primary Care Expert Working Group in 2012 (WHO 2012). The Working 
Group reviewed the literature, prioritized areas needing further research, and 
published essential next steps (WHO 2012). Following this, much work has 
begun, e.g., with increasing research evidence and providing guidance for key 
safety risks in primary care (Panesar et al. 2016, WHO 2016a). The WHO 
developed a Technical Series on Safer Primary Care with technical reports 
providing practical guidance of identified key safety risks and their 
management. The Series consists of nine monographs related to patients 
(WHO 2016b), health workforce (WHO 2016c, 2016d), care processes (WHO 
2016e, 2016f, 2016g, 2016h, 2016i) and tools and technology (WHO 2016j). 
The reports explore the magnitude and nature of harm and provide some 
potential solutions for improving safety in primary care. The topics covered in 
the series are: 
x Patient engagement (WHO 2016b) 
x Education and training (WHO 2016c) 
x Human factors (WHO 2016d) 
x Administrative errors (WHO 2016e)  
x Diagnostic errors (WHO 2016f) 
x Medication errors (WHO 2016g) 
x Multimorbidity (WHO 2016h) 
x Transitions of care (WHO 2016i)  
x Electronic tools (WHO 2016j). 
 
These topics cover a wide range of system-based factors, as well as patient- 
related factors contributing to safety in primary care. Patient engagement was 
identified as a key area when aiming to reduce medication-related problems. 
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The Patient Engagement report highlights educating patients and health care 
providers and encouraging people to ask questions or speak about their 
concerns (WHO 2016b). The Education and Training report focuses on 
competences of primary care providers, highlighting shortcomings in 
education requiring action related to medication safety (WHO 2016c). The 
Human Factors report addresses the safety problem and highlights systems-
based thinking in risk management and the importance of building systemic 
defenses so that errors are less likely to result in harm (WHO 2016d). The 
Medication Errors report brings up injection use, pediatrics, and care homes 
as key areas requiring special consideration (WHO 2016g). Multimorbidity 
report highlights the need for systems approach in the care of people with 
multiple conditions and polypharmacy (WHO 2016h). Enhanced 
communication and coordination across different health care system levels is 
needed, as well as self-management support. People with multiple conditions 
may need specialist care with some health issues, but their overall health care 
needs are likely to be best met by medical generalists. 
The WHO primary care document highlights that understanding the 
epidemiology of errors in the primary care context is crucial to understanding 
risk factors and developing strategies to reduce the risk of iatrogenic harm 
(WHO 2012). Thus, the WHO commissioned an extensive systematic review 
to investigate patient safety incidents in primary care and the resulting severe 
harm (Panesar et al. 2016). A systematic literature review, with 18 databases, 
was conducted on studies published between January 1980 and July 2014. The 
number of screened articles was 61,521, of which nine systematic reviews and 
100 primary studies were included. Of the studies, 36% were from the USA or 
Canada, 39% from Europe, 13% from other OECD countries and 12% from 
non-OECD countries. 
The systematic review by Panesar et al. (2016) suggested that patient safety 
incidents are relatively frequent in primary care, though most of them do no 
result in severe harm to patients. Studies reported between < 1 and 24 patient 
safety incidents per 100 consultations. Due to the heterogeneity of studies, it 
was not possible to provide a single value of the frequency of incidents, but a 
median of around 2–3 incidents per 100 consultations/patient records was 
suggested.  
Based on studies that had documented the type of safety incidents, the 
following three most common safety incident categories were identified: 1) 
administrative and communication incidents; 2) diagnostic incidents; and 3) 
prescribing and medication management incidents (Table 1). Studies based on 
retrospective patient record reviews had a median estimate of 4% of all 
documented incidents being associated with severe harm, defined as 
significantly impacting on a patient’s wellbeing, including long-term physical 
or psychological issues or death (range <1% to 44%). Diagnostic and 
medication-related incidents were most likely to result in harm and severe 
harm to patients.  
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Table 1 Three most common types of patient safety incidents in primary care, identified in the 
systematic review by Panesar et al. 2016
Administrative and
communication incidents 
Diagnostic incidents Prescribing and medication
management incidents 
Administration incidents
occurred in at least 6% of
patient contacts.
Related to:
-Incomplete, unavailable,
unclear or incorrect
documentation
-Inappropriate monitoring of
laboratory tests
-Insufficient communication
between providers or
between professionals and
patients 
Diagnostic incidents were
responsible for 4% to 45% of
all reported patient safety
incidents.
Related to:
-Misdiagnosis
-Missed diagnoses
-Diagnostic incidents were
most commonly associated
with harm to patients, one
study found that 58% of
reported misdiagnoses were
associated with harm
(severity not described).  
Prescribing and medication
management incidence rate
was between 1 and 90 out of
100 prescriptions (n=35
studies), being higher in the
studies focusing on, e.g.,
older adults or those with
polypharmacy.
Related to (e.g.,):
-Strength/dose
-Dosage from
-Length of treatment
-Prescriptions without stating
the daily dosage
8-11% of medication 
incidents were reported to 
result in harm (of any 
severity) 
 
Safety of primary care compared to hospitals 
In their systematic review, Panesar et al. (2016) indicated the frequency of 
patient safety incidents in primary care to be 2–3 incidents for every 100 
consultations/records reviewed. The frequency is generally lower than the 
estimated 9-10% of patients experiencing adverse events in hospitals (de Vries 
et al. 2008; Schwendimann et al. 2018). However, the overall volume of people 
using primary care is notably higher than that of using hospital services in 
many parts of the world. Thus, even though the rate of incidents may be lower, 
this produces a considerable burden of harm globally (Panesar et al. 2016). 
Since the evidence on primary care safety is scarce, estimates should be treated 
with caution. They may underestimate the actual risk rate.  
However, some important aspects need to be taken into consideration in 
Panesar et al.'s estimates. They defined patient safety incident as “any 
unintended or unexpected incident that could have or were judged to have led 
to patient harm”. Within this broad definition, however, the authors chose to 
include only incidents of commission rather than omission (Sarkar 2016). Due 
to this, they counted events where the wrong course of action was undertaken, 
but they did not count events where the right course of action was not 
undertaken. Omissions are found to be a major cause for missed and delayed 
diagnoses (Singh et al. 2013), which Panesar et al. evidenced to be among the 
most harmful of primary care safety incidents. Therefore, this analysis likely 
shows us only the tip of the iceberg (Sarkar 2016).  
Furthermore, in general, medication errors are not reported as 
systematically in primary care as in hospitals (Hakoinen et al. 2017; 
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Holmström 2017). Poor reporting leads to the underestimation of safety risks 
in primary care. For example, in Finland the system for reporting adverse 
events is mainly used in inpatient care institutions and it does not cover all 
outpatient care (Hakoinen et al. 2017, Holmström 2017).  
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2.3 MEDICATION SAFETY RISKS IN OLDER ADULTS IN 
PRIMARY CARE
Studies exploring safety of primary care have highlighted special patient 
groups carrying a higher risk for medication safety incidents. Those are older 
adults and patients taking multiple medications (Panesar et al. 2016; WHO 
2017a). As the proportion of older population (>65 years) is estimated to grow 
markedly, globally, during the following decades, the safety of their 
pharmacotherapy will become even more important (Mair et al. 2017).  
The WHO has recently raised the coordination of care, polypharmacy 
management, and coordination of care for people with multiple illnesses as the 
key global challenges requiring solutions in medication safety (WHO 2017a, 
2018, 2019).  
The model below (Figure 3) summarizes key factors contributing to 
medication safety risks in older adults. The evidence for the model is derived 
from 1) the PCNE Classification for causes leading to drug-related problems 
(Pharmaceutical Care Network Europe Foundation 2017); 2) Basger et al.´s 
aggregated classification system for DRPs and their causes (Basger et al. 
2015); 3) the synthesis of 1) and 2) by Dimitrow (2016) in her academic 
dissertation; 4) presentation of aspects in geriatric pharmacotherapy to 
consider in collaborative comprehensive medication reviews (Leikola 2012; 
Dimitrow 2016); and finally, 5) the WHO’s reports “Medication Errors”, 
“Multimorbidity” and “Administrative Errors” published in the Technical 
Series on Safer Primary Care (WHO 2016e, 2016g, 2016h). 
The following chapters address medication safety risks presented in Figure 
3, and potential tools to manage them as recommended by the WHO or other 
recognized organizations promoting patient and medication safety (National 
Institute for Health and Care Excellence 2015; WHO 2016g, 2017a; Scottish 
Government Polypharmacy Model of Care Group 2018; SIMPATHY 2019; 
WHO 2019).  
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Figure 3 Factors contributing to medication safety risks in older primary care patients (based 
on and modified from Leikola 2012; Basger et al. 2015; Dimitrow 2016, WHO 
2016e, 2016g, 2016h and PCNE 2017). PIM = potentially inappropriate medicine for 
older adults, DDI = drug-drug interaction 
2.3.1 PATIENT-RELATED RISK FACTORS  
Aging, multimorbidities and polypharmacy 
Aging itself is a risk factor for medication safety. This is because aging is 
associated with several physiological changes that influence how medicines 
work in the body and thus how medicines should be used in older people. 
Aging also leads to impaired homeostasis and wide variability in drug response 
between individuals, which makes medicine dosing challenging (Hilmer et al. 
2007). Furthermore, cognitive impairment is common. Despite these common 
features related to aging, older people form a heterogeneous group of 
population, each one having their own mixture of comorbidities and 
disabilities. It has been noted that comorbidities and disabilities correlate with 
age, therefore, older adults have been categorized as the young-old (65–74 
years), the old-old (75–84 years) and the oldest-old (>85 years) (Bernabei et 
al. 2000). However, it is important to remember that the age does not directly 
indicate the health status of an individual old person, but it varies a lot between 
individuals.  
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Older people are prone to multimorbidity (co-existence of two or more 
chronic health conditions), which represents a major challenge in primary 
care, also concerning managing medications (Panagioti et al. 2015). In an 
extensive systematic review covering 75 publications from the years 2002–
2015, patients with multiple long-term conditions and patients with mental-
physical comorbidity were shown to be at heightened risk for patient safety 
failures, such as adverse drug events and medical complications, in primary 
care (Panagioti et al. 2015). Multimorbidity contributes to safety incidents  
which relate to the fact that patients may have to manage polypharmacy, even 
excessive polypharmacy. They may face difficult decisions about self-
management without receiving the communication and support required with 
these demands (WHO 2016h). The frequency and complexity of their 
interactions with health care services, without coordination of care make them 
more vulnerable to failures of care (WHO 2016h).  
Polypharmacy is increasingly prevalent (Saastamoinen and Verho 2015; 
Mair et al. 2017). E.g., in the USA, the prevalence of polypharmacy in older 
people has increased over time, and the national data indicate that 
approximately 39% of older people (>65 years) in the USA took five or more 
prescription medicines in 2011-2012 (Kantor et al. 2015). National data from 
the Irish Longitudinal Study on Ageing have reported polypharmacy (>5 
medications) in 27% of the older population (>54 years) in 2017 (McGarrigle 
et al. 2017). Even though prevalence estimates vary across countries, 
polypharmacy in older people has been recognized as a major and growing 
public health concern worldwide (Mair et al. 2017; WHO 2019). 
Discussions about reducing polypharmacy often suggest a distinction 
between appropriate and inappropriate polypharmacy (Garfinkel et al. 2015; 
Scott et al. 2015; Cadogan et al. 2016). Some authors have defined 
polypharmacy as the use of too many medications (Bushardt et al. 2008). 
Scottish Government Polypharmacy Model of Care Group has defined 
appropriate and inappropriate polypharmacy as follows (Scottish Government 
Polypharmacy Model of Care Group 2018):  
Polypharmacy is appropriate , when (a) all medicines are prescribed for the 
purpose of achieving specific therapeutic objectives that have been agreed with 
the patient; (b) therapeutic objectives are actually being achieved or there is a 
reasonable chance they will be achieved in the future; (c) medication therapy 
has been optimized to minimize the risk of adverse drug reactions (ADRs); and 
(d) the patient is motivated and able to take all medicines as intended (Scottish 
Government Polypharmacy Model of Care Group 2018).  
Inappropriate polypharmacy is present, when one or more medicines are 
prescribed that are not or no longer needed, either because: (a) there is no 
evidence-based indication, the indication has expired or the dose is 
unnecessarily high; (b) one or more medicines fail to achieve the therapeutic 
objectives they are intended to achieve; (c) one, or the combination of several 
medicines cause ADRs, or put the patient at a high risk of ADRs or because (d) 
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the patient is not willing or able to take one or more medicines as intended 
(Scottish Government Polypharmacy Model of Care Group 2018). 
2.3.2 MEDICINE-RELATED RISK FACTORS
Due to age-related body changes, older adults are more prone to adverse 
effects of particular medicines than younger adults are. There is growing 
evidence that certain medicines and medicine groups are harmful (risks 
overweight benefits) in geriatric care and should be preferably avoided 
whenever possible, e.g., benzodiazepines, antipsychotics and strong 
anticholinergics (American Geriatrics Society 2019; Finnish Medicines Agency 
2019). Since the 1990s, several explicit and implicit criteria have been 
established to guide and decrease prescribing of potentially inappropriate 
medicines (PIMs) for older adults (Spinewine et al. 2007a; Dimitrow et al. 
2011; Lucchetti & Lucchetti 2017). One of the earliest, most well-known and 
widely used of these criteria is the Beers criteria (Beers et al. 1991) maintained 
by the American Geriatrics Society (AGS 2019). Beers criteria have also guided 
the Finnish national PIM database Meds75+, launched in 2010 and 
maintained by the Finnish Medicines Agency Fimea (Finnish Medicines 
Agency 2019).  
Drug-drug interactions and cumulative risks (e.g., anticholinergic or 
serotonergic load of medicines) are identified challenges in older adults, 
particularly with polypharmacy (Auvinen et al. 2018; WHO 2019) 
Polypharmacy increases the risk for adverse effects (Gnjidic et al. 2012), which 
can be challenging to identify, and can be misdiagnosed as a new condition 
(Rochon & Gurwitz 1997). When this occurs, it can cause a prescribing 
cascade, where a new medicine is started to manage the adverse effect of 
another medicine (Rochon & Gurwitz 1997; Huh et al. 2019). Older people 
with polypharmacy have an increased risk of experiencing adverse effects, and 
thus prescribing cascades (Hilmer & Gnjidic 2009). The prescribing cascade, 
in turn, can increase the number of medicines used and contribute to 
overprescribing and medication-related burden (Mohammed et al. 2016). 
Clinical guidelines are developed to enhance best evidenced care in 
diseases and to harmonize treatment practices. Thus, they are important tools 
in prospective medication risk management. Despite advances in 
pharmacotherapy, the availability of clinical guidelines for older adults with 
multiple morbidities is limited (Boyd & Fortin 2010; WHO 2019). In Finland, 
a wide range of disease-specific current care guidelines exist, but special 
current care guidelines on geriatric pharmacotherapy are missing (Kivelä & 
Räihä 2007; Dimitrow et al. 2013). Prescribing for multimorbid older adults is 
largely based on evidence-based guidance for single diseases, which does not 
generally take multimorbidity into account. This may lead to a situation in 
which patients are prescribed medicines recommended by a number of 
disease-specific guidelines which in combination makes the management of 
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any single disease or the whole medication challenging, and may even lead to 
patient harm (Molokhia & Majeed 2017; WHO 2019). 
According to estimates, as many as 11% of unplanned hospital admissions 
are caused by medication-related harm, 70% of these incidents concerning 
multimorbid older adults with polypharmacy (Kongkaew et al. 2013). A recent 
study from Finland estimated that 23% of the unplanned geriatric hospital 
admissions resulted from adverse drug events (Laatikainen 2020).  
2.3.3 HEALTH CARE PROFESSIONAL RELATED RISK FACTORS
A number of factors related to healthcare professionals have been 
identified to contribute to medication safety risks in older adults. Lack of 
interprofessional collaboration is a key challenges (Kallio et al. 2016;WHO 
2016g; WHO 2016h). On the other hand, gaps in geriatric pharmacotherapy 
competences and skills affect all healthcare professionals and care provided in 
both primary and secondary care, as well as in social services such as nursing 
homes (Juola et al. 2015; Dimitrow 2016; WHO 2016g, Mononen et al. 2020).  
In addition to geriatric pharmacotherapy, knowledge and understanding of 
the principles of systems-based risk management is essential. The following 
factors have been associated with health care professionals that may 
contribute to medication errors (WHO 2016g): 
x Lack of therapeutic training 
x Inadequate drug knowledge and experience 
x Inadequate knowledge of the patient 
x Inadequate perception of risk 
x Overworked or fatigued health care professionals 
x Physical and emotional health issues 
x Poor communication between health care professionals and patients 
 
In Finland, the current social and health care system does not have an 
appropriate, built-in system to ensure adequate competences of health care 
professionals. This also concerns adequate pharmacological knowledge, 
overall management of medication therapy and the safety culture, including 
application of risk management principles to pharmacotherapies (Hakoinen 
et al. 2017). Furthermore, there is no re-accreditation system in Finland; 
medical and other health care professionals are themselves responsible for 
engaging in life-long learning and continued education to keep up their 
competences (Keskimäki et al. 2019). According to the legislation, employers 
are responsible for providing professional training, though the 
implementation varies across health care organizations. 
2.3.4 SYSTEM-RELATED RISK FACTORS
Systems thinking has been widely recommend as a preferable approach to 
manage patient and medication safety risks. This also applies to implementing 
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safe pharmacotherapy in older adults. This requires a good safety culture and 
leadership, a clear description of medication processes and responsibilities of 
professionals involved (Reason 2000; WHO 2017a, 2017b). Medication safety 
research has largely focused on describing errors – what kinds of errors occur 
and how many, where in the process, and for whom (Assiri et al. 2018). 
However, in order to develop the system, it is crucial to understand the 
underlying system-related factors. The WHO highlights the systems approach 
in developing safer health care, and has raised the following contributing 
factors associated with medication errors in primary care (WHO 2016e, WHO 
2016g, WHO 2017a): 
 
1) Contributing factors associated with the work environment (WHO 
2016g)  
x Workload and time pressures 
x Distractions and interruptions 
x Lack of standardized protocols and procedures 
x Insufficient resources 
x Issues with the physical work environment 
 
2) Contributing factors associated with computerized information 
systems (WHO 2016g)  
x Difficult processes for generating first prescriptions or repeat 
prescriptions 
x Lack of accuracy of patient records 
 
In Finland, the same kinds of system-related risk factors have been identified 
as contributing to medication safety risks in older patients (Kallio et al. 2016, 
Ministry of Social Affairs and Health 2018). 
 
Medication discrepancies  
Even though the importance of an accurate and reconciled medication list is 
acknowledged, many patients do not have such a list including all the 
medicines in use (Sinnemaki et al. 2014; Kekäle 2016; Schepel et al. 2019). The 
challenge is global and various procedures have been developed to address it 
(The European Union Network for Patient Safety and Quality of Care 2012; 
Kwan et al. 2013; WHO 2017a). The maintaining of an accurate medication list 
is challenging when various health care providers and organizations 
participate in the care of a patient (e.g., physicians with different specialties, 
from different public and private organizations). Non-prescribed medicines 
(OTC medicines), herbal products and food supplements are often missing 
from the lists even though they may have harmful interactions with the 
prescribed medications.  
The prevalence of medication discrepancies have been studied especially in 
hospital settings, to occur in up to 70% of patients at discharge (Wong et al. 
2008). In a Finnish study, discrepancies were found to occur in 73% of primary 
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care medication lists (n=174) (Pottonen 2014). In a study conducted in two 
emergency departments in the Helsinki University Hospital (HUS) and 
Kuopio University Hospital (KUH), discrepancies occurred with almost all of 
the patients (age ≥65 years, living at home and using ≥6 medicines): 100% of 
HUS (n=75) and 99% of KUH (n=75 ) patients had discrepancies in their 
admission medication charts (Schepel et al. 2019). 
In Finland, this risk has been identified in the Rational Pharmacotherapy 
Action Plan (Ministry of Social Affairs and Health 2018). One of its primary 
goals is to ensure an accurate medication list for all medicine users. The 
mechanism for establishing the list will be built into the national patient data 
repository (Kanta), including prospective and retrospective data on electronic 
prescriptions (Kanta 2020). Since 2017, all prescriptions in Finland have been 
electronically managed via Kanta. 
 
Deficiencies in monitoring pharmacotherapies 
Monitoring of pharmacotherapies is an essential part of the medication use 
process and deficiencies in monitoring often stem from system-related factors. 
Without proper monitoring, the length of medication therapy may be 
unintentionally prolonged, the expected therapeutic effect may be suboptimal 
or medicines with clinically significant adverse effects are continued without 
proper assessment. This has been brought up in Finland, as well as globally 
(Panesar et al. 2016; WHO 2017a; Ministry of Social Affairs and Health 2018).  
In primary care, nurses and practical nurses are often in charge of 
monitoring medication therapies (Dimitrow et al. 2014). In many 
organizations, particularly within home care and nursing homes, physicians 
meet the patients infrequently and mainly obtain information on a patient’s 
health status and changes thereof from nurses. This leads to risk of missing 
information or changed information. For this reason, nurses need to be 
properly instructed to know precisely which issues to monitor with patients’ 
medications and/or health status and why, and what to do if problems occur, 
e.g., when to consult the physician.  
Community pharmacies could be more involved in the monitoring of 
medication therapies. They see people with chronic conditions at least every 
three months when refilling their prescriptions. These encounters could form 
regular checkpoints to be integrated in the patient's care path. Pharmacy 
owners have indicated willingness to build their capacities to this direction 
(Jokinen et al. 2019, Jokinen 2020). However, progress has been slow in 
Finland and elsewhere, despite the recognized need for improved monitoring 
of medication therapies to ensure desired treatment outcomes. 
 
Lack of coordination of care 
Challenges with coordination of care are significant system-related 
problems appearing in any health system, and are acknowledged globally 
(WHO 2018). Coordination of care, or care coordination, is defined by the 
WHO as “a proactive approach to bringing together care professionals and 
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providers to meet the needs of service users to ensure that they receive 
integrated, person-focused care across various settings” (WHO 2018). This 
means that patients’ needs and preferences are known and communicated at 
the right time, to the right social/health care professionals, and that this 
information is used to guide the delivery of safe, appropriate, and effective care 
(The Agency for Healthcare Research and Quality 2018). Transitions of care 
are particular risks, often producing medication discrepancies (WHO 2016i).  
In Finland, for example, the lack of coordination was identified as the 
major challenge in the National Medicines Agency’s program to optimize 
medicine use in older adults (Kallio et al. 2016; Kumpusalo-Vauhkonen et al. 
2016). The system-based factors were found to lead to a situation where no 
one in the care team can concentrate on an individual patient’s medications. 
Such “dis-organization” is stated to be particularly challenging and risky for 
patients with a complex situation consisting of several chronic conditions, 
taking multiple medications, often prescribed by several specialists who are in 
little or no contact with one another — a recipe for pharmacological chaos 
(Avorn 2010). 
A recent Canadian qualitative study reported on patient experiences, which 
well represents problems in care coordination (Ploeg et al. 2019). The 
experience of living with multiple chronic conditions is complex and multi-
faceted. However, these patients often experienced the services to be 
piecemeal, focusing on single physical conditions rather than on the 
interaction of all their chronic conditions. They felt that health care 
professionals seldom attended to their holistic psychological and social needs 
as a person living with multiple chronic conditions. 
Despite the challenges in the coordination of medication management 
processes in primary care, little research has focused on prospective 
medication risk management of older adults in this setting. Coordination of 
care of home-dwelling older adults has been studied from a nursing approach 
with various interventions focusing on disease management, transitional care 
and self-management education programs (Marek et al. 2010; Kim et al. 
2016), though a prospective medication risk management approach has been 
out of their scope.  
2.3.5 MEDICATION SAFETY IN HOME CARE
Most older people live on their own in their own homes. If their health 
condition and functional ability deteriorate, the first service option in primary 
care is often support by home care services. In Finland, 11% of those aged >75 
years or over received regular home care services in 2018 (Finnish Institute 
for Health and Welfare 2019). The care in home care in primary care mainly 
relies on nurses and practical nurses with home visits. Frequency of home 
visits depends on client’s need, varying from e.g., once a week to four times per 
day (Dimitrow et al. 2014; Keskimäki et al. 2019). Contributions of carers and 
family members are also important. Medicines for home care clients are 
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dispensed from community pharmacies: either the client, family member or 
practical nurse visits pharmacy. Medicines can also be supplied with 
automated dose dispensing in two-week period (Sinnemäki et al. 2014). This 
section discusses medication safety risks in older adults identified in the home 
care setting in primary care. 
Medication safety research on older adults in primary care has focused on 
institutional settings, such as nursing homes (Storms et al. 2017; Devik et al. 
2018). Home care clients live alone or with a spouse or other caregiver, which 
may contribute to different medication safety risks. A recent Norwegian study 
described and compared DRPs in older persons across nursing homes and 
home care (Devik et al. 2018). Significantly more DRPs were identified among 
patients receiving home care than patients living in nursing homes. While 
patients living in nursing homes were often undermedicated, documentation 
discrepancies were more common in home care (Devik et al. 2018). 
Furthermore, home care personnel may face complex situations and have 
to make decisions on their own. They also carry a remarkable responsibility 
for the care, as the home care clients usually meet with their physician 
infrequently (Devik et al. 2018; Meyer-Massetti et al. 2018). Home care nurses 
and practical nurses are expected to monitor the benefits and risks of 
medications, to identify clinically significant DRPs and to communicate them 
to the physician. However, in many cases, their education and skills are not 
adequate to fulfill these demanding tasks (e.g., Mononen et al. 2020). This has 
led to the development of various DRP screening tools that assist in 
medication risk assessment (Dimitrow et al. 2014; Puumalainen et al. 2019).  
Only few recent systematic reviews focus on home care patients’ care in 
general (Kivimaki et al. 2019) or more specifically on their medications 
(Meyer-Massetti et al. 2018). Kivimäki et al. (2019) systematically reviewed 
literature on safety of older people at home (Kivimaki et al. 2019). They 
identified four dimensions of safety at home, namely 1) physical, 2) social, 3) 
emotional and mental, and 4) cognitive safety. However, the study did not 
consider medications.  
Meyer-Massetti et al. (2018) evaluated evidence on the incidence and types 
of DRPs in home care (Meyer-Massetti et al. 2018). Altogether 44 studies were 
included in their systematic review, more than half (n=23) originating from 
the US. The most commonly reported DRPs were the use of PIMs, medication 
errors (mostly medication-related discrepancies), adverse events, and drug-
drug interactions (Table 2). The study indicated a high frequency of DRPs 
among home care patients – up to 50% of patients being influenced by DRPs. 
The authors concluded that medication errors were more frequently reported 
in the home care setting compared to inpatient care. 
Polypharmacy and increasing age of the patients were identified as risk 
factors for DRPs in home care settings (Meyer-Massetti et al. 2018). 
Polypharmacy was associated with an increased prevalence of medication 
discrepancies, DDIs and use of PIMs. Of the patients, only 48% were identified 
to have a reconciled medication list. The rate for adherence problems was 27%.  
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System-related factors, such as missing interdisciplinary team work and a 
lack of medication reviews, were also identified as contributors to DRPs 
(Meyer-Massetti et al. 2018). Home care providers were identified to often face 
acute medical situations where they have to make decisions independently. 
These situations often relate to care transfers that are rushed, resulting in 
limited time for adequate discharge planning. New enrollment in home care 
was associated with an increased risk for potential DRPs. Several health care 
visits and the use of several health care providers were associated with an 
increased risk for potential DRPs. Furthermore, patients and informal 
caregivers were identified to be critically important partners in medication use 
process which should be better taken into account.  
 
Table 2 The most common types of DRPs identified among home care patients in a recent
systematic review by Meyer-Massetti et al. 2018, covering 44 studies from the 
years 2000–2016
PIMs Medication errors (MEs) ADEs
x PIMS were the
most frequently
observed type of
DRPs
x 19.8–48.4% of
home care
patients were
exposed to PIMs
x Psychotropic
medicines and
opioids were more
likely than other
medicines to be
associated with
DRPs
x Medication discrepancies were found in
53.2–83.0% of patients; e.g., additional
medication, continuation of a
medication that had been discontinued,
discrepancies in dose, frequency, dose
reduction in renal insufficiency
x Incorrect home care medication lists:
50% of patients
x Inappropriate splitting of tablets: 21 out
of 102 patients in one study
x DDIs were rarely studied, once studied
prevalence of 10%–57% was reported
x 40% of MEs were found to clinically 
compromise treatment. Most of the MEs 
were considered preventable 
x ADEs were
identified in 8%
of patients with a
PIM
x 2 % of home
care patients
had medication-
related ADEs
associated with
hospitalization
 
 
 
Home care in Finland 
In Finland, home nursing is provided together with home help services, 
forming an integrated service “home care” targeted to those unable to cope on 
at home on their own (Keskimäki et al. 2019). In 2018, 11% of Finnish older 
adults >75 years received regular home care services (Finnish Institute for 
Health and Welfare 2019).  
Currently, home care services are primarily based on regular, usually daily, 
home visits of home practical nurses (PNs), coordinated by home care nurses. 
These personnel offer practical assistance with everyday tasks that extend to a 
range of medical nursing tasks, such as treating chronic ulcers and, 
administering medications. As practical nurses meet older home care clients 
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regularly, they have a good opportunity to identify and solve potential DRPs 
(Dimitrow et al. 2015).  
However, they do not necessarily have online access to the health portal 
and patient records during the home visits to assist them in decision making 
and documenting observations on the health status of their clients. Usually 
they pass on their findings to the home care nurses, who pass the information 
to the attending physician. Physicians are responsible for medications of home 
care patients, and often they have to make treatment decisions without seeing 
the patient. The hierarchical flow of patient information can lead to situations 
where the information does not reach all professionals involved or the 
information content unintentionally changes along the way (Eloranta et al. 
2009). It is likely that each participating professional interprets and 
communicates the information on the patient’s situation according to own 
educational background and work experience. 
The allocation of physicians’ time for home care patients is limited in 
Finland. It is likely to become even more limited in the future, as the 
proportion of older adults of the entire population is growing (Official 
Statistics of Finland 2020). This is putting more pressures on developing new 
collaborative procedures for organizing home care, also managing 
medications. As part of re-organizing the care, PNsʼ involvement in 
monitoring medication risks and benefits could be enhanced. However, their 
enhanced participation requires changes in their knowledge and skills in 
applied geriatric pharmacotherapy (Dimitrow 2016, Mononen et al. 2020). 
A need for enhancing pharmacists’ involvement in medication 
management of older adults has been identified (Kumpusalo-Vauhkonen et al. 
2016; Kallio et al. 2018). The Finnish Medicines Agency’s interprofessional 
network study on medicines optimization of older adults stated that 
pharmacists have been missing from the primary care teams to this day, even 
they could contribute to the rational use of medicines (Kumpusalo-Vauhkonen 
et al. 2016). A stronger contribution by community pharmacies to medication 
safety in home care could be expected, as they dispense and dose dispense 
medicines to home care clients and have regular contacts with home care 
nurses. However, this potential is underused. The research and development 
projects have tried to enhance community pharmacists’ involvement but the 
real breakthrough remains absent. 
The Rational Pharmacotherapy Action Plan published in 2018 represents a 
remarkable recent milestone in improving coordination and integration 
between different health professionals involved in the medication use process 
(Ministry of Social Affairs and Health 2018). The need for pharmacists’ 
contribution to regular medication reviews for older adults was highlighted. 
Pharmacists have improved their competences and skills required for 
comprehensive medication reviews during the last few decades, and 
established national recommendations for medication review competences for 
pharmacists working in community pharmacies as well as other health care 
settings in 2017 (AATE 2017). Since 2014, the pharmacy undergraduate 
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education has incorporated medication review competences in the BSc 
(Pharm) curriculum.  
 
Clinical pharmacy services within home care – selected examples 
from the USA and Australia 
Little research has focused on the involvement of pharmacists in the 
medication use process of home care clients. Available studies are mainly 
conducted in the United States and Australia (Reidt et al. 2014; Clark et al. 
2016; Elliott et al. 2017). In these studies, the pharmacist has worked as a part 
of the home care team. In the global context, as well as in Finland, community 
pharmacists’ contribution to medication use process of home care clients has 
been modest and focused mainly on medicine dispensing, DDI screening, 
automated dose dispensing and assisting in renewing prescriptions (Heikkilä 
et al. 2006; Jokinen et al. 2014; Sinnemaki et al. 2014; Kallio et al. 2018, 
Jokinen 2020). This chapter focuses on the potential benefits of adding a 
clinical pharmacist to the medication use process of home care clients. 
Studies from Australia, the US and the UK have evidenced the need and 
favorable outcomes of adding a pharmacist in the home care team (Reidt et al. 
2014; Clark et al. 2016; Dilks et al. 2016; Elliott et al. 2017). 
Reidt et al., for example, developed a home care model in the US in which 
a pharmacist was a part of a home care team (Reidt et al. 2014). The 
pharmacist made home visits to reconcile and review medications for 
indication, effectiveness and safety (Reidt et al. 2013). After the home visit, the 
pharmacist contacted physicians to recommend changes to medication 
therapy. Recommendations to physicians included dose adjustments of 
medications, initiation of discontinuation of medications as well as laboratory 
monitoring of medications. The pharmacist then coordinated medication 
changes and care follow-ups with the client, caregivers, and the home care 
nurse.  
Currently in the USA, it is mandated that clients referred to home health 
care services receive a comprehensive assessment from the service providing 
agency (Legal Information Institute 2019). The assessment also covers 
medication therapy and the content is defined as follows: “medication review 
of all medications the patient is currently using in order to identify any 
potential adverse effects and drug reactions, including ineffective drug 
therapy, significant side effects, significant drug interactions, duplicate drug 
therapy, and noncompliance with drug therapy”. 
In Australia, a study by Elliot et al. (2017) describes the successful 
development of a collaborative, person-centered model of clinical 
pharmacists’ support for nurses and clients of a home nursing service that 
incorporates direct client care and indirect care (nurse support). The model is 
targeted to a group of community-dwelling older people known to be at high 
risk of medication-related problems and to have poor access to clinical 
pharmacy support (Elliott et al. 2017).  
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2.3.6 KEY SAFETY RISKS IN GERIATRIC PHARMACOTHERAPY IN 
FINLAND
In line with global findings, Finnish studies from medication error reporting 
systems (particularly HaiPro) and from the medication error cases 
investigated by the National Supervisory Authority for Welfare and Health 
(Valvira) indicate that older adults are most vulnerable to be harmed by 
medication errors (Linden-Lahti et al. 2009; Schepel 2018; Laatikainen 
2020). PIMs are commonly used, particularly BZDs, antipsychotics and 
anticholinergics (Leikola et al. 2011; Saastamoinen & Verho 2015; Hyttinen 
2018; Jalava et al. 2018; Kurko et al. 2018; Hyttinen et al. 2019). Furthermore, 
in Finland, nearly half of medication costs are produced by under 5% of 
medicine users (Saastamoinen & Verho 2013, 2015). These patients use the 
highest number of medicines and are older than other medicine users, with 
more than one-fourth of them being older than 75 years (Saastamoinen & 
Verho 2013). Therefore, knowing the medication safety risks for older adults 
is crucial, and thereafter developing strategies and tools for their prospective 
management. This chapter focuses on major policy initiatives and actions 
taken in Finland since 2006 to improve the quality of geriatric 
pharmacotherapy.  
A milestone in the efforts to improve medication safety of older adults in 
Finland was the Ministry of Social Affairs and Health’s report on the state of 
geriatric care in Finland in 2006 (Kivelä 2006). The report highlighted 
challenges in geriatric pharmacotherapy in outpatient and inpatient care, 
calling for urgent action. To tackle the challenges, MSAH established a 
working group (2006–2009) to improve the quality of geriatric 
pharmacotherapy. The working group summarized legal responsibilities for 
municipalities to ensure the safety of geriatric pharmacotherapy in outpatient 
and inpatient care (Ministry of Social Affairs and Health 2007). This 
municipal bulletin also contained an evidence-based list of safety issues 
requiring urgent action (Table 3) and recommended actions to take to manage 
them. The bulletin recommended, e.g., more undergraduate and continuing 
education in geriatric pharmacotherapy for physicians, nurses and practical 
nurses, a national interprofessional program to prevent harmful effects of 
pharmacotherapies in older adults and development of current care guidelines 
by adding specific information regarding the care of older people (MSAH 
2007). Furthermore, annual collaborative medication reviews were 
recommended, and the role of pharmacies in medication counseling was 
emphasized. The working group also coordinated the development of 
guidelines for geriatric pharmacotherapy, which is still in use (Kivelä & Räihä 
2007). Furthermore, the working group started the development of a national 
PIM database under ROHTO (Meds75+), currently maintained by Fimea 
(Finnish Medicines Agency 2019). 
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Has anything changed in geriatric pharmacotherapy since 2007? 
In order to evaluate what has changed in the quality of geriatric 
pharmacotherapy since MSAH sent the municipal bulletin in 2007 a 
comparison was made between the outpatient medication risk list in 2007 and 
the current situation. The estimate of the current situation is based on the 
review of the recent national literature on geriatric pharmacotherapy, 
particularly in outpatient care.  
The literature search revealed that the safety issues identified over 10 years 
ago are still evident and little progress has been made (Table 3). Recent studies 
indicate that we are still facing the same challenges as in 2006 (Pitkälä et al. 
2015; Juola et al. 2016; Kallio et al. 2016; Hakoinen et al. 2017; Auvinen et al. 
2018; Jalava et al. 2018; Kurko et al. 2018; Vartiainen et al. 2018). Use of 
benzodiazepines, antipsychotics, antidepressants, PIMs and the simultaneous 
use of >2 psychotropic medications, as well as high loads of anticholinergic 
and serotonergic medications, combined with the lack of coordination of care, 
remain still prevalent.  
Dimitrow (2016) conducted a literature review on Finnish studies 
(published between January 1, 2000 and December 31, 2015) on medicine use 
known to be potentially harmful for older adults (Dimitrow 2016). Altogether 
75 research articles were found. A majority (87%) of the articles focused on 
describing trends in medication use, polypharmacy and potentially 
inappropriate medicine use. A minority of the studies described interventions 
to solve these problems. It seems that there has been much discussion on the 
need for changes in geriatric care practices, while the actual changes and 
implementation of new practices are still either lacking or under way 
(Kumpusalo-Vauhkonen et al. 2016; Hakoinen et al. 2017; Ministry of Social 
Affairs and Health 2018). Furthermore, fewer research has focused on 
pharmacotherapy of home-dwelling older adults compared to institutional 
care (Dimitrow 2016). Research has also focused more on older patients with 
cognitive impairment such as Alzheimer’s disease than on the mainstream of 
older people living at home on their own (Dimitrow 2016).  
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2.4 STRATEGIES TO MANAGE MEDICATION SAFETY 
RISKS IN OLDER ADULTS IN PRIMARY CARE
As the main safety risks in primary care relate to the care of multi-morbid older 
adults with polypharmacy, this chapter aims to introduce some approaches 
which have recently been recommended to be used to prevent, identify, and 
address these medication safety risks. Recent systematic reviews on 
interventions aiming to manage and optimize medicine use in older adults, 
and recent global guidance provided by the WHO and guidance at the EU-level 
or within EU-countries have been used in the selection of approaches and 
actions (National Institute for Health and Care Excellence 2015; Mair et al. 
2017; Scottish Government Polypharmacy Model of Care Group 2018; 
SIMPATHY 2019; WHO 2019).  
The following chapter (2.4.1) discuss approaches and interventions used to 
manage medication safety risks in older adults. Effectiveness of the 
interventions is discussed in Chapter 2.4.2.  
2.4.1 MEDICINES OPTIMIZATION
 
Recently, progress in scientific research has notably extended the 
understanding of the pathophysiology of diseases which reflects the 
understanding of how medicines work in the body. With this knowledge, it is 
possible to customize medications according to each individuals’ body 
function. Even though customized or personalized medication is usually 
associated with genomic information, there are many other aspects in 
pharmacotherapy that can be –and need to be – customized and optimized to 
improve treatment outcomes and reduce preventable risks and harms. 
There is a growing international interest for summarizing evidence of 
medicines optimization and using this evidence for establishing 
recommendations and guidelines for implementing medicines optimization in 
clinical practice. For example, the UK National Authority for Healthcare 
Recommendation emphasizes not only system-based medication 
management but also the importance of personalized planning of of safe and 
effective medicines use (The King's Fund 2013; National Institute for Health 
and Care Excellence 2015). 
Continuous weighing of patient needs, changing state of health and the 
benefits and disadvantages of medications are central for optimizing 
treatment (NICE 2015). International interest highlights the need for 
optimization, especially in older adults who are particularly a risk group for 
drug-related harm due to morbidity and aging (The King's Fund 2013; Mair et 
al. 2017; Scottish Government Polypharmacy Model of Care Group 2018; 
SIMPATHY 2019; WHO 2019). Therefore, their pharmacotherapy should be 
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'fine-tuned' more generally according to their individual needs. This applies 
to, e.g., adjusting the right dose and combination of medicines, duration of 
treatment, management of individual drug-related risks, including renal 
function, and choice of dosage form considering, e.g., problems of swallowing 
tablets (Figure 4).  
 
 
Figure 4 Examples of items to be considered and continuously re-evaluated when 
optimizing medication of an older patient. AC=Anticholinergic, DDI=drug-drug 
interaction
Medicines optimization process starts from the identification of the need 
for reducing medication-related risks, in which medication reconciliation, 
medication review and deprescribing processes are tools often used. Figure 5 
presents aspects of medicines optimization. 
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Figure 5 Identified needs for reducing medication-related risks, effective procedures and global 
recommendations form a framework for medicines optimization. PIM=potentially 
inappropriate medicine for older adults; ADR=adverse drug reaction.
2.4.1.1 Incorporating medicines optimization in medication 
management processes 
Medication management and medicines optimization are key terms used when 
discussing appropriate medicines use. The main difference between 
medication management, or medicines management, and medicines 
optimization is the approach. Medicines optimization focuses on a single 
patient’s medication, while medication management focuses on healthcare 
systems and processes (Royal Pharmaceutical Society 2013). Medication 
management is a key enabler for medicines optimization (National Institute 
for Health and Care Excellence 2015). Medicines optimization is defined as “a 
person-centered approach to safe and effective medicines use, to ensure 
people obtain the best possible outcomes from their medicines” (Royal 
Pharmaceutical Society 2013; National Institute for Health and Care 
Excellence 2015). As stated by the SIMPATHY consortium in the EU, these 
terms are often used in the same context together with the term 
“polypharmacy management”. It relates to the whole systems approach for 
optimizing the entire care of multi-morbid patients through maximizing care 
benefits while reducing risks of inappropriate polypharmacy (Mair et al. 2017).  
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- Renal insufficiency
- Symptoms indicating ADRs
Effective procedures 
and tools to reduce 
medication related 
risks
Medication 
reconciliation
Medication review
Deprescribing
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According to the WHO, the prevention of medication safety incidents and 
DRPs in older adults should be part of normal clinical practice, requiring, e.g., 
consideration of the patient’s whole medication and health status as a part of 
prescribing, assessment of benefits and harms and critical assessment of the 
need for continuation of medicines used (Figure 6, WHO 2019). If the desired 
response is not achieved, or the medicine is useless, it is worth stopping 
medication, as unnecessary medication exposes older people to only 
unnecessary harm. 
 
 
 
 
Figure 6  The WHO’s key steps for ensuring medication safety in older adults (WHO 2019) 
 
2.4.1.2 Initiatives in Europe on medicines optimization and 
polypharmacy management 
As part of the Global Patient Safety Challenge: Medication without Harm, 
medication safety in polypharmacy was named as a key challenge (WHO 
2017). Facing the challenge of reducing patient harm, the European Union 
(EU) issued a public health call to identify, develop and implement innovative 
solutions to address the problem of polypharmacy. Stimulating Innovation 
Management of Polypharmacy and Adherence in the Elderly (SIMPATHY) 
was one of the projects funded to deliver tools to implement polypharmacy 
management programs throughout the EU in the context of quality, economic 
and political factors (SIMPATHY 2019). The Scottish Government markedly 
contributed to the work on polypharmacy management by, e.g., producing a 
practical guidance tool that helps health care professionals to work in 
partnership with patients when optimizing their medicines (Scottish 
Government Polypharmacy Model of Care Group 2018).  
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Further, in 2019, the WHO launched guidance particularly for 
polypharmacy management (WHO 2019). The technical report “Medication 
Safety in Polypharmacy” was published to support the goals of the third global 
patient safety challenge (WHO 2017; WHO 2019). This report outlines the 
polypharmacy challenge, the current situation, and key strategies to reduce 
medication-related harm in polypharmacy. The report has much in common 
with the report of the SIMPATHY project (Scottish Government Polypharmacy 
Model of Care Group 2018; SIMPATHY 2019). 
In the UK, in 2013, The King’s Fund published the paper “Polypharmacy 
and Medicines Optimisation – Making It Safe and Sound” (The King's Fund 
2013). This paper outlined the view that polypharmacy is something to avoid. 
It proposed an alternative approach to the concept of polypharmacy: it may 
have positive (appropriate) or negative (problematic) potential. Reducing the 
number of medicines a person is taking, may not be the only factor to consider 
when reviewing polypharmacy; instead, optimization was highlighted. Some 
years later, The National Institute for Health and Care Excellence (NICE) 
published a paper “Medicines Optimization – the Safe and Effective Use of 
Medicines to Enable the Best Possible Outcomes,” which is one of the first 
documents focusing particularly on medicines optimization (National 
Institute for Health and Care Excellence 2015). The paper highlighted the fact 
that continuous evaluation of patient needs, changing health situations, and 
the benefits and disadvantages of medication therapy are central to optimizing 
the treatment.  
2.4.1.3 Optimization process as proposed by the Scottish Government
In line with the aims of the SIMPATHY project, the Scottish Government has 
developed a 7 Step patient-centered medicines review tool (Scottish 
Government Polypharmacy Model of Care Group 2018) (Figure 7). The tool 
helps in medicines optimization and provides a checklist for reviewing 
medicines by a pharmacist, physician, or nurse. The process is recommended 
to be started by a patient interview in order to identify and set objectives of 
drug therapy together with the patient and to evaluate the need of the 
medication, its effectiveness, safety, and efficiency for this particular patient, 
as well as the patient’s willingness and capability to take the medicine. The 
process applies the principles of clinical interview (Kurz 2002; Guirquis 2012; 
Jyrkkä et al. 2017). The 7 Steps medication review procedure is included into 
the recent WHO polypharmacy guidance (WHO 2019). 
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Figure 7  7 Steps medication review to optimize medicines, modified from the Scottish 
Government Polypharmacy Model of Care Group 2018 
2.4.1.4 Medication reconciliation 
An accurate medication list is a starting point for optimizing medicines. 
Medication reconciliation is the “process of identifying the most accurate list 
of all medications a patient is taking…and using this list to provide correct 
medications for patients anywhere within the health care system” (Institute 
for Healthcare Improvement 2011). The best possible medication history 
(BPMH) provides the cornerstone for medication reconciliation. The BPMH 
can be obtained through a systematic process by using a structured patient 
interview, and verification of this information with at least one other reliable 
source of information (e.g., a medication database, patient medication lists, a 
community pharmacy, or a primary care physician) (Kwan et al. 2013). 
Patients and their family members can be valuable and active participants in 
this medication history taking process by maintaining a current medicine list 
that is updated when any medicine changes occur (WHO 2017a). 
2.4.1.5 Medication review 
Medication review provides a method for a more comprehensive evaluation of 
the medication than medication history taking and reconciliation. Medication 
reviews are a tool for medicines optimization and prospective medication risk 
management (Hepler and Strand 1990). Medication reviews are among the 
1
• Aim – What matters to the patient? Identify and set objectives of drug therapy together 
with the patient
2
• Need – Identify essential medication therapy
3
• Need – Does the patient take unnecessary drug therapy (e.g., drugs with temporary 
indication)?
4
• Effectiveness – Are therapeutic objectives being achieved?
5
• Safety – Does the patient have ADRs/side effects or is he/she at risk of them? 
6
• Efficiency – Is the drug therapy cost-effective?
7
• Patient-centered – Is the patient willing and able to take drug therapy as intended?
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basic tasks of physicians, but collaborative medication reviews are becoming 
more common in many countries (Jokanovic et al. 2017). In the overview of 
systematic reviews, Jokanovic et al. have defined pharmacist-led medication 
review as a “systematic assessment of a consumer’s medications and the 
management of those medications, with the aim of optimizing consumer 
health outcomes and identifying potential medication-related issues within 
the framework of the quality use of medicines” (Jokanovic et al. 2017). This 
definition is in line with the Pharmaceutical Society of Australia’s definition 
for Home Medicines Review (HMR), the Medication Therapy Management 
(MTM) program in the United States, Clinical Medication Review in the 
United Kingdom, and Pharmaceutical Care Network Europe’s (PCNE) 
definition of Medication review, as well as medication review practices in 
several other European countries (American Pharmacist Association and the 
National Association of Chain Drug Stores 2008; Pharmaceutical Society of 
Australia 2010; Blenkinsopp et al. 2012; Bulajeva et al. 2014; PCNE 2016; 
Griese-Mammen et al. 2018; Imfeld-Isenegger et al. 2019). Pharmacist-led 
medication review services are increasingly used with different variations and 
studied across the world (Bulajeva et al. 2014; Huiskes et al. 2017; Jokanovic 
et al. 2017; Imfeld-Isenegger et al. 2019; Kiiski et al. 2019). 
Medication review procedures vary in terms of access to clinical data, 
patient, pharmacist and physician involvement and the purpose of the 
medication review (Bulajeva et al. 2014; Kiiski et al. 2016; Griese-Mammen et 
al. 2018; Kallio et al. 2018; Kiiski et al. 2019). Australia, the United States and 
the United Kingdom were the first countries to incorporate collaborative 
medication reviews into primary outpatient care, and the procedures in these 
countries are well-described in published literature (Burns 2005; Blenkinsopp 
et al. 2012; Leikola et al. 2012; Kiiski et al. 2016). In Europe, several countries 
are either developing or have recently implemented collaborative medication 
review procedures (Imfeld-Isenegger et al. 2019). Clyne’s and PCNE’s 
classifications of medication reviews are often applied to assess 
comprehensiveness of the procedures (Clyne et al. 2008; PCNE 2016; Griese-
Mammen et al. 2018). According to PCNE, type 1 medication review is based 
on the medication history, type 2a is based on medication history and patient 
interview, type 2b on medication history and clinical data, and type 3 
medication review is based on medication history, patient interview, and 
clinical data. 
2.4.1.6 Deprescribing
Deprescribing has recently emerged as a new important action to be taken 
in medicines optimization (National Institute for Health and Care Excellence 
2015). Most medicines do not need to be used lifelong (Duerden et al. 2013). 
Therefore, deprescribing is often needed to optimize medication therapy in 
medication review processes. Deprescribing is defined as “the process of 
withdrawal of inappropriate medication, supervised by a health care 
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professional with the goal of managing polypharmacy and improving 
outcomes” (Reeve et al. 2015).  
Much advice and evidence is available when starting a new medicine, but 
far less information and evidence is available to support decisions to stop 
therapy (Duerden et al. 2013). Due to this, deprescribing has recently become 
the subject of intensive research internationally (Garfinkel et al. 2015; Reeve 
et al. 2015; Page et al. 2016; Farrell et al. 2018). Some countries have produced 
first-line guidance and tools for deprescribing (including the Deprescribing 
website in Canada, http://deprescribing.org/about/, and NICE 2015 in the 
UK). In Finland, deprescribing is mentioned as a tool to optimize medications 
in the recent Rational Pharmacotherapy Action Plan and its implementation 
roadmap by the Ministry of Social Affairs and Health (Ministry of Social 
Affairs and Health 2018, 2019).  
Deprescribing can reduce the risk of adverse events such as medication- 
related hospital admissions, falls and decreased cognitive function 
(Woodward 2003; Page et al. 2016; Reeve et al. 2017). Despite the potential 
benefits, many barriers prevent physicians from deprescribing (Djatche et al. 
2018). Identified key barriers include the fear of the recurrence of previous 
conditions for which a medication was initially prescribed and hesitance to 
deprescribe medications initially prescribed by another physician, particularly 
if there is limited communication between the physicians.  
Furthermore, according to physicians, patient and/or caregiver belief in 
continuation of medications is a substantial barrier to deprescribing (Djatche 
et al. 2018). Moreover, the literature indicates that many patients and/or 
caregivers fear adverse drug withdrawal effects, and they believe there are 
more benefits than harms associated with their medications (Reeve et al. 
2016). However, physicians’ recommendations and support have a positive 
impact on patients’ fears.  
Based on the evidence emerging from randomized trials and observational 
studies, Australian medical researchers have developed a process for 
deprescribing (Reeve et al. 2014; Scott et al. 2015). The process includes a five-
step approach: 
(1) Consider all medications currently taken and the indication for each 
medication;  
(2) Evaluate the overall risk of medication-induced harm in an individual 
person;  
(3) Assess each medication for its potential to be deprescribed;  
(4) Sort medications by the order of priority to deprescribe;  
(5) Implement and monitor the deprescribing regimen.  
 
These steps are described in more detail in Table 4. 
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Recent literature has also introduced the term “undiagnosing” which is 
defined as an approach considering the relevance of diagnoses (Page & 
Etherton-Beer 2019). The approach assesses whether the condition may have 
resolved or, represents normal aging and also the selection of individual 
targets. By undiagnosing conditions that are no longer relevant, medicines for 
the undiagnosed condition can correspondingly be deprescribed. 
2.4.2 EFFECTIVENESS OF INTERVENTIONS TO IMPROVE 
APPROPRIATENESS OF MEDICINE USE IN OLDER ADULTS
A number of interventions have been developed and studied to improve 
appropriateness of medication use in older adults. This chapter summarizes 
the recent evidence of these interventions, based on the literature search 
conducted for this thesis in 2019. Systematic reviews and meta-analyses (n=9) 
published in 2015–2019 were included (Table 5). 
According to this literature search, pharmacist-led medication 
reconciliations are effective in reducing medication discrepancies, and 
medication reconciliation programs during hospital transitions decrease ADE-
related hospital revisits, all-cause re-admissions and emergency department 
visits (Mekonnen et al. 2016; Cheema et al. 2018).  
Several recent systematic reviews and meta-analyses were found to 
summarize evidence on the effectiveness of collaborative medication reviews 
in various healthcare settings (Table 5) (Viswanathan et al. 2015; Kiiski et al. 
2016; Jokanovic et al. 2017; Kallio et al. 2018). For example, in the overview 
of systematic reviews, Jokanovic et al. (2017) found several favorable 
outcomes with pharmacist-led medication reviews (Jokanovic et al. 2017). 
Primary studies reported positive impact on medication management, 
improvements in glycosylated hemoglobin, blood pressure, cholesterol and 
number and appropriateness of medications. Furthermore, a significant 
increase in quality of life was reported. However, medication reviews are often 
operationalized as isolated cross-sectional assessments of patients’ 
medications without proper integration and coordination with other patient 
care procedures, which has minimized their effectiveness (Huiskes et al. 2017). 
Furthermore, studies often lack descriptions of the procedures used (Kiiski et 
al. 2016, Kallio et al. 2018). 
Page et al. (2016) studied the feasibility and effect of deprescribing in older 
adults on mortality and health in their systematic review and meta-analysis 
(Table 5) (Page et al. 2016). Deprescribing was not shown to significantly 
modify mortality in RCTs although nonrandomized data suggested that it 
reduced mortality. Mortality was significantly reduced when patient-specific 
deprescribing interventions were applied in RCTs.  
Rankin et al. (2018) and Soler and Barreto (2019) in their research papers 
systematically summarized interventions aiming to enhance appropriate 
polypharmacy (Table 5) (Rankin et al. 2018b; Soler & Barreto 2019). It was 
uncertain whether pharmaceutical care improves medication appropriateness, 
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but may make little or no difference to hospital admissions or quality of life 
(Rankin et al. 2018). According to Soler and Barreto (2019), community-level 
pharmaceutical interventions can improve various clinical, epidemiological, 
humanistic and economic outcomes and potentially reduce risks associated 
with polypharmacy in the older population (Soler and Barreto 2019). 
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m
e 
vi
si
t, 
pa
tie
nt
 c
ou
ns
el
lin
g 
or
 
bo
th
 d
ur
in
g 
th
e 
fir
st
 3
0 
da
ys
 o
f f
ol
lo
w
-u
p)
Po
si
tiv
e 
ou
tc
om
es
:d
ec
re
as
e 
in
 A
D
E-
re
la
te
d 
ho
sp
ita
l r
ev
is
its
, a
ll-
ca
us
e 
re
ad
m
is
si
on
s 
an
d 
ED
 v
is
its
C
on
cl
us
io
n :
 P
ha
rm
ac
is
t-l
ed
 m
ed
ic
at
io
n 
re
co
nc
ilia
tio
n 
pr
og
ra
m
s
ar
e 
ef
fe
ct
iv
e 
at
 
im
pr
ov
in
g 
po
st
-h
os
pi
ta
l h
ea
lth
ca
re
 u
til
iz
at
io
n
an
d 
at
 im
pr
ov
in
g 
m
ed
ic
at
io
n 
sa
fe
ty
C
he
em
a 
et
 a
l. 
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e 
pr
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se
ss
m
en
t o
f 
ph
ar
m
ac
is
t-l
ed
 
m
ed
ic
at
io
n 
re
co
nc
ilia
tio
n 
by
 
re
st
ric
tin
g 
th
e 
re
vi
ew
 
to
 ra
nd
om
iz
ed
co
nt
ro
lle
d 
tri
al
s 
(R
C
Ts
) o
nl
y
H
os
pi
ta
l s
et
tin
g
Sy
st
em
at
ic
 re
vi
ew
 
an
d 
m
et
a-
an
al
ys
is
in
cl
ud
in
g 
18
 R
C
Ts
Ph
ar
m
ac
is
t’s
 in
te
rv
en
tio
ns
 
in
cl
ud
ed
; m
ed
ic
at
io
n 
re
co
nc
ilia
tio
n 
at
 
ad
m
is
si
on
s 
an
d 
di
sc
ha
rg
e,
 
ta
ilo
re
d 
pa
tie
nt
 c
ou
ns
el
lin
g,
 
pr
ov
is
io
n 
of
 te
le
ph
on
ic
 
co
ns
ul
ta
tio
n 
w
ith
 p
at
ie
nt
’s
 
po
st
-h
os
pi
ta
l d
is
ch
ar
ge
 
an
d 
cr
ea
tio
n 
of
 p
os
t-
di
sc
ha
rg
e 
m
ed
ic
at
io
n 
lis
ts
C
on
cl
us
io
ns
:
Ph
ar
m
ac
is
ts
-le
d 
in
te
rv
en
tio
ns
 w
er
e 
ef
fe
ct
iv
e 
in
 re
du
ci
ng
 m
ed
ic
at
io
n 
di
sc
re
pa
nc
ie
s
M
ed
ic
at
io
n 
re
vi
ew
 in
te
rv
en
tio
ns
(n
=4
)
Vi
sw
an
at
ha
n 
et
 a
l. 
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en
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M
ed
ic
at
io
n 
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er
ap
y 
M
an
ag
em
en
t (
M
TM
) 
se
rv
ic
e 
in
te
rv
en
tio
ns
 
in
 o
ut
pa
tie
nt
s 
w
ith
 
ch
ro
ni
c 
illn
es
se
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Th
e 
ar
tic
le
 is
 b
as
ed
Va
rie
ty
 o
f 
ou
tp
at
ie
nt
 s
et
tin
gs
 
(fr
om
 a
nd
 o
ut
si
de
 
of
 th
e 
U
S)
 
in
cl
ud
in
g 
co
m
m
un
ity
 
ph
ar
m
ac
ie
s,
 
ce
nt
ra
liz
ed
 
Sy
st
em
at
ic
 re
vi
ew
 
an
d 
m
et
a -
an
al
ys
is
 
in
cl
ud
in
g 
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st
ud
ie
s 
(2
1 
R
C
Ts
, 
4 
no
n -
R
C
Ts
, 1
9 
co
ho
rt 
st
ud
ie
s)
Ph
ar
m
ac
is
t-p
ro
vi
de
d 
in
te
rv
en
tio
ns
 in
 o
ut
pa
tie
nt
 
ca
re
 w
ith
 th
e 
fo
llo
w
in
g 
pr
e-
sp
ec
ifi
ed
 M
TM
 in
te
rv
en
tio
n 
ch
ar
ac
te
ris
tic
s:
a 
co
m
pr
eh
en
si
ve
 
m
ed
ic
at
io
n 
re
vi
ew
, p
at
ie
nt
-
di
re
ct
ed
 e
du
ca
tio
n,
 c
ar
e
M
ai
n 
po
si
tiv
e 
ou
tc
om
es
: M
TM
 in
te
rv
en
tio
ns
 
im
pr
ov
ed
 m
ed
ic
at
io
n 
ap
pr
op
ria
te
ne
ss
, 
ad
he
re
nc
e,
 a
nd
 re
du
ce
d 
m
ed
ic
at
io
n 
do
si
ng
,
re
du
ce
d 
h e
al
th
 p
la
n 
ex
pe
nd
itu
re
s 
on
 
m
ed
ic
at
io
n 
co
st
s
Fo
r p
at
ie
nt
s 
w
ith
 d
ia
be
te
s 
m
el
lit
us
 o
r h
ea
rt 
fa
ilu
re
, M
TM
 in
te
rv
en
tio
ns
 lo
w
er
ed
 th
e 
od
ds
 
of
 h
os
pi
ta
liz
at
io
n
R
ev
ie
w
 o
f t
he
 li
te
ra
tu
re
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 o
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y 
de
si
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Nu
m
be
r o
f 
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ud
ie
s
Pr
ov
id
er
 a
nd
 In
te
rv
en
tio
n
Re
su
lts
an
d 
co
nc
lu
si
on
on
 a
 s
ys
te
m
at
ic
 
ev
id
en
ce
 re
po
rt 
by
 
th
e 
U
S 
Ag
en
cy
 fo
r 
H
ea
lth
ca
re
 
R
es
ea
rc
h 
an
d 
Q
ua
lit
y 
(A
H
R
Q
) t
o 
de
te
rm
in
e 
th
e 
ef
fe
ct
iv
en
es
s 
of
 
ou
tp
at
ie
nt
 M
TM
(V
is
w
an
at
ha
n 
et
 a
l. 
20
14
)
ph
ar
m
ac
ie
s 
or
 
ph
ar
m
ac
y 
ca
ll 
ce
nt
er
s,
 o
ut
pa
tie
nt
 
m
ed
ic
al
 c
lin
ic
s,
 
an
d 
pa
tie
nt
s 
ho
m
es
.
Ex
cl
ud
ed
:
M
TM
 s
er
vi
ce
s 
pr
ov
id
ed
 w
ith
in
 
in
pa
tie
nt
 s
et
tin
gs
 
or
 s
ho
rtl
y 
af
te
r 
ho
sp
ita
l d
is
ch
ar
ge
 
co
or
di
na
tio
n,
 a
nd
 
op
po
rtu
ni
ty
 fo
r f
ol
lo
w
-u
p
H
ow
ev
er
, t
he
 e
vi
de
nc
e 
fro
m
 th
e 
st
ud
ie
s
w
as
 
in
su
ffi
ci
en
t t
o 
de
te
rm
in
e 
th
e 
ef
fe
ct
 o
f M
TM
 
in
te
rv
en
tio
ns
 o
n
m
os
t e
va
lu
at
ed
 o
ut
co
m
es
 
(e
.g
., 
dr
ug
 th
er
ap
y 
pr
ob
le
m
s,
 a
dv
er
se
 d
ru
g 
ev
en
ts
, d
is
ea
se
-s
pe
ci
fic
 m
or
bi
di
ty
, d
is
ea
se
-
sp
ec
ifi
c 
or
 a
ll-
ca
us
e 
m
or
ta
lit
y,
 a
nd
 h
ar
m
s)
 
C
on
cl
us
io
n :
 C
lin
ic
al
ly
 e
ffe
ct
iv
e 
M
TM
 c
an
 
ei
th
er
 in
cr
ea
se
 o
r d
ec
re
as
e 
he
al
th
 c
ar
e 
us
e 
an
d 
ex
pe
nd
itu
re
s 
ba
se
d 
on
 th
e 
ne
ed
s 
of
 th
e 
pa
tie
nt
 
H
ui
sk
es
 e
t 
al
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 a
ss
es
s
ef
fe
ct
iv
en
es
s 
of
 
m
ed
ic
at
io
n 
re
vi
ew
 
as
 a
n 
is
ol
at
ed
 s
ho
rt-
te
rm
 in
te
rv
en
tio
n 
(<
3 
m
on
th
s)
 ir
re
sp
ec
tiv
e 
of
 th
e 
pa
tie
nt
 
po
pu
la
tio
n 
an
d 
th
e 
ou
tc
om
e 
m
ea
su
re
s 
us
ed
H
os
pi
ta
l 
ph
ar
m
ac
y,
 
ph
ys
ic
ia
n 
cl
in
ic
s,
 
an
d 
ho
m
e 
ca
re
Sy
st
em
at
ic
 re
vi
ew
 
an
d
m
et
a-
an
al
ys
is
of
 3
1 
R
C
T 
st
ud
ie
s
Ph
ar
m
ac
is
t, 
nu
rs
e 
or
 
ph
ys
ic
ia
n 
pr
ov
id
ed
 
m
ed
ic
at
io
n 
re
vi
ew
s 
irr
es
pe
ct
iv
e 
of
 p
at
ie
nt
 
po
pu
la
tio
n
Po
si
tiv
e 
ou
tc
om
es
:A
n 
ef
fe
ct
 w
as
 fo
un
d 
on
 
m
os
t d
ru
g-
re
la
te
d 
pr
ob
le
m
s:
 m
ed
ic
at
io
n 
re
vi
ew
 re
su
lte
d 
in
 a
 d
ec
re
as
e 
of
 d
ru
g-
re
la
te
d 
pr
ob
le
m
s,
 m
or
e 
ch
an
ge
s 
in
 m
ed
ic
at
io
n 
(d
os
e 
de
cr
ea
se
, g
re
at
er
 d
ec
re
as
e 
or
 s
m
al
l i
nc
re
as
e 
in
 n
um
be
r o
f d
ru
gs
)a
nd
 re
du
ce
s 
th
e 
nu
m
be
r 
of
 fa
lls
N
eg
at
iv
e 
ou
tc
om
es
:N
o 
ef
fe
ct
 o
f m
ed
ic
at
io
n 
re
vi
ew
 w
as
 fo
un
d 
on
 c
lin
ic
al
 o
ut
co
m
es
 
(m
or
ta
lit
y,
 h
os
pi
ta
l a
dm
is
si
on
s/
he
al
th
ca
re
 
us
e,
 th
e 
nu
m
be
r o
f p
at
ie
nt
s 
fa
llin
g,
 p
hy
si
ca
l 
an
d 
co
gn
iti
ve
 fu
nc
tio
ni
ng
) , 
qu
al
ity
of
 li
fe
an
d 
ec
on
om
ic
 o
ut
co
m
e 
m
ea
su
re
s
Jo
ka
no
vi
c 
et
 
al
. 2
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To
 c
rit
ic
al
ly
 e
va
lu
at
e 
pu
bl
is
he
d 
sy
st
em
at
ic
 re
vi
ew
s 
re
le
va
nt
 to
 
ph
ar
m
ac
is
t-l
ed
 
m
ed
ic
at
io
n 
re
vi
ew
s 
in
 c
om
m
un
ity
 
se
tti
ng
s
C
om
m
un
ity
 
ph
ar
m
ac
y
O
ve
rv
ie
w
 o
f 
sy
st
em
at
ic
 
re
vi
ew
s
(n
=3
5)
 
O
f t
he
se
, 2
4 
w
er
e 
of
 m
od
er
at
e 
an
d 
se
ve
n 
of
 h
ig
h 
qu
al
ity
 a
nd
 w
er
e 
in
cl
ud
ed
 in
 th
e 
da
ta
 s
yn
th
es
is
.
Ph
ar
m
ac
is
t-l
ed
 m
ed
ic
at
io
n 
re
vi
ew
s
Po
si
tiv
e 
ou
tc
om
es
:R
es
ul
ts
 fr
om
 th
e 
m
et
a-
an
al
ys
es
 (p
er
fo
rm
ed
 in
 1
2 
sy
st
em
at
ic
 
re
vi
ew
s)
 in
di
ca
te
d 
po
si
tiv
e 
im
pa
ct
s 
on
 
gl
yc
os
yl
at
ed
 h
em
og
lo
bi
n,
 b
lo
od
 p
re
ss
ur
e,
 
ch
ol
es
te
ro
l, 
an
d 
nu
m
be
r a
nd
 
ap
pr
op
ria
te
ne
ss
 o
f m
ed
ic
at
io
ns
.
O
f t
he
 p
rim
ar
y 
st
ud
ie
s,
 fa
vo
ra
bl
e 
ou
tc
om
es
 
w
er
e 
de
m
on
st
ra
te
d 
fo
r d
ia
be
te
s 
co
nt
ro
l (
78
%
 
of
 s
tu
di
es
 re
po
rti
ng
 th
e 
ou
tc
om
e)
, b
lo
od
 
 63
 
Re
fe
re
nc
e
Ai
m
 o
f t
he
 s
tu
dy
Se
tti
ng
 
St
ud
y 
de
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m
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r o
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ie
s
Pr
ov
id
er
 a
nd
 In
te
rv
en
tio
n
Re
su
lts
an
d 
co
nc
lu
si
on
pr
es
su
re
 c
on
tro
l (
74
%
), 
ch
ol
es
te
ro
l (
63
%
), 
m
ed
ic
at
io
n 
ad
he
re
nc
e 
(5
6%
) a
nd
 m
ed
ic
at
io
n 
m
an
ag
em
en
t (
47
%
).
Si
gn
ifi
ca
nt
 re
du
ct
io
ns
 in
 m
ed
ic
at
io
n 
an
d/
or
 
he
al
th
ca
re
 c
os
ts
 w
er
e 
re
po
rte
d 
in
 3
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 o
f 
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ar
y 
re
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ar
ch
 s
tu
di
es
Ka
llio
 e
t a
l. 
20
18
To
 id
en
tif
y 
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at
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re
vi
ew
 
in
te
rv
en
tio
ns
 fo
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de
r a
du
lts
 
in
vo
lv
in
g 
co
m
m
un
ity
 
ph
ar
m
ac
is
ts
 a
nd
 
ev
id
en
ce
 o
f 
ou
tc
om
es
 o
f t
he
se
 
in
te
rv
en
tio
ns
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tic
le
s 
in
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lv
in
g 
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m
m
un
ity
 
ph
ar
m
ac
is
ts
 in
 
m
ed
ic
at
io
n 
re
vi
ew
s 
fo
r 
ou
tp
at
ie
nt
s 
ag
ed
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 a
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 o
ld
er
 w
er
e 
in
cl
ud
ed
Sy
st
em
at
ic
 re
vi
ew
 
of
 1
6 
ar
tic
le
s
C
om
m
un
ity
 p
ha
rm
ac
is
ts
 
pr
ov
id
ed
 m
ed
ic
at
io
n 
re
vi
ew
 
in
te
rv
en
tio
ns
, o
f w
hi
ch
 6
 
w
er
e 
co
m
pl
ia
nc
e 
an
d 
co
nc
or
da
nc
e 
re
vi
ew
s,
 4
 
w
er
e 
cl
in
ic
al
 m
ed
ic
at
io
n 
re
vi
ew
s,
 a
nd
 2
w
er
e 
pr
es
cr
ip
tio
n 
re
vi
ew
s
C
om
m
un
ity
 p
ha
rm
ac
is
ts
’ 
co
nt
rib
ut
io
ns
 to
 re
vi
ew
in
g 
m
ed
ic
at
io
ns
 v
ar
ie
d 
fro
m
 
se
nd
in
g 
th
e 
di
sp
en
si
ng
 
hi
st
or
y 
to
 o
th
er
 h
ea
lth
ca
re
 
pr
ov
id
er
s 
to
 
co
m
pr
eh
en
si
ve
 
in
vo
lv
em
en
t i
n 
m
ed
ic
at
io
n 
m
an
ag
em
en
t
Po
si
tiv
e 
ou
tc
om
es
:T
he
 m
os
t c
om
m
on
ly
 
as
se
ss
ed
 o
ut
co
m
es
 o
f t
he
 in
te
rv
en
tio
ns
 w
er
e 
m
ed
ic
at
io
n 
ch
an
ge
s 
le
ad
in
g 
to
 re
du
ct
io
n 
in
 
ac
tu
al
 o
r p
ot
en
tia
l d
ru
g-
re
la
te
d 
pr
ob
le
m
s 
(n
=1
2)
 a
nd
 im
pr
ov
ed
 a
dh
er
en
ce
 (n
=5
).
M
ed
ic
at
io
n 
re
vi
ew
 in
te
rv
en
tio
ns
 s
ee
m
ed
to
re
du
ce
 D
R
Ps
 a
nd
 im
pr
ov
e 
m
ed
ic
at
io
n 
ad
he
re
nc
e.
C
o n
cl
us
io
n:
Be
tte
r d
es
ig
ne
d,
 ri
go
ro
us
 
st
ud
ie
s
w
ith
 m
or
e 
se
ns
iti
ve
 a
nd
 s
pe
ci
fic
 
ou
tc
om
es
 m
ea
su
re
s
ar
e 
ne
ed
ed
 to
 a
ss
es
s 
th
e 
ef
fe
ct
 o
f c
om
m
un
ity
ph
ar
m
ac
is
t 
co
nt
rib
ut
io
ns
 to
 re
vi
ew
in
g 
m
ed
ic
at
io
ns
.
De
pr
es
cr
ib
in
g 
in
te
rv
en
tio
ns
(n
=1
)
Pa
ge
 
et
 
al
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en
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to
 m
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 m
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at
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et
a-
an
al
ys
es
 in
cl
ud
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g 
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2
st
ud
ie
s,
of
 
w
hi
ch
 5
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w
er
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R
C
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st
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ie
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Va
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us
 d
ep
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sc
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g
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te
rv
en
tio
ns
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 h
ea
lth
 
ca
re
 p
ro
fe
ss
io
na
l 
(p
hy
si
ci
an
, p
ha
rm
ac
is
t,
nu
rs
e 
or
 m
ul
tid
is
ci
pl
in
ar
y 
te
am
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O
ut
co
m
es
/c
on
cl
us
io
ns
:D
ep
re
sc
rib
in
g 
to
 
re
du
ce
 p
ol
yp
ha
rm
ac
y
w
as
 n
ot
 s
ho
w
n 
to
 
si
gn
ifi
ca
nt
ly
 m
od
ify
 m
or
ta
lit
y 
in
 R
C
Ts
 
al
th
ou
gh
no
nr
an
do
m
iz
ed
 d
at
a 
su
gg
es
te
d 
th
at
 it
 re
du
ce
d 
m
or
ta
lit
y
M
or
ta
lit
y 
w
as
 s
ig
ni
fic
an
tly
 re
du
ce
d 
w
he
n 
pa
tie
nt
-s
pe
ci
fic
de
pr
es
cr
ib
in
g 
in
te
rv
en
tio
ns
w
er
e 
ap
pl
ie
d 
in
 R
C
Ts
D
ep
re
sc
rib
in
g 
ap
pe
ar
ed
to
 b
e 
fe
as
ib
le
 a
nd
 
ge
ne
ra
lly
 s
af
e
R
ev
ie
w
 o
f t
he
 li
te
ra
tu
re
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su
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To
 d
et
er
m
in
e 
w
hi
ch
 
in
te
rv
en
tio
ns
, a
lo
ne
 
or
 in
 c
om
bi
na
tio
n,
 
ar
e 
ef
fe
ct
iv
e 
in
 
im
pr
ov
in
g 
th
e 
ap
pr
op
ria
te
 u
se
 o
f 
po
ly
ph
ar
m
ac
y 
an
d
re
du
ci
ng
 
m
ed
ic
at
io
n -
re
la
te
d 
pr
ob
le
m
s 
in
 o
ld
er
 
pe
op
le
In
te
rv
en
tio
ns
 w
er
e 
pr
ov
id
ed
 in
 a
 
va
rie
ty
 o
f s
et
tin
gs
 
an
d 
w
er
e 
co
nd
uc
te
d 
in
 h
ig
h-
in
co
m
e 
co
un
tri
es
.
Sy
st
em
at
ic
 re
vi
ew
 
(C
oc
hr
an
e 
R
ev
ie
w
) i
nc
lu
di
ng
 
32
 s
tu
di
es
, (
18
 
R
C
Ts
, 1
0 
cl
us
te
r 
ra
nd
om
iz
ed
tri
al
s,
 
tw
o 
no
n-
ra
nd
om
iz
ed
tri
al
s 
an
d 
tw
o 
co
nt
ro
lle
d 
be
fo
re
-a
fte
r 
st
ud
ie
s)
In
te
rv
en
tio
ns
 w
er
e 
de
liv
er
ed
 b
y 
he
al
th
ca
r e
pr
of
es
si
on
al
s 
su
ch
 a
s 
ge
ne
ra
l p
hy
si
ci
an
s,
 
ph
ar
m
ac
is
ts
, a
nd
 
ge
ria
tri
ci
an
s.
 O
ne
 
in
te
rv
en
tio
n 
co
ns
is
te
d 
of
 
co
m
pu
te
riz
ed
de
ci
si
on
 
su
pp
or
t (
C
D
S)
; a
nd
 3
1 
w
er
e 
co
m
pl
ex
, m
ul
ti-
fa
ce
te
d 
ph
ar
m
ac
eu
tic
al
-
ca
re
 b
as
ed
 a
pp
ro
ac
he
s.
O
ut
co
m
es
/c
on
cl
us
io
ns
:I
t w
as
 u
nc
er
ta
in
 
w
he
th
er
 p
ha
rm
ac
eu
tic
al
 c
ar
e 
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2.4.3 METHODOLOGICAL ASPECTS WITH INTERVENTIONS AIMING 
TO ENHANCE MEDICATION SAFETY IN OLDER ADULTS
Recently, several systematic reviews have been published which combine 
evidence of the effectiveness of interventions to optimize medication 
treatment in older adults in outpatient care (Table 5). The following chapters 
describe the key methodological aspects that should be considered when 
planning and conducting interventions and evaluating their effectiveness. 
2.4.3.1 Selection of study design 
Intervention study designs are often used to develop new approaches in 
health care services. There are several different study designs for intervention 
studies, of which the randomized, controlled trial (RCT) study design provides 
the most reliable information on the effectiveness of the intervention. 
However, when applied to the daily life of health care, the effectiveness of the 
intervention may seem very different. This is influenced by a number of 
confounding factors which are part of real-life in clinical practice and may be 
due to a variety of operating, professional and patient factors (Ford & Norrie 
2016).  
Recent research and methodological discussion has revolved around 
pragmatic trials, which, from the outset, begin to develop an approach to 
normal clinical life (Ford & Norrie 2016). Pragmatic trials represent the real 
world better than RCTs, due to including complex interventions, sometimes 
consisting of several interacting components and often involving the skills and 
experience of one or more health care professionals to deliver the intervention. 
2.4.3.2 Selection of primary and secondary outcomes
Due to the above mentioned challenges, the outcome measures for the 
effectiveness of interventions aimed at rationalizing medication use in older 
adults require a special remark. The set of outcome measures should be made 
up of a variety of measures assessing potential changes in the 
safety/appropriateness of medication, clinical health status and possibly 
health service utilization and cost (Kozma et al. 1993).  
Kiiski et al. carried out a systematic review of the interventions and related 
outcomes used to optimize medications of older adults (Kiiski et al. 2016; 
Kallio et al. 2018). The included studies used a variety of different outcome 
measures, which were summarized according to the ECHO (Economic, 
Clinical, and Humanistic Outcomes) model (Kozma et al. 1993) (Table 6). The 
systematic review showed that a wide variety of outcomes and outcome 
measures have been used in studies without being always optimally selected. 
Measuring the number of medicines in use alone does not make sense, since 
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underuse has also been observed in the older population with polypharmacy, 
and its correction increases the number of medicines. Furthermore, 
monitoring the direct cost of medicines is not always reliable. There is also a 
risk of misinterpretation when measuring the use of health services. Especially 
at the outset of medication optimization, more physician visits may be needed 
related, e.g., to deprescribing or individualizing the dose. 
These various challenges make it difficult to demonstrate the effectiveness 
of interventions aimed at optimizing the medication of the patients, and to 
compare and compile results in systematic reviews and meta-analyzes. They 
also make it more difficult to convince policy makers to implement new 
policies and practices that may require resources and  funding. 
The Core Outcome Measures for Effectiveness Trials (COMET) initiative 
has proposed the development and reporting of a core outcome set (COS) as a 
solution to the challenge of measuring outcomes (Williamson et al. 2012; 
Prinsen et al. 2014). A COS is an agreed-upon standardized set of outcomes 
that should be measured and reported as a minimum in all trials in a specific 
clinic area (Williamson et al. 2012). In line with this, two recent Delphi studies 
have developed core outcome sets for trials aimed at improving the 
appropriateness of polypharmacy in older adults (Beuscart et al. 2018; Rankin 
et al. 2018a). Themes included in both COSs relate to medication-related 
outcomes, adverse effects or harm, clinical outcomes and patient-related 
outcomes. The sets are quite similar; there are differences between some 
specific outcomes and in the number of themes (Table 7).  
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2.5 A SYSTEMATIC REVIEW: DRUG-DRUG 
INTERACTIONS IDENTIFIED IN COMMUNITY 
PHARMACIES
2.5.1 INTRODUCTION
Drug-drug interactions (DDIs) are the first system-based medication safety 
risk that have been addressed in health care for a long time. Since the 1960s 
the importance of DDIs has increased over time due to the increased use of 
medicines and polypharmacy, which has increased the risk of DDIs. On the 
other hand, research evidence about DDIs has increased and has been utilized 
in DDI electronic alert systems. In the USA, for example, such systems have 
been in use for decades (also by consumers) (Greenlaw & Zellers 1978). In 
Finland, the first electronic medication risk management tools were designed 
for DDI risk management, and community pharmacies have been actively 
implementing these tools at the forefront of health care. The first screening 
tools were launched in community pharmacies in early 2000 (Toivo et al. 
2005; Heikkila et al. 2006). 
Existing studies on DDI incidence has focused on interactions in 
hospitalized patients (Laine et al. 2000; Reimche et al. 2011; Gonzaga de 
Andrade Santos et al. 2020). Studies have also focused on certain patient 
groups, e.g., aged people or cancer patients (Obreli Neto et al. 2012; van 
Leeuwen et al. 2013; Sanchez-Fidalgo et al. 2017) or on certain medicine 
groups, such as HIV drugs (Evans-Jones et al. 2010; Molas et al. 2018). A 
patient’s age, number of prescribers involved and polypharmacy significantly 
increases the risk for drug-drug interactions (Sanchez-Fidalgo et al. 2017; 
Andersson et al. 2018). Less is known regarding DDIs in outpatients, 
particularly how community pharmacists could contribute to DDI 
management by applying their surveillance systems to the identification of 
high-risk medications. 
The aim of this study was to systemically review the literature of existing 
studies on the incidence and prevalence of DDIs in outpatients, and 
particularly studies on DDIs identified in community pharmacies.  
2.5.2 SEARCH STRATEGY 
The Medline (Ovid) and Scopus databases were searched from January 1, 1995 
to September 25, 2015 (Table 8). The literature search was updated on 
December 17, 2015. The systematic review was conducted applying the 
PRISMA guidelines (Moher et al. 2015). 
The literature search process was conducted with the help of an 
information specialist at the Medical Library, University of Helsinki. In 
PubMed, MeSH (Medical Subject Headings) terms were used and all fields 
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were searched. In Scopus, the following fields were searched: title, abstract 
and keywords. To avoid searching for duplicates in Scopus, the search was 
filtered with “AND NOT INDEX (MEDLINE)”.  
 
Table 8 Databases and search terms used in the systematic literature search 
Databases Medline (Ovid Medline and Ovid Medline 
In-Process & Other Non-Indexed 
Citations)
Scopus (Elsevier)
Search terms Related to DDIs (OR search): 
drug interactions, drug* or medic* 
interact*, ddi
Related to outpatient care (OR search):
outpatients, ambulatory care, outpatient* 
or ambulatory*, communit* pharma*, 
primary health care, primary healthcare, 
primary care
Main themes were combined with AND 
search
Filters Publication date from 1995/01/01 to 
2015/09/25
2.5.2.1 Inclusion and exclusion criteria
Studies describing the incidence or prevalence of DDIs in outpatients and 
which included all their medication were included (Table 9). Studies 
describing the incidence or prevalence of DDIs in hospitalized patients were 
excluded, as well were studies focusing on DDIs of certain drugs (e.g., 
warfarin, antineoplastics, HIV drugs) or on specific patient groups (e.g., HIV 
patients, cancer patients). Articles were included if written in English and if 
full-text version was available through the University of Helsinki Library. 
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Table 9 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Patients (P) x Outpatientsx Studies including 
patients of all ages, or
older adults (≥ 60 
years)
x Number of dispensed 
prescriptions or 
medicines used not 
defined or ranged
x Inpatients, hospitalized patients
x Studies focusing on DDIs of certain 
drugs (e.g., warfarin, 
antineoplastics, HIV drugs) or on 
specific patient groups (e.g., HIV
patients, cancer patients) 
x Number of dispensed prescriptions 
or medicines used ranged other 
than ≥2
Methods x Any study design, 
excluding narrative 
reviews
x Narrative reviews
Outcome (O) x Prevalence or 
incidence of DDIs is 
presented 
x Prevalence or incidence of DDIs is 
not presented
Time frame (T) x Publication date from 
Jan 1, 1995 to Sep 25, 
2015
x Publication date outside of the 
presented time frame
2.5.2.2 Selection of the studies
The titles and abstracts of the studies were read by authors TT and EN (author 
of the thesis and Emmi Nieminen). Studies were selected based on the title 
and abstract. Reference lists of the included studies were reviewed and studies 
that met the inclusion criteria were included. 
Full-text articles were read, and the following data were extracted and 
analyzed qualitatively: country of origin; study design and setting; cohort or 
sample; DDI screening tool and DDI categorization used; prevalence or 
incidence of DDIs; identified risk factors for DDIs; the most prevalent DDIs 
and drugs involved. A detailed summary table of the included studies was 
made. 
2.5.3 RESULTS 
2.5.3.1 Included studies
The literature search produced 2,333 research articles. The study selection 
process is shown in Figure 8. In total, 34 studies described DDIs in an 
outpatient setting. Of these, nine studies were conducted in community 
pharmacies and used data from dispensed prescriptions (Buurma et al. 2006; 
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Heikkilä et al. 2006; Cremades et al. 2009; Chatsisvili et al. 2010; Vaidhun 
and Satnish 2011; Bucsa et al. 2012; Obreli-Neto et al. 2012b; Nicolas et al. 
2013; Dirin et al. 2014). The studies reporting DDIs identified in the 
prescriptions dispensed from community pharmacies (n=9) are presented in 
this thesis (Table 11). 
 
 
Figure 8. Selection of the included articles (n=9)
2.5.3.2 Origin of the studies, screening tools and DDI categorization 
used 
Of the studies, two were conducted in the Netherlands (Buurma et al. 2006; 
Geerts et al. 2009), and one in Finland (Heikkilä et al. 2006). Other studies 
were from Spain, Greece, India, Romany, Germany and Iran (Cremades et al. 
2009; Chatsisvili et al. 2010; Vaidhun & Sathish 2011; Bucsa et al. 2012; 
Nicolas et al. 2013; Dirin et al. 2014) (Table 10).  
The studies (n=9) used a total of eight different methods or screening tools 
in DDI identification and classification. Databases used included, e.g., the 
FASS database (Heikkilä et al. 2006), Micromedex's Drug-Reax (Bucsa et al. 
2012), Medscape database (Vaidhun and Satnish 2011), Hansten & Horn 
classification (Chatsisvili et al. 2011), databases from the Scientific Institute of 
Dutch Pharmacists (Buurma et al. 2006; Geerts et al. 2009) and from the 
Spanish Pharmacists Association (Cremades et al. 2009).  
Records identified through the 
database search in Sep 2015, 
n=2,333
Medline n=1,637
Scopus n=696 
Excluded based on the 
abstract n=194
Records included based on the title
n=245
Records included based on the full-
text n=33
Excluded based on the 
title
n=2,088
Excluded based on the 
full-text n=25
Records included based on the 
abstract n=51
Additional 
records
identified 
through other 
sources n=7
Records included in the systematic 
review, describing DDIs in community 
pharmacy prescriptions
n=9
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2.5.3.3 Prevalence or incidence of DDIs and drugs included
The DDI prevalence rate varied markedly across the studies. The rate of 
identified DDIs in prescriptions varied from 4.4% (Nicolas et al. 2013) to 
34.4% (Bucsa et al. 2012). The rate of DDIs classified as severe, major or 
contraindicated varied from 0.35% to 19.8% depending on DDI classification 
system and country. Drugs most frequently involved in DDIs were 
cardiovascular medicines, NSAIDs and antithrombotic agents (Table 11). 
Summary of the included studies is presented in Table 10. 
Table 11 Drugs most frequently leading to a drug–drug interaction in the studies (n=9)
Drug class Most prevalent DDIs in the drug class Studies
Cardiovascular 
medicines
ACE inhibitors/angiotensin II antagonists –
diuretics
Beta-blocking agents – anti diabetics
Potassium sparing diuretics – potassium 
ACE inhibitors/angiotensin receptor 
antagonists + potassium-sparing diuretics
Verapamil – betablocker
Sildenafil – nitrate
Buurma et al. 2006
Heikkilä et al. 2006
Geerts et al. 2009
Chatsisvili et al. 
2010
Bucsa et al. 2012
Vaidhun and 
Sathish 2011
NSAIDs NSAID – ACE inhibitors/angiotensin II 
antagonists/beta-blocking agents/diuretics
NSAID – warfarin
NSAID – methtotrexate
Buurma et al. 2006
Heikkilä et al. 2006
Bucsa et al. 2012
Antithrombotics Warfarin – NSAID Heikkilä et al. 2006
2.5.3.4 Recent studies (2015–2018)
An update of the literature search was conducted on October 24, 2018 using 
the same search strategy as in the original search. The timeframe was limited 
from January 1, 2015 to October 24, 2018.  
Literature search produced a total of 612 articles (Medline n=473, Scopus 
n=139). From these, five studies met the original inclusion criteria (Table 9) 
(Guthrie et al. 2015; Heringa et al. 2016; Goren et al. 2017; Andersson et al. 
2018; Jazbar et al. 2018). One of these studies was conducted in community 
pharmacy setting in the Neatherlans (Heringa et al. 2016). 
Heringa et al. retrospectively analyzed drug therapy alerts generated by a 
CDSS in Dutch community pharmacies (Heringa et al. 2016). They 
investigated the frequency, nature, and determinants of drug therapy alerts 
generated by a CDSS in community pharmacies. The goal was to be able to 
propose CDSS improvement strategies for community pharmacies, aiming to 
reduce overridden alerts. Data was extracted from 1,672,169 prescriptions, 
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dispensed from a random sample of 123 community pharmacies in the period 
from August 2013 to July 2014. Of all prescriptions, 15% led to DDI alerts. The 
most common alerts involved antithrombotic agents, ACE-inhibitors and 
beta-blocking agents. The interactions between ACE inhibitors/angiotensin II 
antagonists and diuretics were the most common DDI alerts (14.8%), followed 
by the interactions between antidiabetics and beta-blocking agents (9.1%).  
2.5.3.5 Discussion 
 
Community pharmacies use different DDI screening tools to identify 
clinically significant DDIs requiring intervening action. Studies show 
differences between countries concerning the state of DDI screening. Most 
studies were conducted during the first decade of the 2000s (Table 10). The 
update of the literature search in 2018 yielded only one new study, aimed to 
develop clinical decision support systems with decreased alert rate (Hering et 
al. 2016).  
DDI incidence estimates vary markedly across studies from different 
countries since the healthcare environments and systems vary. Drugs that are 
approved and marketed vary by country, and so do prescribing patterns. There 
are also big differences between drug interaction screening programs and 
databases regarding inclusion, severity classification and documentation 
levels of DDIs. Even widely used interaction screening programs differ in 
detecting interacting drug-drug pairs (Andersson et al. 2013; Andersson et al. 
2015; Roblek et al. 2015). These differences produce markedly varying results 
across DDI incidence studies. 
In addition to contextual differences in DDI studies, research methods used 
in DDI incidence studies vary. The existing studies conducted in community 
pharmacies were primarily focused on describing the rate of DDIs, but not 
service development for community pharmacists’ involvement in systematic 
management of clinically significant DDIs in collaboration with local 
physicians. 
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2.6 SUMMARY OF THE KEY FINDINGS OF THE 
LITERATURE REVIEW
Patient and medication safety risks have raised the global discussion on the 
need for a development of health services and systems. Health services strive 
to provide good quality of care, but sometimes people are unintentionally 
harmed. Errors in patient care and related harm is a remarkable challenge in 
health care, influencing public health and health care costs.  
A majority of medicine use takes place in primary care, where ensuring safe 
use is even more challenging than in hospitals since medicines are mainly 
taken by patients without supervision. The care has become fragmented 
leading to a situation where several prescribing physicians and other health 
professionals may participate in the care of the patient without coordinating 
their actions. Lack of coordination increases the risk of inappropriate 
medications, such as DDIs. 
Cumulating worldwide evidence shows that older adults with multi-
morbidities and polypharmacy are a patient group at the highest risk of 
medication errors and problems. Care of multi-morbid patients with 
polypharmacy is a growing global challenge. In addition to human suffering, 
medication-related adverse events cause burden to health care organizations. 
According to estimates, up to 11% of unexpected hospital admissions are 
caused by medication-related harm, 70% of them concerning multi-morbid 
older adults with polypharmacy (Kongkaew et al. 2013). In Finland, it is 
estimated that 23% of the unplanned geriatric hospital admissions result from 
adverse drug events (Laatikainen 2020). 
The proportion of aged population (>65 years) will grow markedly during 
the next decades – it is estimated to grow from 11% in 2010 to 22% in 2050 
(Mair et al. 2017). The importance of polypharmacy management is 
acknowledged globally in the WHO’s third global Patient Safety Challenge 
“Medication Without Harm” (WHO 2017a). The trend in geriatric care is to 
transfer care from care homes and inpatient facilities to home care. 
Management of medication safety risks of these home-dwelling older patients 
is particularly difficult, and there is an urgent need for new strategies and 
practices in this respect.  
Community pharmacists today already contribute remarkably to safe 
medication use in primary care. Finnish community pharmacies have been 
actively involved in patient and medication safety initiatives since the 
beginning of systems-based initiatives in Finland in the 2000s. They have 
actively developed new tools and services to improve medication safety. These 
include, e.g., medication counseling services (TIPPA Project 2004), automated 
dose dispensing, collaborative medication reviews, and DDI screening. The 
information technology development in community pharmacies has also 
aimed to support safe medication management. Even though these innovative 
prospective medication risk management tools and databases are widely 
available in Finland, they do not form an integrated medication management 
Review of the literature 
82 
process. Utilization of these tools is suboptimal unless dynamic 
interprofessional collaboration, including definition of roles, tasks and 
responsibilities is established.  
A remarkable milestone towards better integration of pharmacy services in 
Finnish health care was the 2015 Government Program, which aimed to 
promote rational pharmacotherapy (Finnish Government 2015). The same 
Government Program also aimed to increase collaborative medication reviews 
in older patients. The 2018 Rational Pharmacotherapy Action Plan by the 
MSAH highlighted the importance of improving medication management as a 
whole (Ministry of Social Affairs and Health 2018). The Action Plan clearly 
states the need for collaborative medication reviews and pharmacists’ 
contributions in this respect. The Action Plan goals continue to underpin the 
implementation-driven long-term roadmap that the MSAH produced in 2019 
(Ministry of Social Affairs and Health 2019). To support the implementation, 
local demonstration projects are needed to find new approaches and pilot 
more coordinated practices, particularly to ensure the rational and safe 
medication use of older patients in primary care, as a part of social and health 
services reform. 
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3 AIMS OF THE STUDY
The aim of this study was to enhance prospective medication risk management 
in outpatient care, by enhancing coordination of care with community 
pharmacists’ participation and use of risk management screening tools. 
Specific objectives of studies I-III were: 
 
x To demonstrate how community pharmacies can utilize their 
prospective surveillance system for screening clinically significant DDIs 
in outpatients and develop a collaborative procedure with local 
physicians to manage clinically significant DDIs, and to assess the rate 
of clinically significant DDIs in a large national outpatient prescription 
sample (I).  
 
x To integrate risk assessment tools, procedures and databases available 
in Finland in order to form a coordinated medication management 
model (CoMM) involving home care nurses and practical nurses (PNs), 
physicians and community pharmacists in the medication process of 
older home care clients. An RCT study design was also developed to 
assess the effectiveness of the intervention (II).  
 
x To assess the impact of the care coordination intervention (CoMM) on 
medication risks identified in drug regimens of older home care clients 
over a one-year period (III). 
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4 MATERIALS AND METHODS
The theoretical framework of this study is systems-based risk management 
theory (Reason 2000) and its application to safe use of medicines. The 
empirical part of this thesis consists of two implementation studies in primary 
care (Figure 9). The Phase I study concerned implementation of the first 
electronic database to identify clinically significant DDIs in community 
pharmacies in Finland. The Phase II studies focused on 1) developing and 
implementing a collaborative procedure to enhance coordination in 
medication management between home care and community pharmacy and 
2) assessing the effectiveness of the procedure (Figure 9). 
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Figure 9 Outline of the study
 
Community pharmacists’ involvement in management of clinically significant 
DDIs in outpatients, and assessment of DDI prevalence in outpatient 
prescriptions (I)
A prospective implementation study, based on retrospective analysis of register-
based data
x To investigate the rate and types of clinically significant, potentially harmful DDIs 
occurring in a national sample of primary care outpatient prescriptions (n= 276,891)
x To study how community pharmacists can prospectively contribute to identification 
and management of DDIs in collaboration with physicians
Development of a coordinated medication management model for older home 
care clients >65 years with community pharmacy involvement (CoMM) (II)
The study applied system-based risk management theory and action research 
method
x To integrate risk assessment tools, procedures and databases available in Finland 
to form a coordinated medication management model (CoMM)
x To utilize existing resources of the involved home care nurses and practical nurses, 
physicians and community pharmacists in the medication process of older home care 
clients
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Impact of CoMM on medication risks in older home care clients: A 
randomized controlled trial (III)
Two-arm, parallel, cluster randomized controlled trial 
x With baseline, and follow-up assessment at 12 months
x Outcomes measured as changes in medication risks: use of potentially inappropriate 
medications and psychotropics; anticholinergic and serotonergic load; drug-drug 
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4.1 IDENTIFYING HIGH RISK MEDICATIONS CAUSING
POTENTIAL DRUG-DRUG INTERACTIONS IN 
OUTPATIENTS: A PRESCRIPTION DATABASE
STUDY BASED ON AN ONLINE SURVEILLANCE 
SYSTEM (STUDY I)
4.1.1 METHODS
4.1.1.1 The DDI screening system 
The prescription database study related to the implementation of the first 
online DDI screening system in Finnish community pharmacies. The study 
was conducted in the University Pharmacy, and sixteen of its seventeen outlets 
participated in the study.  
University Pharmacy is owned by the University of Helsinki, and it is the 
largest community pharmacy operating in Finland dispensing about 5.8 
million prescriptions per year (University Pharmacy 2018). This is about 10% 
of all outpatient prescriptions dispensed in Finland annually. University 
Pharmacy has 17 outlets in 12 large cities in different parts of the country, and 
the largest outlets being located in Helsinki.  
University Pharmacy started to use a prospective DDI surveillance system 
(based on FASS) in June 2004. The surveillance system was linked to the 
prescription processing software (Linnea®; Receptum, Helsinki, Finland). 
While a prescription was processed, the surveillance system automatically 
screened for possible interactions in client’s current and previous (in the prior 
13 months) prescriptions dispensed from any of the 17 University Pharmacy 
outlets. Before starting this systematic, prospective interaction screening as 
part of the routine dispensing process, University Pharmacy trained their 
pharmacists and informed local physicians about this new service. The service 
model developed and implemented in University Pharmacy focused only on 
clinically significant DDIs to avoid any unnecessary work and physician 
consultations caused by DDI alerts that were not clinically significant.  
The surveillance system was based on the FASS database (Farmaseutiska 
Specialiteten i Sverige), which classified DDIs according to their clinical 
importance (Classes A–D) and documented evidence (1–4) (Sjöqvist 1997; 
FASS 2003) (Table 12). The FASS database was produced by the Division of 
Clinical Pharmacology of the Karolinska University Hospital in Sweden (FASS 
2003). The FASS classification was made by Swedish experts and was updated 
once a year at the time of the study. The current Inxbase (previous name 
SFINX) database uses the same FASS classification system (A–D), derived 
from the earlier Swedish interactions screening system used in this study 
(Böttiger et al. 2009; Andersson et al. 2015). The surveillance system recorded 
all potential DDIs (Classes A–D), but only clinically significant DDIs (Class D 
and C) were included in this study. 
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Table 12 The drug-drug interaction classification used in the online surveillance system in 
the University Pharmacy during the time of the study (FASS 2003)
 
CLINICAL SIGNIFICANCE
A. Probably no clinical importance.
B. Clinical importance not yet confirmed.
C. Interaction may modify the effect of the drug, but this can be controlled for 
example, by dose adjustment or by controlling serum level.
D. Interaction may have serious clinical consequences, for example, in form of 
serious adverse effects or diminished drug effect. This type of drug interaction 
should be avoided. 
DOCUMENTED EVIDENCE
1. Incomplete case reports, in vitro studies, or a drug interaction is presumed based 
on the evidence coming from similar drugs.
2. At least one well documented case report.
3. Based on studies in healthy volunteers or on pilot studies in patients.
4. Based on controlled studies on relevant patient groups.
4.1.1.2 Data collection
All interaction alerts provided by the DDI surveillance system were 
collected during a one-month period (July 2004) at the University Pharmacy. 
Study data included the following information: pharmacy outlet´s name, 
number of all detected interactions, classification of interactions, drug names 
according to the Anatomical Therapeutic Chemical classification system (ATC) 
and dispensing dates. Patient information included only the year of birth and 
gender (male/female). Individual prescribers or patients could not be 
identified in the dataset. Thus, no ethical approval from Finnish authorities 
was required. The management team of University Pharmacy approved the 
study protocol before the study was started. The research group included two 
experienced clinical pharmacologists with academic PhD degrees in order to 
assure quality of study design, data collection, and analysis. 
4.1.1.3 Data analysis
The DDI alerts were categorized into classes A, B, C and D according to the 
FASS database, and their frequencies and percentages were calculated. The 
most common interacting drug combinations in each class were analyzed. The 
top ten list of drugs causing potential DDIs was formed by identifying the ten 
drugs with the highest number of class D interaction alerts. Class C interaction 
alerts caused by the same drugs were also calculated.  
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4.2 COORDINATING RESOURCES FOR PROSPECTIVE 
MEDICATION RISK MANAGEMENT OF OLDER 
HOME CARE CLIENTS IN PRIMARY CARE: 
PROCEDURE DEVELOPMENT (STUDY II)
4.2.1 METHODS
 
This study was conducted within publicly funded primary care in Lohja, a 
municipality in Southern Finland with 47,000 inhabitants. Health care units 
involved in the study were Lohja Home Care Unit, Lohja Health Center and a 
private community pharmacy (Lohja 1st Pharmacy). A clinically trained 
researcher (TT) from the research group coordinated the development of the 
medication management model and the study design.  
Home care clients were recruited for the study by nurses and PNs. 
Announcements in the local newspaper were also used. The recruitment 
process was carried out between September 2015 and December 2015. The 
inclusion criteria were: 1) ≥65 years old, home-dwelling resident; 2) receives 
regular home care from the city of Lohja; 3) uses at least one medicine; and 4) 
participates voluntarily, with a written informed consent to participate in the 
study given by the participant or closest proxy. 
4.2.1.1 Ethics approval and consent to participate
The study protocol was approved by the Coordinating Ethics Committee of the 
Hospital District of Helsinki and Uusimaa (HUS), Finland (number 
153/13/03/00/15). Informed written consent was obtained from each patient 
and/or their closest proxy before any study procedure was performed. The 
study is registered in the Clinical Trials.gov (NCT02545257). 
4.2.1.2 Study design
The procedure development was carried out using the action research 
method. The action research method is increasingly being used in health 
services research (Lewin 1946; Meyer 2000). When applying this method, the 
idea is that the researcher works with and for people rather than undertakes 
research on them (Meyer 2000). Reason’s systems-based risk management 
theory (Reason 2000) and Hepler and Strand’s basic principles of identifying, 
solving and preventing DRPs (Hepler & Strand 1990) were applied as 
theoretical frameworks. Clyne’s model was applied for categorization of 
comprehensiveness of medication reviews (Clyne et al. 2008). 
The goal was to construct a collaborative procedure utilizing each 
profession’s existing resources. The coordination of the use of the risk 
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management tools and resources illustrated in Figure 10 was part of the 
process. 
 
 
Figure 10 Medication risk management tools and databases launched in Finland since 2004 and 
currently widely available in health care and community pharmacies
4.2.1.3 Model development process
The procedure development process consisted of four main steps (Figure 
11). During each step, the coordinating pharmacist/researcher (TT) worked 
closely with the home care nurses and PNs, their manager (nurse), physicians 
involved in home care and the community pharmacists.  
The exploration step (Step I, Figure 11) included orientation to each 
organization’s current medication management practices, targeted to older 
home care clients. It also covered identification of medication management 
tools and procedures applied locally in Lohja, compared to those generally 
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available in Finland (Figure 10). Actual tasks and responsibilities for each 
professional were defined in regular joint meetings with the coordinating 
pharmacist (TT), the pharmacy owner (ES) and the nurse responsible for the 
home care service area (KP). 
The installation step (Step II, Figure 11) was to prepare the participating 
organizations for the implementation of CoMM. Home care nurses, PNs, 
physicians and pharmacists were informed prior to implementation of the 
procedure, and continuously encouraged to comment on the model 
construction. Personnel training sessions needed to support the model 
construction were jointly planned with the researchers and home care and 
community pharmacy management. The coordinating pharmacist organized 
trainings for PNs related to the recruitment process, medication reconciliation 
(Institute for Healthcare Improvement 2011) and use of clinical tests. PNs 
were also trained on the content and use of the Drug-Related Problem Risk 
Assessment Tool (DRP-RAT) (Dimitrow et al. 2014; Dimitrow et al. 2015) and 
regarding the Lohja Home Care Unit’s principles in medication management 
(Finnish Institute for Health and Welfare 2015). 
Finishing the CoMM (Step III, Figure 11) aimed to select the appropriate 
manner to solve the identified clinically significant DRPs and allocate 
medication reviews according to the severity of the DRPs. After finishing the 
development of CoMM, its full operation started (Step IV, Figure 11). The 
coordinating pharmacist worked closely with the home care practitioners and 
community pharmacists, facilitating integration between stages and tasks of 
the health care providers involved. This enabled reflection of the model’s 
feasibility. 
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Figure 11 Development process of the coordinated medication management model (CoMM) 
using the action research method (modified from Lewin 1946 and Meyer 2000),  
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4.3 IMPACT OF ENHANCED COORDINATION OF CARE 
ON OUTCOMES OF PROSPECTIVE MEDICATION 
RISK MANAGEMENT OF OLDER HOME CARE 
CLIENTS: A RANDOMIZED CONTROLLED TRIAL
(STUDY III)
4.3.1 METHODS
This study was a clustered RCT with a one-year follow-up period. 
Participants were cluster randomized to intervention and control groups by 
home care service area (Figure 12). The study was considered as open-label. 
The intervention group (IG) received the intervention (CoMM) during the first 
year, while the control group (CG) received standard home care. After the 12-
month follow-up, the CG received the same intervention. 
4.3.1.1 Outcome measures and participants’ characteristics
This study focused on clinically significant medication-related risks (i.e., 
DRPs requiring intervening actions) as primary outcomes for assessing the 
effectiveness of the intervention. Aspects assessed revolved around potentially 
inappropriate medications (PIMs), excessive use of psychotropics, 
anticholinergic and serotonergic load, as well as clinically significant drug-
drug interactions (DDIs) (Table 13).  
Participants’ characteristics included demographics and the following 
clinical outcomes: functional ability (Rava) (Finnish Consulting Group 2019); 
physical performance (the five-times-sit-to-stand test) (Csuka & McCarty 
1985; Guralnik et al. 1994); Mini-Mental State Examination (MMSE) (Folstein 
et al. 1975); Geriatric Depression Scale-15 (GDS-15) (Kurlowicz & Greenberg 
2007); the Mini Nutritional Assessment (MNA) (Vellas et al. 1999); Urinary 
Distress Inventory (UDI-6) (Uebersax et al. 1995); Orthostatic hypotension 
(Short test) (Freeman et al. 2011); and Alcohol Use Disorder Identification 
Test, version C (AUDIT-C) (Bush et al. 1998). All clinical measures used in this 
study were administered by the PNs and nurses during a separate home visit. 
Majority of the applied outcome measures were already part of normal clinical 
use in Lohja Home Care. 
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Figure 12 Study flow chart
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Table 13 Clinically significant medication-related risks that were assessed as outcomes in 
this study 
 
 
  
Outcome Aspects assessed
Medication-related outcomes
Number of all medications The total number of regular and pro re nata (when required) medications 
that have been prescribed (i.e., prescribed medication that is scheduled), 
over-the-counter and herbal products are not included
Use of harmful medications  Included Beers Criteria medications (American Geriatrics Society 2015),
psychotropic and anticholinergic medications according to Puustinen et 
al. (2012)
Use of Beers Criteria medications
(American Geriatrics Society 
2015)
Potentially inappropriate medicines for older adults according to Beers 
Criteria (American Geriatrics Society 2015)
Use of central nervous system 
(CNS) medications
Opioids (ATC code N01AH, N02A, N02BE51, R05DA, R05FA); 
anticholinergic drugs according to Puustinen et al. (2012), antiepileptics 
(ATC code N03A); BZDs and related drugs (ATC codes N05BA, N05CD, 
N03AE01, N05CF, A03CA, C01DA70, M05AA51, N06CA01, N02BA71); 
antidepressants (ATC codes N06A, N06CA); antipsychotics (ATC codes 
N05A, N06CA01)
Use of psychotropic medications
Proportion of study participants 
using >3 psychotropic 
medications, n (%)
BZDs and related drugs (ATC codes N05BA, N05CD, N03AE01, N05CF, 
A03CA, C01DA70, M05AA51, N06CA01, N02BA71); antidepressants 
(ATC codes N06A, N06CA); antipsychotics (ATC codes N05A, 
N06CA01) (Puustinen et al. 2012)
Proportion of study participants 
using >2 serotonergic 
medications, n (%)
Serotonergic medications according to Salko database (Leikola et al. 
2013)
Proportion of study participants 
using anticholinergic medications
Anticholinergic medicines according to Puustinen et al. (2012)
Proportion of study participants 
using antipsychotics, n (%)
ATC codes N05A, N06CA01 
Proportion of benzodiazepine 
(BZD) users, n (%)
BZDs and related drugs (ATC codes N05BA, N05CD, N03AE01, N05CF,
A03CA, C01DA70, M05AA51, N06CA01, N02BA71) (Puustinen et al. 
2012)
Proportion of opioid users, n (%) ATC codes N01AH, N02A, N02BE51, R05DA, R05FA
Proportion of proton-pump 
inhibitor (PPI) users, n (%)
ATC A02BC
Prevalence of clinically significant 
drug-drug interactions (SFINX 
class D) (Böttiger et al. 2009)
Interactions that should be avoided or used with caution (Böttiger et al. 
2009)
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4.3.2 STATISTICAL ANALYSES
Reconciled medication lists gathered from both intervention and standard 
care group participants at baseline and at the 12-month follow-up point were 
analyzed for medication-related risks. All participants who were assessed at 
baseline and at 12-month follow-up were included in the analyses. Since 
medication changes proposed in the medication reviews were only partly 
implemented, data was analyzed with the intention to treat (ITT) and per 
protocol analysis.  
4.3.2.1 Baseline analyses
Baseline analyses were conducted to compare the participants’ 
characteristics and the clinically significant medication risks between the IG 
and CG participants. Participants’ characteristics included demographics and 
the following clinical outcomes: functional ability (Rava) (Finnish Consulting 
Group 2019); physical performance (the five-times-sit-to-stand test) (Csuka & 
McCarty 1985; Guralnik et al. 1994); Mini-Mental State Examination (MMSE) 
(Folstein et al. 1975); Geriatric Depression Scale-15 (GDS-15) (Kurlowicz & 
Greenberg 2007); The Mini Nutritional Assessment (MNA) (Vellas et al. 
1999); Urinary Distress Inventory (UDI-6) (Uebersax et al. 1995); Orthostatic 
hypotension (Short test) (Freeman et al. 2011); and Alcohol Use Disorder 
Identification Test, version C (AUDIT-C) (Bush et al. 1998).  
Analyses were performed using a two-sample t-test for normally 
distributed variables and by Mann-Whitney U-test for non-normally 
distributed variables. Chi-square or Fisher’s exact test was used for categorical 
variables. 
4.3.2.2 Intention to treat- and per protocol analyses
For the ITT analysis all the participants were included in the group in which 
they belonged to  (IG or CG) regardless of whether medication changes agreed 
on were implemented. Per protocol analysis included only those IG 
participants who had at least one of the medication changes actually 
implemented during the follow-up.  
Descriptive statistics (mean, median, or percentages as appropriate) were 
used to present the participant characteristics. The changes within and 
between groups in continuous variables were analyzed with repeated 
measures analysis of variance. Dichotomous outcomes were analyzed through 
binary logistic regression using generalized estimating equations to account 
for the correlation between the repeated measurements. Results are expressed 
using odds ratios (OR) with 95% confidence intervals (CI). ITT analyses were 
adjusted for functional ability and the use of antiepileptic medications, and per 
protocol analyses were adjusted for functional ability (Rava), use of central 
nervous system medications (CNS-medications), GDS-15 and MNA due to 
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group differences at baseline. The longitudinal analysis included participants 
with baseline measurement and at least one follow-up measurement at the 12-
month follow-up point. Two-sided statistical tests with a 5% level of 
significance were used. 
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5 RESULTS
5.1 IDENTIFYING HIGH RISK MEDICATIONS CAUSING
POTENTIAL DRUG-DRUG INTERACTIONS IN 
OUTPATIENTS: A PRESCRIPTION DATABASE 
STUDY BASED ON AN ONLINE SURVEILLANCE 
SYSTEM (STUDY I)
5.1.1 RATE OF POTENTIAL DDIS IN PRESCRIPTIONS
Potential drug–drug interactions were studied using 276,891 dispensed 
prescriptions. Potential DDIs were associated with 11.2% of all prescriptions 
(Table 14). Clinically significant interactions belonging to FASS class D (most 
severe, should be avoided) and C (clinically significant but controllable) were 
associated with 0.5% and 7.2% of prescriptions, respectively.  
 
 
Table 14 Potential drug-drug interactions in the study material (n=276,891 outpatient 
prescriptions) according to their clinical significance (FASS 2003) 
 
Code and clinical significance of interaction n Percentage of all 
interactions, %
Interaction rate in 
prescriptions, %
D   Most severe, interaction that should 
be avoided 
1,512 4.8 0.5
C   Interaction may modify the effect of 
the drug, controllable, e.g., by dose 
adjustment
20,026 64.4 7.21
B   Clinical importance not yet confirmed 8,824 28.4 3.22
A   Probably no clinical importance 748 2.4 0.3
Total 31,110 100.0 11.23
1The value presented in the publication (Toivo et al. 2016) is 7.0, the difference is due to rounding of 
numerical values; 2The value presented in the publication (Toivo et al. 2016) is 3.0, the difference is due 
to rounding of numerical values; 3The value presented in the publication (Toivo et al. 2016) is 10.8, the 
difference is due to rounding of numerical values
5.1.2 MOST FREQUENT CLINICALLY SIGNIFICANT INTERACTION 
ALERTS AND DRUGS INVOLVED 
 
The most frequent class D (most severe, should be avoided) interactions 
were methotrexate combined with NSAIDs (n=549), warfarin combined with 
NSAIDs (n=404), fluoroquinolones combined with cations (e.g. iron, calcium) 
(n=91) and spironolactone/amiloride combined with potassium (n=66) (Table 
15). 
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Potential drug–drug interactions belonging to class C were the most 
common interactions in this study. Class C DDIs accounted for 64.4% of all 
detected DDIs (n = 20,026), the rate in prescriptions being 7.2%. They most 
commonly concerned interactions between antihypertensive drugs and 
NSAIDs (35.3% of all class C interactions, n=7,066) and interactions between 
psychotropic drugs. Interactions involving antidepressants accounted for 
20.2% of class C interaction alerts (n=4,044). DDIs of antidepressants were 
most commonly between antipsychotics (11.5%, n=2,312) and between other 
antidepressants, of which venlafaxine, fluoxetine and paroxetine were most 
common (5.0%, n=995). 
 
 
Table 15 The most common potentially serious drug-drug interactions and their percentage 
of all class D interaction alerts (n=1,512) and the nature of the interaction. Study 
material: 276,891 dispensed outpatient prescriptions
 
Drug(s) Drug(s) % (n) Nature of interaction (FASS 2003) 
Methotrexate NSAIDs1 36.3 (549) NSAIDs may reduce the tubular clearance 
of methotrexate
Warfarin NSAIDs1 26.7 (404) Risk for gastrointestinal bleeding
Fluoroquinolones Calcium/iron 6.0 (91) Inhibition of the absorption of 
fluoroquinolones
Spironolactone/ 
amiloride
Potassium 4.4 (66) Risk for hyperpotassemia
Verapamil ß-adrenoceptor 
blockers
2.6 (39) Risk for bradycardia
Sildenafil Organic nitrate 3.0 (46) Risk for severe hypotension, ischemia 
and damage in brain and hearth
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5.2 COORDINATING RESOURCES FOR PROSPECTIVE 
MEDICATION RISK MANAGEMENT OF OLDER 
HOME CARE CLIENTS IN PRIMARY CARE: 
PROCEDURE DEVELOPMENT (STUDY II)
5.2.1 CARE COORDINATION MODEL FOR HOME CARE CLIENTS
(COMM)
The developed coordinated medication management model (CoMM) 
consists of five main stages in which clinically significant DRPs can be 
identified and solved using collaborative procedures and medication reviews 
(Figure 13). PNs were trained to observe potential medication risks on routine 
home visits more systematically than before and to report detected clinically 
significant DRPs to the coordinating pharmacist (Figure 13: Stage I: Risk 
Assessment). The coordinating pharmacist prepared the cases for the triage 
meeting (Figure 13: Stages I and II), in which the leading home care physician 
and the coordinating pharmacist decided on further action for clients with 
clinically significant DRPs (50–70 cases per triage meeting of two hours). The 
actions included more comprehensive medication reviews according to the 
needs of the clients, involving their own physicians and nurses/PNs. In the 
most complicated cases home visits were undertaken and the client’s clinical 
interview was conducted (Figure 13: Stage III).  
After the collaborative medication reviews, each client’s physician made 
the final decisions regarding the changes to the medication regimens (Figure 
13, Stage IV). In some cases, the physician wanted to meet the home care client 
and discuss the changes. In most cases, home care nurses who knew the clients 
discussed the changes with them and implemented the changes according to 
the physician’s orders. This was a normal routine in the home care context of 
Finland, due to the limited physician resources. At the follow-up stage (Figure 
13, Stage V), PNs and nurses monitored clients’ condition, particularly when 
medication changes were implemented. Collaborative tasks of each healthcare 
professional in the developed model (Figure 13) are described in Table 16. 
Nurses and PNs had a key role in clinical follow-up and identifying clients with 
clinically significant DRPs, through gathering and bringing information about 
clients’ symptoms and signs using the DRP-RAT.  
Community pharmacists’ pharmacotherapeutic skills were utilized in 
medication reviews at Stage III (Figure 13). Physicians’ resources were 
allocated for clinical decision-making at the triage stage (Stage II) and for 
deciding on actions for clients with complicated DRPs, analyzed in more detail 
in the prescription review (PR), medication review (MR) or comprehensive 
medication review (CMR) (Stage IV). The coordinating pharmacist had a key 
role in organizing and coordinating medication management processes 
between the fragmented organizations involving different health care 
providers, and in preparing and participating in the triage meetings followed 
by different level medication reviews.
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Table 16 Agreed tasks of each healthcare professional and tools used in the coordinated 
medication management model (CoMM)
 
Healthcare 
professionals
Tasks in the coordinated 
medication management 
model
Tools used
Home care 
nurses, 
practical 
nurses
Medication reconciliation 
Medication risk assessments
Clinical tests to assess 
clients’ functional ability and 
disability (at baseline, follow-
ups at 12 and 24 months)
Medication lists, usual home visits
Clinical interviews with the DRP-RAT
a) Measures used in usual clinical practice: functional 
ability (RAVA), physical performance (the five-times-sit-to-
stand test), cognitive functioning (MMSE), depression 
(GDS-15) and malnutrition (MNA)
b) Added measures: difficulties related to urination (UDI-6),
orthostatic hypotension (3 minutes test) and alcohol use 
(AUDIT-C)
Implementing medication 
changes and monitoring 
their outcomes 
Regular home visits as usual
Informing physicians when needed
Community 
pharmacists
Prescription review (PR) Clinically significant drug-drug interactions (DDIs) (SFINX). 
Potentially inappropriate medicines (PIMs) according to 
Beers 2015 criteria (AGS 2015), anticholinergic and 
serotonergic loads of medicines (Salko)
Medication review (MR) Patient information: medication list, DRP-RAT and 
glomerulus filtration rate (GFR) results
Screening tools used: 
SFINX (DDIs); Pharao (Cumulative scoring of the 
anticholinergicity, bleeding risk, constipation, orthostatic 
hypotension, prolongation of QT interval, nephrotoxicity, 
sedation, convulsion risk and serotonergicity of the patient’s 
medication); Salko (PIMs); Renbase (Renal function and 
appropriateness of doses/medicines used)
Comprehensive medication 
review (CMR) conducted by 
a qualified pharmacist 
(TT,SL)
Patient information: medication list, DRP-RAT and GFR 
results, diagnosis, laboratory test results
Tools used: As in MR, complemented by client’s clinical 
interview
Coordinating 
pharmacist
Trainings of the PNs for the 
recruitment process, CoMM 
and use of DRP-RAT (MD)
Meetings, discussions, personal guidance, DRP-RAT 
training (Dimitrow et al. 2015)
Coordinating and organizing 
processes for CoMM
Constructing the CoMM structure through observations, 
meetings, contacts and negotiations with organizations, 
health care professionals, researchers and home care 
clients involved, organizing processes and interactive 
training, providing training, guidance and feedback, 
reflecting the literature and guidelines on geriatric care and 
pharmacotherapy
Preparing triage meetings 
with the leading home care 
physician to decide on 
actions for clients with 
clinically significant DRPs 
Prescription review findings (from SFINX and Salko
databases) and DRP-RAT results
Leading 
home care 
physician
Triage meetings with the 
coordinating pharmacist and 
nurse to decide on actions 
for clients with clinically 
significant DRPs (50-70
cases per triage meeting of 
2 hours)  
Prescription review findings (from SFINX and Salko
databases) and DRP-RAT results
Client’s 
personal 
physician
Case-conferences with 
pharmacists concerning 
clients with clinically 
Medication lists accomplished with the SFINX and Salko 
data, DRP-RAT results, results from the clinical and
laboratory test (GFR)
Results 
102 
significant DRPs identified in 
MR and CMR.
Decisions on the medication 
changes and how they will 
be implemented
Reports with clinically significant findings from prescription 
review, MR and CMR (CMR report including client’s clinical 
interview)
Abbreviations: DRP-RAT, Drug-Related Problem Risk Assessment Tool (Dimitrow 2016); MMSE, Mini Mental 
State Examination (Folstein et al. 1975); GDS-15, Geriatric Depression Scale (Kurlowicz et al. 2007); MNA, 
The Mini Nutritional Assessment (Vellas et al.1999); UDI-6 (Urinary Distress Inventory) (Uebersax et al. 1995);
AUDIT-C (Alcohol Use Disorder Identification Test, version C) (Bush et al. 1998); SFINX: Drug-drug interaction 
database’s new name since March 2017 is INXBASE; Pharao: adverse effects database’s new name since 
March 2017 is RISKBASE.
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5.3 IMPACT OF ENHANCED COORDINATION OF CARE
ON OUTCOMES OF PROSPECTIVE MEDICATION 
RISK MANAGEMENT OF OLDER HOME CARE 
CLIENTS: A RANDOMIZED CONTROLLED TRIAL 
(STUDY III)
5.3.1 STUDY PARTICIPANTS
Of 384 eligible home care clients, 191 (49.7%) clients or their proxies 
provided written consent to participate (Figure 12). The intervention group 
(IG) included 104 participants, of which three dropped out before baseline 
data gathering. The control group (CG) included 87 study participants. There 
was a remarkable attrition rate, with 59 participants (31.4%) lost to follow-up 
at 12 months. In the IG, attrition rate was 35.6% (n=36) and in the CG 26.4% 
(n=23) (p=0.18) (Figure 12). Drop-out analysis between the IG and CG 
participants did not show statistically significant differences in baseline 
characteristics (data not shown). The number of participants with baseline and 
12-month follow-up data available, included into the analyses, was 129.  
The mean age of the participants (n=129) was 82.8 years (SD 7.05), 82.5% 
(n=104) were living alone and 69.8% (n=90) were women (Table 17). The 
mean number of prescription medications (regular and pro re nata, i.e., when 
required) was 13.5 (SD 3.87) in the IG compared with 12.7 (SD 4.30) in the CG 
(p=0.25).  
5.3.2 USE OF PIMS AT BASELINE
Use of PIMs, excessive use of psychotropics and high anticholinergic and 
serotonergic load was common in both groups at baseline (Table 18). 
Prevalence of Beers Criteria (American Geriatrics Society 2015) medication 
use was 93.9% in IG and 90.6% in CG (p=0.53); anticholinergic use was 27.7% 
in IG and 18.8% in CG (p=0.23); and >3 psychotropics use was 20.0% in IG 
and 9.4% in CG (p=0.09) (Table 18). The most commonly used Beers Criteria 
medications were proton pump inhibitors (PPIs), when used for longer than 
two months without precise indication: this was the case for 50.4% (n=60) of 
the Beers Criteria medication users (n=119).  
Results 
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Table 17 Baseline characteristics of participants (including all participants assessed at 
baseline and at 12-month follow-up)
 N  Total 
 
Intervention 
Group (n=65) 
Control Group 
(n=64) 
pc  
Female, n (%) 129 90 (69.8) 44 (67.7) 46 (71.9) 0.61 
Mean age; years, (SD), range 129 82.8 (7.1), 65–96 81.6 (7.1), 65–95  84.0 (6.8),67–96 0.05 
Age group, n (%) 129    0.08  
65–69  8 (6.2) 5 (7.7) 3 (4.7)  
70–74  9 (7.0) 5 (7.7) 4 (6.3)  
75–79  17 (13.2) 13 (20.0) 4 (6.3)  
80–84  41 (31.8) 21 (32.3) 20 (31.3)  
85+-  54 (41.9) 21 (32.3) 33 (51.6)  
Living alone, n (%) 126 104 (80.6) 53 (84.1) 51 (81.0) 0.64 
Rava indexa,b, mean (SD) 128 1.98 (0.61) 2.19 (0.63) 1.77 (0.51) <0.001 
 MD  1.83 2.08 1.59  
MNA Screeningb  127    0.14 
Normal nutritional status (12–14 
points), n (%) 
 65 (51.2) 30 (46.9) 35 (55.6)  
At risk of malnutrition (8–11 
points), n (%) 
 54 (42.5) 32 (50.0) 22 (34.9)  
Malnourished (0–7 points), n (%)  8 (6.3) 2 (3.1) 6 (9.5)  
MMSEb  126    0.44  
    25–30 (no cognitive impairment), 
    n (%) 
 44 (34.9) 19 (30.7) 25 (39.1)  
    18–24 (mild cognitive impairment), 
   n (%) 
 70 (55.6) 38 (61.3) 32 (50.0)  
    0–17 (moderate to severe cognitive 
    impairment), n (%) 
 12 (9.5) 5 (8.1) 7 (10.9)  
GDS-15b  >6 (suggestive of 
depression), n (%) 
127 39 (30.7) 21 (33.3) 18 (28.1) 0.52  
Proportion with orthostatic 
hypotension, n (%) 
106 24 (22.6) 14 (29.2) 10 (17.2) 0.14 
UDI-6 , mean (SD) 126 3.2 (4.0) 3.26 (4.4) 3.2 (3.6) 0.92 
 MD  2.0 2.0 2.0  
AUDIT-C , mean (SD) 128 0.9 (1.7)  1.2 (1.9) 0.0 0.72 (1.5) 0.59 
 MD  0.0 0.0 0.0  
The five-times-sit-to-stand testb. 
Participants with inability to 
complete the test, n (%) 
128  
52 (40.6) 
 
32 (50.0) 
 
20 (31.3) 
 
0.03 
Medication use  129     
Number of regular medications, 
mean (SD) 
 10.1 (3.3) 10.4 (3.3) 9.8 (3.2) 0.25 
Number of pro re nata medications, 
mean (SD) 
 3.0 (1.8) 3.1 (1.7) 2.9 (1.8) 0.54 
Number of all medications, mean 
(SD) 
 13.1 (4.1) 13.5 (3.9) 12.7 (4.3) 0.25 
Number of all medication, classified     0.53 
   1–6, n (%)  5 (3.9) 1 (1.5) 4 (6.3)  
   7–9, n (%)  16 (12.4) 7 (10.8) 9 (14.1)  
   10–15, n (%)  76 (58.9) 40 (61.5) 36 (56.3)  
   16+, n (%)  32 (24.8) 17 (26.2) 15 (23.4)  
SD: standard deviation; MD: median; MNA: the Mini Nutritional Assessment (Vellas et al. 1999); MMSE: Mini-Mental State Examination)
(Folstein et al. 1975); GDS-15: Geriatric Depression Scale (Kurlowicz and Greenberg 2007); UDI-6: Urinary Distress Inventory (Uebersax et al.
1995); AUDIT-C: Alcohol Use Disorder Identification Test, version C (Bush et al. 1998); the five-times-sit-to-stand test (Csukat et al. 1985;
Guralnik et al. 1994); aRava index (FCG 2019), describes the need of help based on functional ability (scale 1.29–4.03; results 1.50–1.99 mean
need for regular help); bmeasure used in usual clinical practice in Lohja Home Care; cdifferences between the groups were tested with Chi-
squared test or Fischer exact test in categorical variables and with Mann-Whitney test or two-sample t-test in continuous variables
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5.3.3 EFFECT OF THE INTERVENTION ON THE USE OF PIMs (ITT 
ANALYSES)
No clinically significant medication-related risks requiring collaborative 
medication review were found for 45.5% (n=45) of the 99 IG participants who 
had DRP-RAT assessment available (Figure 12). Of the remaining 54.5% 
(n=54), prescription review was needed in 29.6% (n=16), medication review 
in 63.0% (n=34), and comprehensive medication review in 7.4% (n=4) of the 
cases. 
The mean number of all medications in use increased in both groups over 
the 12-month follow-up period: in IG from 13.5 to 14.1 (adjusted mean change 
0.77 95% CI 0.05–1.48; p=0.04) and in CG from 12.7 to 13.0 (adjusted mean 
change 0.52 95% CI -0.37–1.41; p= 0.25) (Table 18). The prevalence of PIM 
use remained mainly constant in both groups. No significant changes (p<0.05) 
were found in any selected medication-related outcomes between the IG and 
CG in the ITT analyses (Table 18).  
5.3.4 PER PROTOCOL ANALYSES
Per protocol analysis compared IG participants with at least one 
implemented medication change (n=27) with CG participants (n=64) (Table 
19). No significant differences (p<0.05) were found in medication-related 
outcomes between the IG per protocol (IGpp) and CG over the 12-month 
follow-up period (Table 19). However, a tendency for a decrease was found in 
the use of central nervous system (CNS) medications between the groups 
(p=0.08): in IGpp a decrease of 18.5% was observed (adjusted OR 0.15 95% CI 
0.03–0.80), compared to a decrease of 3.1% (adjusted OR 0.81 95% CI 0.37–
1.77) in CG. 
5.3.4.1 Analyses within the per protocol group (n=27)
In the analyses within the IGpp, in addition to a decrease in CNS use (from 
92.6% to 74.1%; adjusted OR 0.15, 95% CI 0.03–0.80; p=0.03), the use of 
benzodiazepines (BZDs) decreased from 55.6% to 37.0% (adjusted OR 0.43, 
95% CI 0.21–0.91; p=0.03). A tendency for a decrease within the IGpp (p<0.10) 
was shown in the following outcomes: proportion of persons using >3 
psychotropic medications decreased from 18.5% to 7.4% (p=0.07) and opioid 
use decreased from 40.7% to 26.0% (p=0.09) (Table 19). 
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6 DISCUSSION
6.1 IDENTIFYING HIGH RISK MEDICATIONS CAUSING 
POTENTIAL DRUG-DRUG INTERACTIONS IN 
OUTPATIENTS: A PRESCRIPTION DATABASE 
STUDY (STUDY I)
The major implication of this study was to demonstrate that community 
pharmacists can remarkably influence safe use of medicines in outpatient care 
by identifying and managing clinically significant DDIs in collaboration with 
local physicians. There were more than 31,000 potential DDIs in a sample that 
comprised about 10% of all prescriptions dispensed to outpatients in Finland 
in one month. Extrapolating the number of clinically significant DDIs in our 
sample (n=21,538) to all prescriptions dispensed in Finland during that time 
period indicates that a remarkable number of outpatients were exposed to 
medications that may have serious clinical consequences. This is an important 
demonstration that pharmacists can be are a great asset in protecting patients 
from harm and could be more actively involved in patient care. Pharmaceutical 
expertise should be more effectively used to manage DDIs and to prevent 
them, e.g., by finding safer alternatives for drugs that can cause severe 
interactions. According to the findings of this study, risk for severe DDIs could 
be substantially decreased simply by focusing on the use of some high risk 
medications, such as NSAIDs, warfarin, methotrexate, potassium and 
spironolactone in outpatient care.  
According to this study, 10.8% of all prescriptions dispensed during the 
study period included a potential DDI. Alerts for clinically significant DDIs 
were found in 7.0% (class C) and 0.5% (class D) of all dispensed prescriptions. 
This is congruent with previous Nordic studies, which used the same 
interaction classification (FASS) (Merlo et al. 2001; Heikkilä et al. 2006). In a 
more recent Swedish study describing the impact of the SFINX database on 
incidence of potentially serious DDIs in primary care, class D interactions were 
only found in 0.18–0.22% of prescriptions (Andersson et al. 2013). This may 
indicate that the use of DDI screening tools has decreased the rate of DDIs. 
However, changes in the DDI databases are another major explanation for the 
differences in the DDI rates between the studies. The current SFINX database 
is more specific than the previously used FASS database (Böttiger et al. 2009). 
Furthermore, the current SFINX database is structured according to 
individual substance names, not according to therapeutic groups or ATC 
codes, which were partially used in the FASS database (Böttiger et al. 2009). 
In this study class D interactions occurred most commonly between 
methotrexate and NSAIDs (36.3% of all class D interaction alerts) and between 
warfarin and NSAIDs (26.7%). Other common interactions involved 
fluoroquinolone antibiotics and cations (e.g., iron, calcium) (6.0%), and DDIs 
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between potassium sparing diuretics and potassium supplements (4.4%). 
These findings are quite similar to the findings of the previous studies using 
the same interaction database (Merlo et al. 2001; Heikkilä et al. 2006).  
The significance of methotrexate-NSAID interaction is, however, 
controversial. According to the FASS database, the combination may cause 
reduction in elimination of methotrexate (FASS 2003). The current 
Micromedex database still categorizes methotrexate-NSAID interaction as 
“major” (Micromedex 2015). Many studies have, however, shown that the use 
of NSAIDs does not have an effect on the kinetics of methotrexate or 
significantly increase the toxicity in the cure of rheumatoid arthritis 
(Colebatch et al. 2011). The risk of toxicity is greater in patients receiving high-
dose methotrexate for neoplastic disease than in patients receiving low-dose 
methotrexate. Patients with impaired renal function also appear to be at 
greater risk (Iqbal et al. 1998). The current Inxbase (previous name SFINX) 
database categorizes methotrexate-NSAID interaction as class A (no clinical 
relevance) with enteral methotrexate and class B (clinical outcome of the 
interaction is uncertain and/or may vary) with parenteral methotrexate. 
Regarding low-dose methotrexate–NSAID interaction, which represented all 
the cases in the present study, the current database classifies the interaction 
in class A (no clinical relevance). Thus, methotrexate-NSAID interaction alerts 
belong to the limitations of this study. 
Warfarin-NSAID interactions have high potential to cause harm to patients 
(Shorr et al. 1993; Hauta-Aho et al. 2009). Ibuprofen, ketoprofen and 
acetylsalicylic acid are available in Finland without a prescription. Thus, 
interactions with warfarin are an underestimate of the actual risk for warfarin-
NSAID interactions because OTC-NSAIDs were not identified by the database.  
Potassium-potassium sparing diuretic interactions may cause 
hyperkalemia and arrhythmia, but clinical guidelines, e.g., in the SPCs 
(Summary of Product Characteristics) of various potassium and 
spironolactone preparations, recommend monitoring these patients for their 
potassium values if these drugs are used concurrently. 
The most common drug combination in class C interaction alerts was 
antihypertensive drugs and NSAID (35.3% of class C interactions). Both drugs 
were among the most commonly used medicines in Finland at the time of the 
study, which may explain the high interaction rate (Finnish Statistics on 
Medicines 2004). Regular use of NSAIDs during antihypertensive treatment 
has shown to raise blood pressure and reduce the effectiveness of many 
antihypertensives and to increase the risk of myocardial infarction, as well as 
cause or worsen the symptoms of heart failure (Bleumink et al. 2003; Bavry et 
al. 2011; Fournier et al. 2014).  
This study was conducted using data collected in 2004. A follow-up study 
using the same method would be useful to show the current DDI prevalence in 
outpatient care. As our systematic review indicated (see Chapter 2.5.3), 
internationally, there are not many publications with extensive data, 
describing the prevalence of DDis in outpatients. Currently, DDI screening 
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systems are widely used in Finnish community pharmacies, and DDIs are 
screened as a part of routine dispensing process (AATE 2017, Kallio et al. 
unpublished). DDI screening tools are also widely available for physicians, 
providing support with prescribing. This could be expected to have reduced 
the prevalence of DDIs. However, community pharmacists have reported need 
for training, particularly with interpretation and managing of clinical 
significance of DDIs (Kallio et al., unpublished). Enhanced collaboration and 
better defined roles and responsibilities of physicians and pharmacists in 
management of severe DDIs are areas needing action. 
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6.2 COORDINATING RESOURCES FOR PROSPECTIVE 
MEDICATION RISK MANAGEMENT OF OLDER 
HOME CARE CLIENTS IN PRIMARY CARE: 
PROCEDURE DEVELOPMENT (STUDY II)
This study produced a 5-stage medication management procedure suitable for 
screening medications of a high number of home care clients and identifying 
clients with potentially clinically significant DRPs. The model coordinates 
existing resources with prospective medication risk assessment, an also 
provides tools to solve identified DRPs. Nurses and PNs’ roles in conducting 
DRP risk assessments, medication reconciliation, and clinical tests during 
their usual home visits was clarified and reinforced. They also had a key role 
in implementing and following up medication changes.  
Triage meetings was a new and feasible strategy for allocating medication 
reviews according to clinical needs, while using a minimum of physicians’ 
time. The coordinating pharmacist prepared triage meetings by summarizing 
each client’s DRP risk information from different sources and making 
preliminary proposals for required actions for physician’s consideration. 
Community pharmacists’ contributions changed and became more clinical in 
the model. They conducted medication reviews and worked closer than before 
with nurses, PNs and physicians. In future, the coordinating role could be 
delegated to community pharmacists.  
The CoMM model contains an adequate follow-up stage to confirm that the 
agreed medication changes will actually be implemented and the client’s 
health status monitored. This stage is often missing, though it is crucial for 
obtaining any benefits from DRP risk assessments and medication reviews 
(Kiiski et al. 2016). 
The model focuses on clinically significant DRPs which may occur due to 
patient-related factors (e.g., age-related physiological changes, co-
morbidities, poor adherence), pharmacological effects of the medications 
(particularly adverse drug reactions, and high-risk medications) or the 
medication process of the client (e.g., poor medication management, 
infrequent follow-ups, various health care providers) (Dimitrow et al. 2014). 
These are the aspects that PNs were trained to observe during home visits by 
using the DRP-RAT tool as a guide when communicating with their client or 
the proxy. Home visits were primarily conducted by clients’ own PNs, who 
knew them. A clinically trained pharmacist conducted home visits only in 
cases in which risk assessment conducted by a PN indicated serious DRPs 
requiring more comprehensive investigation. These cases were a minority in 
our data. 
The CoMM development process revealed educational needs both in 
geriatric pharmacotherapy and for understanding system-based medication 
risk management. These needs were identified in all participating health care 
professionals, including physicians and community pharmacists. This kind of 
model development processes should include interprofessional training that 
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supports competence and practice development (Holmström et al. 2015a). In 
our process, home care nursing staff and physicians had training for 
identifying clinically significant DRPs by using DRP-RAT and deprescribing 
(Dimitrow et al. 2014, Dimitrow 2016, Page et al. 2016). Community 
pharmacists were identified requiring training for conducting DRP risk 
assessments and assuming more responsibility of the triage stage in the future. 
The coordinating pharmacist was a valuable resource in identifying 
educational needs and educating staff. Practical nurses were identified to carry 
a remarkable role in the medication use process of home care clients. In line 
with findings from a recent national study, home care practical nurses need 
additional training in pharmacotherapy to meet the requirements of their 
current work duties in geriatric care (Mononen et al. 2020).   
Our experience is that health care teams in home care benefit from having 
a coordinating pharmacist with qualifications in CMRs, geriatric 
pharmacotherapy and system-based medication risk management. Our study 
revealed that organizations and health care units involved in home care clients’ 
medication therapy are working independently in silos, where no specific 
individual takes holistic responsibility for medications. The same has been 
found by the Finnish Medicines Agency’s program to improve 
interprofessional collaboration in medicines optimization for older adults 
(Kallio et al. 2016; Kumpusalo-Vauhkonen et al. 2016). The coordinating 
pharmacist was needed to facilitate construction of new processes and 
introduce new tools and approaches in medication management. She 
scheduled the progression of risk management stages (see Figure 12 and 13) 
and regularly highlighted the primary goal of the project to those involved: the 
purpose being to find a feasible way in which to manage and prevent clinically 
significant DRPs of the home care clients – not to conduct scientific research.  
Practitioners involved were not used to working in such close collaboration, 
which was crucial for the model. Scarce availability of physicians’ resources 
and partly reluctant attitudes towards the new collaborative way of working 
complicated the arrangement of case-conferences of MRs and CMRs.  
System-based risk management perspectives, using Reason’s Swiss Cheese 
Model (Reason 2000) and Hepler and Strand’s model (1990) in order to 
identify and prevent DRPs, were useful in guiding model development and 
constructing a shared understanding of medication safety and prospective 
medication risk management. This study indicated that practitioners in 
Finnish health care are not well acquainted with systems thinking and this 
requires reinforcement in the future. The same challenge was identified in the 
WHO report dealing with contributing factors to medication errors in primary 
care (WHO 2016g). 
The strength of using an action research method (Lewin 1946) in model 
development lies in its ability to consider practical challenges and produce 
solutions, considering existing resources. The method contributed to the step 
by step construction of the CoMM model and description of the 
responsibilities of each professional involved in the model, which is missing in 
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many other studies (Kiiski et al. 2016). Transferring the model to other home 
care localities is possible. It will require long-term effort from a qualified 
coordinator, committed personnel, and managers to reach the mature stage of 
the collaboration that is necessary for sustainable changes in working 
patterns. This study used action research method to develop the care 
coordination model (intervention) and published the development process 
(Study II), which is a strength of this study.  
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6.3 IMPACT OF ENHANCED COORDINATION OF CARE 
ON OUTCOMES OF PROSPECTIVE MEDICATION 
RISK MANAGEMENT OF OLDER HOME CARE
CLIENTS: A RANDOMIZED CONTROLLED TRIAL
(STUDY III)
The core of the intervention in this study consisted of triage meetings which 
proved to be a feasible method for customizing comprehensiveness of 
collaborative medication reviews (CMRs) for older home care clients 
according to their clinical needs while minimizing the use of physician’s time. 
Of the older home care clients, 45.5% had no need for more comprehensive 
medication reviews. Thus, the triage enabled focusing on clients with clinically 
significant DRPs instead of comprehensively reviewing medications of all 
clients, as has been the case in many previous studies (Kallio et al. 2018).  
The intervention did not show an impact on the use of PIMs between the 
original intervention group and the control group in the intention to treat 
analysis, though the per protocol analysis indicated a tendency for 
effectiveness, particularly in optimizing CNS medication (especially in BZD) 
use during a 12-month follow-up. As the original IG included many home care 
clients whose medication changes were not actually implemented as proposed 
(50% of the intervention group participants), the intervention was incomplete 
for them. Thus, per protocol analysis is a better predictor of the effectiveness 
of the coordinated home care model than a comparison between the original 
intervention group and the control group. 
Our baseline findings demonstrate a high prevalence of PIM use. 
Particularly, the prevalence of potentially inappropriate psychotropic 
medication use was high (58.1%, n=75) in the entire study population (IG and 
CG, n=129) included in the intention to treat analysis. Most common was BZD 
use (41.1%) and antidepressant use (36.4%). National register-based data 
shows that long-term use of BZDs is the major PIM-related concern in 
Finland, particularly the use of temazepam (Leikola et al. 2011). A more recent 
study indicates a declining trend in the long-term BZD use over the last few 
years (2006–2014), while the long-term BZD use among older adults has 
remained constant, and at a higher level compared to other populations 
(Kurko et al. 2018). The decline has not been uniform between the substances: 
the long- term use of clonazepam and zolpidem has even increased (Kurko et 
al. 2018). These findings indicate an urgent need for effective deprescribing 
interventions that should be actively promoted so as to make them part of the 
routine clinical practice. There are recent promising results of successfully 
reducing long-term BZD use in older adults through community-based 
interventions in primary care (Puustinen et al. 2014; Puustinen et al. 2018). 
Inappropriate use of antipsychotics (APs) is another major concern in 
geriatric pharmacotherapy, which can also be seen in our data (baseline users: 
15.5%, n=20). APs are usually prescribed for behavioral and psychological 
symptoms of dementia though the use may even continue for years without 
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proper follow-ups (Jalava et al. 2018). International criteria, e.g., Beers 
Criteria, have updated their recommendations on the use of APs in recent 
years: use should be avoided unless nonpharmacological options have failed 
or are not possible and the individual is threatening substantial harm to self 
or others (AGS 2015, AGS 2019). However, Finnish guidelines are not as strict 
concerning AP use in older adults as the most recent international guidelines 
(Fimea 2019, Meds75+). This may partly explain their wide use among older 
outpatients and inpatients in Finland (Jalava et al. 2018). It would be 
important to reconsider our domestic guidelines and care practices to meet 
current international standards of AP use.  
Another contributing factor to excessive use of antipsychotics in older 
adults is culture of care (Nurminen et al. 2009; Sawan et al. 2018). Our 
experience in Lohja Home Care was that some of the physicians and nurses 
were reluctant to actually stop the AP treatment even though the potential 
need for deprescribing was agreed on in the triage meeting. As previous 
studies have shown, this may be due to concerns regarding stopping 
medications started and prescribed by other physicians, limited knowledge of 
how to stop APs and concerns regarding a relapse of behavioral disorders 
(Reeve et al. 2016; Bjerre et al. 2018; Sawan et al. 2018). Further research is 
needed to better understand these systems-based factors influencing AP use 
which can lead to unnecessary and harmful long-term medications. 
 
Implementation of the intervention 
We experienced challenges in implementing the new procedure. This was 
also seen in the analysis of the effectiveness of the intervention. Physicians’ 
limited resources, partly reluctant attitudes, and weak engagement to the new, 
more collaborative medication management practice were evaluated as the 
main contributing factors for the intervention not being fully implemented. 
Some physicians were reluctant and did not approve of and implement any of 
the recommended clinically significant medication changes. Thus, these 
factors affecting medicines optimization require further investigation.  
This trial represents the real world and includes features of pragmatic 
trials, which frequently include complex interventions, involving the skills and 
experience of various health care providers to deliver the intervention (Ford & 
Norrie 2016). Our experience is that implementation of this kind of new 
coordinated procedure requires long-term and goal-oriented commitment of 
all healthcare providers involved, in order to break organizational barriers and 
change working behaviors and patterns. Educational needs in both geriatric 
pharmacotherapy and understanding system-based medication risk 
management were identified in all participating health care providers, 
including PNs, nurses, physicians and community pharmacists. The most 
striking competence gap observed relates to deprescribing. Thus, a better 
deprescribing protocol needs to be used in future studies. 
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6.4 RELIABILITY AND VALIDITY OF THE RESEARCH
METHODS (I-III)
Study I 
This study has some advantages compared to previous DDI incidence 
studies (see Table 10). The study sample was quite large and covered all age 
groups of Finnish medicine users in outpatient care from different parts of the 
country (11 locations across the country). Some of the previous studies 
gathered their data from only two or three cities (Heikkilä et al. 2006; 
Chatsisvili et al. 2010) or from one province of the country (Astrand et al. 
2007; Lopez-Picazo et al. 2010). Furthermore, some studies had remarkably 
smaller sample sizes compared to this study (Heikkilä et al. 2006).  
Although the data were collected quite a long time ago, the study is still 
relevant. According to the systematic literature review that we recently 
conducted on DDI incidence studies in outpatients, few studies have focused 
on community pharmacy settings (Table 11). Publishing the results of this 
study will facilitate comparisons with more recent data to indicate whether any 
improvements have taken place in safety of medication use in outpatients in 
terms of clinically significant DDIs. 
This study focused solely on DDIs and the service development regarding 
the DDI-surveillance system available 16 years ago. With current databases 
and surveillance systems it is possible to also identify other risks, such as drug-
disease, drug-food or drug-herbal product interactions. If these other potential 
risks were to be screened in the community pharmacy, the same kind of 
collaborative service model needs to be developed with the local health care 
providers as developed for DDIs in this study. Aspects that need to be agreed 
upon include: how to coordinate utilization of the surveillance system; in 
which cases pharmacists can manage DDIs and when they should contact the 
prescribers and how the potential risks should be communicated with the 
patients.    
As the surveillance system did not take into consideration the timing of 
dispensing of the drugs, it is not known whether the interacting drugs were 
used concurrently, which is a prerequisite for an actual interaction to occur. 
Therefore, this study may overestimate the number of actual DDIs occurring. 
In 50.0% of all interactions in this study, both drugs were dispensed between 
April and July. In such cases at least, drugs for long-term therapies were most 
likely still in use. Even though the interacting drugs may have been used 
concurrently, it is not known whether they resulted in any harm to the exposed 
patients. Some studies conducted in hospitals have estimated that 10–50% of 
potential DDIs are clinically significant on patients (Wiltink 1998). A Finnish 
study on DDIs between warfarin and cisapride revealed that over 70% of 
theoretical interactions caused some clinical changes or harm to patients 
(Laine et al. 2000). 
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The data contained only the total number of dispensed prescriptions, not 
for any individual drugs. Thus, it was not possible to ascertain the ratio of 
observed interactions for a drug and its total dispensing rate.  
 
The data was also incomplete because it did not include drugs sold over the 
counter (OTC). There are many OTC drugs with a potential to interact with 
prescribed medicines. These include ibuprofen, ketoprofen and acetylsalicylic 
acid (NSAIDs). According to a Finnish study, 4% of OTC drug users had taken 
a drug combination with a potential for a clinically significant drug interaction 
(Sihvo et al. 2000). These potential interactions between OTC drugs and 
prescribed medicines are missing from this study. In addition to previous 
limitations, interactions were only screened between drugs dispensed from the 
University Pharmacy outlets. It is known that consumers use different 
pharmacies, thus interactions between drugs dispensed from pharmacies 
other than the University Pharmacy outlets were undetected in this study.  
 
Study II 
System-based risk management approaches using Reason’s Swiss Cheese 
Model (Reason 2000) and Hepler and Strand’s model (Hepler and Strand 
1990) to identify and prevent DRPs, were useful in guiding model 
development and constructing a shared understanding of medication safety 
and prospective medication risk management. Our study indicated that 
practitioners in Finnish health care are not well acquainted with systems 
thinking, a fact which need to be addressed in the future. 
The strength of using an action research method (Lewin 1946, Meyer 2000) 
in model development lies in its ability to consider practical challenges and 
produce solutions, taking existing resources into consideration. The method 
contributed to the step by step construction of the CoMM model and 
description of the responsibilities of each professional involved in the model, 
which is missing from many other studies (Kiiski et al. 2016). 
 
Study III 
Strengths and limitations of the methods 
This study produced an RCT with a combination of outcome measures to 
assess general health status and functional ability of older adults, and also 
targeted to symptoms suggestive of adverse effects of medications.  
Our study design and randomization strategy worked well. At baseline, the 
characteristics of the participants in the IG and the CG were similar, despite 
functional ability (Rava) and use of antiepileptics, which were adjusted in the 
ITT-analyses. We used cluster randomization to avoid contamination related 
to home care nurses and PNs. Contamination related to community 
pharmacists and physicians was not considered, since these professionals did 
not have regular encounters with the home care clients. Clustering by service 
area was not accounted for in the data analysis.  
Discussion 
120 
We selected outcome measures and follow-up periods which have been 
proven appropriate in previous studies (Kiiski et al. 2016; Huiskes et al. 2017; 
Kallio et al. 2018). A 12-month follow up period has shown to be long enough 
to implement medication changes, demonstrate potential changes in study 
participants’ health outcomes and sustainability of changes made in their 
medications (Kiiski et al. 2016). Selected measures were congruent with recent 
studies proposing core outcome measures for trials aiming to improve 
appropriate medication use in older adults (Beuscart et al. 2018; Rankin et al. 
2018a). Our goal in future research is to investigate whether there is an 
association between the intermediate measures used in this study (medication 
risks) and improved health/function/cognition outcomes.  
A limitation of this study is the relatively small sample size, which may have 
affected the weak effectiveness of the intervention. Half of the eligible 
residents did not provide written consent to participate. High workload of the 
recruiting nursing staff, as well as frail and multi-morbid home care clients 
were evaluated as main contributing factors. The high attrition rate during the 
first study year, due to old age and multiple morbidities of the participants also 
contributed to the small sample size. In future studies with multi-morbid and 
frail older adults, these methodological issues crucially influencing the power 
of the study needs to be better considered. The same has been observed in 
other studies with multi-morbid older adults (Juola et al. 2015).  
We included in the analysis only participants with baseline and 12-month 
follow-up data available (Dumville et al. 2006). Poor implementation of 
recommended medication changes was the rationale for conducting per 
protocol analyses, including only participants with at least one clinically 
significant medication change actually implemented. As we were able to show 
a tendency for effectiveness in the per protocol analysis, it would be important 
to repeat the intervention with larger study populations to confirm the 
findings.  
This demonstration study was carried out by including only one 
community pharmacy operating in Lohja in the intervention. This strategy was 
chosen to keep the study design simple, as adding more community 
pharmacies to the study would have increased risk of bias. It would be 
important to repeat the intervention in the home care of other municipalities 
and involve other community pharmacies in future research. 
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6.5 PRACTICAL IMPLICATIONS
Study I was undertaken to support implementation of the first online DDI 
surveillance system in Finnish community pharmacies. The study is a 
demonstration of how community pharmacies can use information provided 
by their surveillance system for risk-management research purposes and their 
own service development. This study described the new service model 
developed by a national community pharmacy operating in 17 locations (in 
2004) across Finland, in co-operation with local physicians. The service 
development was initiated by identifying the most common and clinically 
significant DDIs and their prevalence rate. This evidence laid the foundation 
for establishing in-house guidelines for managing DDIs within the University 
Pharmacy.  
The same kind of strategy as applied in this study to integrate community 
pharmacists’ contribution to DDI management could be used for 
implementing other patient-care-oriented services. Such services could relate 
to implementation of other screening tools for medication risk loads, extended 
to cover, e.g., anticholinergic and serotonergic loads, and PIM use in older 
adults. Community pharmacies have advanced tools and willingness to 
participate more systematically in medication risk management (Jokinen et al. 
2019). The remaining challenge is how their contributions can be increased 
and integrated into the collaborative medication use process (Kallio et al. 
2018). Their contributions could add to scarce resources available in primary 
care to manage medications of a growing number of older people.  
 
Studies II–III 
The developed CoMM procedure is feasible for screening and reviewing 
medications of a high number of older home care clients to identify clients with 
severe DRPs and provide interventions to solve them utilizing existing primary 
care resources. The coordinating pharmacist was required to facilitate the 
construction of new processes and introduce new tools and approaches in 
medication management, while other health care practitioners worked as a 
part of their normal clinical work.  
Our experience was that health care teams benefit from having a 
coordinating pharmacist with qualifications in CMRs, geriatric 
pharmacotherapy and system-based medication risk management. Our study 
revealed that each organization and health care unit involved in home care 
clients’ medication therapy is still today working independently in silos, where 
no individual assumes holistic responsibility for medications. 
The CoMM study was a demonstration study showing preliminary and 
promising positive results. The procedure can be transferred to other home 
care units and adopted to their local circumstances. The procedure could be 
particularly designed to reduce CNS use in older adults, as it is among the 
major problems in geriatric pharmacotherapy in Finland (Leikola et al. 2011, 
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Juola et al. 2015; Pitkälä et al. 2015; Hyttinen 2018; Jalava et al. 2018; Kurko 
et al. 2018; Vartiainen et al. 2018).  
The triage method used in the CoMM proved to be a feasible method for 
customizing comprehensiveness of collaborative medication reviews for older 
home care clients according to their clinical needs, while minimizing the use 
of physicians’ time. Physicians’ resources were only needed for identified 
clinically significant DRPs requiring intervening action, while in nearly 50% 
of the cases physician resource was not needed. The triage method should be 
more widely used to identify and solve drug-related problems in older home 
care clients. The utilization of artificial intelligence in the screening stage in 
future is under way. 
 
During this study, much was learned about conducting an implementation 
and intervention study. Few studies of this kind have been carried out in 
Finland. However, implementation and intervention studies are important for 
learning from the organization of Finnish health and social care, particularly 
how primary care works and what the development needs there are. This study 
has produced remarkable information and evidence on Finnish health care, 
particularly home care, and contributed many new research projects. Results 
have had many practical implications, e.g., in developing the Rational 
Pharmacotherapy Action Plan 2018–2022 established in 2018 (Ministry of 
Social Affairs and Health 2018). Furthermore, the experience of this study is 
used in developing professional services for pharmacies, and developing 
undergraduate, specialization, accreditation and other continuing education 
(including the development of medication review practices and the criteria for 
competencies they require) (AATE 2017). Data from the study have also been 
utilized in other studies, such as the use of QT-prolonging drugs (Skullbacka 
2019), deprescribing (Nurminen 2019), systemic factors contributing 
excessive polypharmacy and prescribing cascade (Luoma 2018). 
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6.6 FUTURE RESEARCH
Related to managing DDI risks, future research is needed to assess whether 
any changes have occurred in the incidence and type of clinically significant 
DDIs in primary care patients during the past 16 years. Our updated 
systematic review on DDI studies evidenced that there is still not much 
research on DDIs in outpatients in primary care. Furthermore, it would be 
interesting to study how this service model to collaboratively manage DDIs has 
changed community pharmacists’ practice and their cooperation with 
physicians. It may also have a spillover effect on physicians’ prescribing. 
With the CoMM procedure, we were able to show a tendency for 
effectiveness in the per protocol analysis, and it would thus be important to 
repeat the intervention with larger study populations in order to confirm the 
findings. It would also be important to repeat the intervention in the home 
care of other municipalities.  
In future, utilization of artificial intelligence in the screening of medication 
risks is a potential and useful area of research. 
Further studies are needed on care culture and other contributing factors 
to high prevalence of PIM use and other risks for clinically significant DRPs 
identified in this study. Particularly, physicians’ reluctance to implement 
recommended medication changes in cases of inappropriate polypharmacy, 
and relationships between inappropriate medication use and medication 
errors require further investigation. Particularly, further investigation on 
system-based factors contributing to situations where identified preventable 
clinically significant medication risks are left unsolved is required.  
 
Conclusions 
124 
7 CONCLUSIONS
x Study I demonstrated that community pharmacies can actively contribute 
to DDI risk management and systematically use their surveillance systems 
for identifying patients having clinically significant DDIs. The findings also 
indicated that the majority of potentially serious (class D) interactions in 
outpatients involved a limited number of drugs, particularly NSAIDs, 
warfarin and methotrexate.  
 
x In Study II, the developed care coordination intervention (CoMM) was 
feasible for screening and reviewing medications of a high number of older 
home care clients to identify clients with severe DRPs and provide 
interventions to solve them utilizing existing primary care resources.  
 
x Triage meetings proved to be a feasible method for customizing 
collaborative medication reviews according to home care clients’ clinical 
needs, while minimizing physician’s time demands. Of the clients, 45.5% 
had no need for more comprehensive medication reviews. Thus, the triage 
enabled focusing on clients with clinically significant DRPs instead of 
comprehensively reviewing medications of all clients, as has been the case 
in many previous studies. 
 
x In Study III, the intervention (CoMM) indicated a tendency for 
effectiveness when implemented as planned, particularly in optimizing 
CNS medication use during a 12-month follow-up. 
 
x This study demonstrates the challenges that have to be overcome when 
trying to change clinical practice and improve coordination between units 
involved in medication management of home care clients. Even though the 
outcomes of the intervention were not optimal, the value of the study is in 
discussing the real world experiences and challenges of implementing new 
practices in home care. Our study indicated that practitioners in Finnish 
health care are not well acquainted with systems thinking and this needs 
reinforcement in the future. 
 
x Community pharmacists’ contribution to medication safety, particularly in 
older adults, should be better utilized in the future, as this thesis shows 
promising demonstrations. Health care teams in home care could benefit 
from having a coordinating pharmacist with qualifications in CMRs, 
geriatric pharmacotherapy and system-based medication risk 
management, to facilitate construction of new processes. 
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